<SEC-DOCUMENT>0001178913-23-002711.txt : 20241204
<SEC-HEADER>0001178913-23-002711.hdr.sgml : 20241204
<ACCEPTANCE-DATETIME>20230807070038
ACCESSION NUMBER:		0001178913-23-002711
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		46
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230807
DATE AS OF CHANGE:		20230807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		231145555

	BUSINESS ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2330082.htm
<DESCRIPTION>6-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--INTEGIX by Ez-XBRL--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:cgen="http://cgen.com/20230630" xmlns:ecd="http://xbrl.sec.gov/ecd/2023"  ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><title>COMPUGEN LTD - 1119774 - 2023</title></head><body>
        <div style="display:none">
        <ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20230101to20230630"  id="FFact_306" >0001119774</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="C_20230101to20230630"  id="FFact_307" >--12-31</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20230101to20230630"  id="FFact_309" >false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="C_20230101to20230630"  id="Fdei_DocumentFiscalPeriodFocus20220803133013452" >Q2</ix:nonNumeric><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="C_20230101to20230630"  id="Fdei_DocumentPeriodEndDate20220803135349061" >2023-06-30</ix:nonNumeric></ix:hidden>
<ix:references>
        <link:schemaRef xlink:type="simple" xlink:href="cgen-20230630.xsd"/>
        </ix:references></ix:header></div><div><div style="">
  <div>
    <div>
      <div style="font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
          <hr style="border:none;border-bottom:1px solid black;border-top:4px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center" />
        </div>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;margin-top:0pt;margin-bottom:0pt">&#160;</div>
      <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>UNITED STATES</span></span></span></span></div>
      <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>SECURITIES AND EXCHANGE COMMISSION</span></span></span></span></span></div>
      <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Washington, D.C. 20549</span></span></span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Form <ix:nonNumeric id="Fxbrl_20220803132217335" name="dei:DocumentType" contextRef="C_20230101to20230630">6-K</ix:nonNumeric></span></span></span></span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</span></span></span></span></div>
      <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>UNDER THE SECURITIES EXCHANGE ACT OF 1934</span></span></span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>For the month of August <ix:nonNumeric id="Fxbrl_20220803135229207" name="dei:DocumentFiscalYearFocus" contextRef="C_20230101to20230630">2023</ix:nonNumeric></span></span></span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Commission File Number <ix:nonNumeric id="Fxbrl_20220803132624667" name="dei:EntityFileNumber" contextRef="C_20230101to20230630">000-30902</ix:nonNumeric></span></span></span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:16pt;font-weight:bold"><span style="font-size:16pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="Fxbrl_20220803132653437" name="dei:EntityRegistrantName" contextRef="C_20230101to20230630">COMPUGEN LTD.</ix:nonNumeric></span></span></span></span></span></div>
      <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(Translation of registrant&#8217;s name into English)</span></span></span></span></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:100%;vertical-align:middle;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;color:rgb(0, 0, 0)">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width:100%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonNumeric id="Fxbrl_20220803132710165" name="dei:EntityAddressAddressLine1" contextRef="C_20230101to20230630">26 Harokmim Street</ix:nonNumeric></span></span></span></span></div>
            </td>
          </tr>
          <tr>
            <td style="width:100%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonNumeric id="Fxbrl_20220803132729395" name="dei:EntityAddressCityOrTown" contextRef="C_20230101to20230630">Holon</ix:nonNumeric>&#160;<ix:nonNumeric id="Fxbrl_20220803132743972" name="dei:EntityAddressPostalZipCode" contextRef="C_20230101to20230630">5885849</ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20220803132757086" name="dei:EntityAddressCountry" contextRef="C_20230101to20230630" format="ixt-sec:countrynameen">Israel</ix:nonNumeric></span></span></span></span></div>
            </td>
          </tr>
          <tr>
            <td style="width:100%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(Address of Principal Executive Offices)</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</span></span></span></span></div>
      <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Form 20-F &#9745;&#160; &#160; &#160; &#160; &#160; Form 40-F &#9744;</span></span></span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</span></span></span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</span></span></span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="page-break-after:always">
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
        </div>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Compugen Ltd.</span></span></span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25">
        <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>On August 7, 2023, Compugen Ltd. (the &#8220;<span style="font-weight:bold">Company</span>&#8221;) issued a press release reporting the Company&#8217;s 2023 second quarter results (the &#8220;<span style="font-weight:bold">Press Release</span>&#8221;), a copy of which is furnished as Exhibit 99.1 to this Report on Form 6-K. With the exception of the 2<sup style="vertical-align:text-top;line-height:1;font-size:smaller">nd</sup>, 3<sup style="vertical-align:text-top;line-height:1;font-size:smaller">rd</sup> and 4<sup style="vertical-align:text-top;line-height:1;font-size:smaller">th</sup> paragraphs of the Press Release, the information contained in the Press Release is hereby incorporated by reference herein.</span></span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-style:italic;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Second Quarter 2022 Financial Results</span></span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The unaudited interim consolidated financial statements of the Company and its subsidiary as of June 30, 2023 and December 31, 2022 and for the six months ended June 30, 2023 and 2022 are furnished as Exhibit 99.2 to this Report on Form 6-K and incorporated by reference herein. Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition of the Company as of and for the six months ended June 30, 2023 are furnished as Exhibit 99.3 to this Report on Form 6-K and incorporated by reference herein.</span></span></span></span></div>
      </div>
      <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The information contained in this Report on Form 6-K is hereby incorporated by reference into the Company&#8217;s Registration Statement on Form F-3, File No. 333-270985.</span></span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      </div>
      <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Exhibits</span></span></span></span></div>&#160;<div style="line-height:1.25">
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:72pt;vertical-align:bottom;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">
                <div style="line-height:1.25;color:rgb(0, 0, 0);font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Exhibit</span></span></span></span></div>
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold;color:rgb(0, 0, 0);text-decoration:underline">Number</span></span></span></span></span></div>
              </td>
              <td style="width:auto;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
                <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold;color:rgb(0, 0, 0);text-decoration:underline">Description of Exhibit</span></span></span></span></span></div>
              </td>
            </tr>

        </table>
      </div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt;vertical-align:top;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><a href="exhibit_99-1.htm"><span><span>99.1</span></span></a></span></span></span></span></td>
            <td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><a href="exhibit_99-1.htm"><span><span>Press Release dated August 7, 2023<span style="color:rgb(0, 0, 0)">.</span></span></span></a></span></span></span></span></div>
            </td>
          </tr>

      </table>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><a href="exhibit_99-2.htm">99.2</a></span></span></span></span></td>
            <td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><a href="exhibit_99-2.htm">Unaudited interim consolidated financial statements as of June 30, 2023 and December 31, 2022 and for the six months ended June 30, 2023 and 2022.</a></span></span></span></span></div>
            </td>
          </tr>

      </table>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><a href="exhibit_99-3.htm"><span><span>99.3</span></span></a></span></span></span></span></td>
            <td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="color:rgb(0, 0, 0)"><span><span><span style="color:rgb(0, 0, 0)"><span><span><span style="color:rgb(0, 0, 0)"><span><span><span style="color:rgb(0, 0, 0)"><span><span><span style="color:rgb(0, 0, 0)"><span><span><span style="color:rgb(0, 0, 0)"><span><span><span style="color:rgb(0, 0, 0)"><span><span><span style="color:rgb(0, 0, 0)"><a href="exhibit_99-3.htm">Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition of the Company as of and for the six months ended June 30, 2023</a></span></span></span></span></span></span></span></span></span></span></span></span><a href="exhibit_99-3.htm">.</a></span></span></span></span></span></span></span></span></span></span></span></span></span></span></div>
            </td>
          </tr>

      </table>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:72pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>101</span></span></span></span></td>
            <td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif">
              <div style="color:rgb(0, 0, 0)"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The following financial information from Compugen Ltd.&#8217;s Report on Form 6-K, formatted in Inline XBRL (ieXtensible Business Reporting Language): (i) condensed consolidated balance sheets as of June 30, 2023 and December 31, 2022; (ii) condensed consolidated statements of comprehensive loss for the six months ended June 30, 2023 and 2022; (iii) condensed consolidated statements of changes in shareholders&#8217; equity for the six months ended June 30, 2023 and 2022; (iv) condensed consolidated statements of cash flows for the six months ended June 30, 2023 and 2022; and (v) notes to condensed consolidated financial statements.</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="page-break-after:always">
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
        </div>
      </div>
      <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Signatures</span></span></span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></span></span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:50%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;color:rgb(0, 0, 0)">&#160;</div>
            </td>
            <td colspan="3" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;color:rgb(0, 0, 0);font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>COMPUGEN LTD.</span></span></span></span></div>
            </td>
          </tr>
          <tr>
            <td colspan="4" style="vertical-align:middle;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;color:rgb(0, 0, 0)">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width:50%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;color:rgb(0, 0, 0)"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Date: August 7, 2023</span></span></span></span></div>
            </td>
            <td style="width:3%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;color:rgb(0, 0, 0)"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>By:</span></span></span></span></div>
            </td>
            <td style="width:38.3%;vertical-align:bottom;border-bottom:2px solid black">
              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="color:rgb(0, 0, 0)">/s/ </span><span>Eran Ben Dor </span></span></span></span></span></div>
            </td>
            <td style="width:12%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0)">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width:50%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;color:rgb(0, 0, 0)">&#160;</div>
            </td>
            <td style="width:3%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;color:rgb(0, 0, 0)">&#160;</div>
            </td>
            <td style="width:38.3%;vertical-align:bottom">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Eran Ben Dor</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>General Counsel</span></span></span></span></div>
            </td>
            <td style="width:12%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">
              <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0)">&#160;</div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    </div>
  </div>
  <div>
    <hr style="border:none;border-bottom:4px solid black;border-top:1px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center" />
  </div>
</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div><br>
    </div>
    <div>
      <div style="line-height: 1.25;">
        <div style="text-align: right;"><b><u>Exhibit 99.1</u></b><br></div>
        <div style="text-align: right;"><font style="font-weight: bold;"> <br>
          </font></div>
        <img width="128" height="53" src="image00001.jpg"></div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">FOR IMMEDIATE RELEASE</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Compugen Reports Second Quarter 2023 Results</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="zed75c49270db460bb7f962852dbc6f4c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Advancing enrollment in two proof-of-concept studies evaluating triple blockade of DNAM-1 axis in patients with microsatellite stable colorectal cancer and platinum
                resistant ovarian cancer; initial findings expected by year end</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z910233fac2844cb9ad050f2a13bd64a9" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Data from multiple studies planned to be presented by the end of the year:</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zc11f28f167a04af8bbf422945f1e24bc" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">o</td>
            <td style="width: auto; vertical-align: top;">
              <div>New data from metastatic breast cancer study evaluating COM701+ nivolumab</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z1a0e673474d04b0bacf0e525fa2c629d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">o</td>
            <td style="width: auto; vertical-align: top;">
              <div>New translational data and initial biomarker data from platinum resistant ovarian cancer studies evaluating COM701 + nivolumab &#177; BMS anti-TIGIT</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zc0d4f1180ed048e59a932fe8fbbaef38" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">o</td>
            <td style="width: auto; vertical-align: top;">
              <div>Longer-term patient follow up from platinum resistant ovarian cancer study evaluating COM701 + nivolumab + BMS anti-TIGIT</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z16636de7cb8741ab8f661ec1fd0780a9" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">o</td>
            <td style="width: auto; vertical-align: top;">
              <div>New data from COM503 lead pre-clinical program</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">HOLON, ISRAEL &#8211; August 7, 2023 - Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in
        computational target discovery, today&#160;announced financial results for the second quarter ended June 30, 2023 and provided a corporate update on key events since the start of 2023.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">&#8220;In the first half of the year, we continued to execute on our goals,&#8221; said Anat Cohen-Dayag, Ph.D., President, and Chief Executive
        Officer of Compugen. &#8220;Patient enrollment is advancing in our two proof-of-concept studies with our unique triple immunotherapy combination approach and initial findings are expected by the end of the year. We presented new clinical data in
        metastatic endometrial cancer at ASCO in June showing durable responses, including in a patient failing immunotherapy which is consistent with data we previously presented in other hard to treat tumors. The totality of our data to date, suggest
        that our COM701 based combinations have the potential to offer a treatment option with a favorable safety profile for hard-to-treat patients, across the spectrum of PD-L1 expression levels, including in patients who are anti-PD-1 refractory,
        pointing to a potential COM701 mediated mechanism of action.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Dr. Cohen-Dayag added, &#8220;Our immediate focus is on expanding our data in two indications, platinum resistant ovarian cancer and
        microsatellite stable colorectal cancer, while continuing to invest in biomarker discovery, which is important to efficiently set our development path forward. We believe that the therapeutic potential of COM701 and COM902 as part of the DNAM-1
        axis may be much broader than these two indications.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Dr. Cohen-Dayag concluded, &#8220;In the second half of the year we are planning to present new and follow up data with our COM701 combinations
        including in ovarian and breast cancer as well as additional data on our COM503 lead pre-clinical program. Additionally, we are delighted to see the continued advancement in the development of rilvegostomig derived from COM902 by our partner
        AstraZeneca.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Corporate Update:</div>
      <div style="line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z42c9c4141ff14e8b892f7a685d5e3495" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div><font style="font-weight: bold;">March 2023:</font> First patient dosed in microsatellite stable
                colorectal cancer study; enrollment is on track to complete by year end.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zff9f147ea0e14792ba800da079e79c5a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div><font style="font-weight: bold;">CIMT May 2023:</font>&#160;Presentation of data on lead pre-clinical asset COM503, an anti- IL-18BP antibody, designed to induce a potent anti-tumor response and pronounced localized tumor microenvironment immune modulation
                by unleashing natural IL-18 activity in the tumor and potentially overcoming the challenges of administering a cytokine therapeutic.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z1f3072fc9c7348d09ee28bb69f52b6ec" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div><font style="font-weight: bold;">June 2023</font>: First patient dosed in platinum resistant ovarian
                cancer study. Enrollment to date is slower than anticipated, however we believe that we can catch up on enrollment with the planned activation of additional sites.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z3778cc0ca6ad49c1a60f963b0fa7cfa9" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div><font style="font-weight: bold;">June 2023:</font> Win at the European Patent Office (EPO), which ruled
                to uphold the Company&#8217;s broad PVRIG patent for the treatment of cancer reflecting the strength of Compugen&#8217;s patent strategy in novel target discovery. The EPO ruling is subject to appeal.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z0fa439934fbf43c4b264d1865ee44c29" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div><font style="font-weight: bold;">ASCO June 2023:</font> Presentation of data from triple immunotherapy
                combination (COM701+&#160; nivolumab + BMS anti-TIGIT) in microsatellite stable endometrial cancer study showing durable partial responses in patients who failed standard of care, including pembrolizumab and lenvatinib.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z6581c600bca04666af9ade1d0ab3f87a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div><font style="font-weight: bold;">ASCO June 2023:</font> Presentation of clinical data by partner
                AstraZeneca on rilvegostomig, a PD-1/TIGIT bispecific derived from COM902, establishing its safety and pharmacokinetic profile and showing anti-tumor activity in checkpoint inhibitor experienced NSCLC patients who typically do not respond
                to immunotherapy.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Next Planned Milestones in H2 2023:</div>
      <table cellspacing="0" cellpadding="0" id="zceabd19dd46c4e54aae1b15e521902ae" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Report initial findings from ongoing triple combination (COM701+COM902+ pembrolizumab) proof-of-concept studies in microsatellite stable colorectal and platinum
                resistant ovarian cancer by end of the year.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z87420280cd354ecfaa028fe6fda74b44" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Presentation of new translational data and initial biomarker data from platinum resistant ovarian cancer studies evaluating COM701 + nivolumab &#177; BMS anti-TIGIT.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z8eda25820f8c45f7a721532d8659857e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Presentation of longer-term patient follow up from platinum resistant ovarian cancer study evaluating COM701 + nivolumab + BMS anti-TIGIT.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zb3577c34744340d48f06e4484364ae03" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Presentation of new data from the metastatic breast cancer cohort expansion study of patients treated with COM701 and nivolumab.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zf85267cbdca24489b00a9ad2909d6618" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Presentation of data from COM503 lead pre-clinical program.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zb3c4389cdc5449e4a9d043396a78c391" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Rilvegostomig (PD-1/TIGIT bispecific derived from COM902): AstraZeneca continues to advance the development of rilvegostomig in multiple trials, including a Phase 2
                trial in checkpoint inhibitor na&#239;ve NSCLC and a Phase 2 trial in hepatobiliary cancer. AstraZeneca disclosed plans to initiate a Phase 3 trial with rilvegostomig this year.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Financial Results</div>
      <div style="line-height: 1.25;">As of June 30, 2023, cash, cash equivalents and cash investments were approximately $66.5 million, compared with approximately $83.7
        million as of December 31, 2022. The Company expects its existing cash and cash related balances to be sufficient to fund its operating plan into at least the end of 2024, based on current plans. During the three months ended June 30, 2023, the
        Company sold approximately 1.6 million ordinary shares under its &#8220;at-the-market offering&#8221; (ATM) facility pursuant to a sales agreement entered with Leerink Partners on January 31, 2023, for aggregate gross proceeds of approximately $1.6 million.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Compugen has no debt.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">R&amp;D expenses for the second quarter ended June 30, 2023, were approximately $7.8 million, up from $6.8 million for the comparable
        period in 2022. The increase is mainly due to end of the amortization of the deferred participation in R&amp;D expenses following the termination of the agreement with Bristol Myers Squibb in the third quarter of 2022, and an increase in
        preclinical and CMC activities associated with COM503, offset by a decrease in clinical trial expenses, headcount and currency exchange effect.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">General and administrative expenses for the second quarter ended June 30, 2023, were approximately $2.4 million down from approximately
        $2.6 million for the comparable period in 2022.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Net loss for the second quarter ended June 30, 2023, was approximately $9.3 million, or $0.11 per basic and diluted share, compared with
        a net loss of approximately $9.1 million, or $0.11 per basic and diluted share, for the comparable period in 2022.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Full financial tables are included below</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">Conference call and webcast information</div>
      <div style="line-height: 1.25;">The Company will hold a conference call today, August 7, 2023, at 8:30 AM ET to review its second quarter 2023 results. To access the
        live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through the Company&#8217;s website, located at the following <u>link</u>. Following the live audio webcast, a replay will be available on the Company's website.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">About&#160;Compugen</div>
      <div style="line-height: 1.25;">Compugen&#160;is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational
        discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies.&#160;Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902,&#160;a
        potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bi-specific derived from COM902, in Phase 2 development by
        AstraZeneca through a license agreement for the development of bi-specific and multi-specific antibodies.&#160;In addition, the Company&#8217;s therapeutic pipeline of early-stage&#160;immuno-oncology programs consists of programs aiming to address various
        mechanisms of immune resistance. The most advanced program, COM503 is in IND enabling studies. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing
        natural IL-18 to inhibit cancer growth in the tumor microenvironment. Compugen&#160;is headquartered in Israel, with offices in San Francisco, CA.&#160;Compugen&#8217;s&#160;shares are listed on Nasdaq and the Tel Aviv&#160;Stock Exchange under the ticker symbol CGEN.</div>
      <div style="line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Forward-Looking Statement</div>
      <div style="line-height: 1.25;">This press release contains &#8220;forward-looking statements&#8221;
          within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current
          beliefs, expectations, and assumptions of Compugen. Forward-looking statements can be identified using terminology such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;potential,&#8221; &#8220;plan,&#8221; &#8220;goal,&#8221; &#8220;estimate,&#8221; &#8220;likely,&#8221; &#8220;should,&#8221;
          &#8220;confident,&#8221; and &#8220;intends,&#8221; and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to,
          our expectation to share initial finding from two proof-of-concept studies evaluating triple blockade of DNAM-1 axis in patients with microsatellite stable colorectal cancer and platinum resistant ovarian cancer by year; our plans to present data from multiple studies by the end of the year; COM701 based combinations having the potential to offer a treatment option with a favorable
        safety profile for hard-to-treat patients, across the spectrum of PD-L1 expression levels, including in patients who are anti-PD-1 refractory, pointing to a potential COM701 mediated mechanism of action; our belief that the therapeutic potential of
        COM701 and COM902 as part of the DNAM-1 axis may be much broader than in platinum resistant ovarian cancer and microsatellite stable colorectal cancer; our beliefs as to the pace and timing of trial patient enrollment; our belief that we can catch
        up on enrollment with the planned activation of additional sites for platinum resistant ovarian cancer study; and our expectation that existing cash and cash related
          balances will be sufficient to fund our operating plan through the end of 2024. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance, or achievements of Compugen to be
          materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: In the near term, Compugen is highly dependent on the success of COM701 and of COM902; Compugen
          may not be able to advance its internal clinical stage programs through clinical development or manufacturing or successfully partner or commercialize them, or obtain marketing approval, either alone or with a collaborator, or may experience
          significant delays in doing so; Clinical development involves a lengthy and expensive process, with an uncertain outcome and Compugen may encounter substantial delays or even an inability to begin clinical trials for any specific product or may
          not be able to conduct or complete its trials on the timelines it expects; Compugen relies and expect to continue to rely on third parties to conduct its clinical trials and these third parties may not successfully or professionally carry out
          their contractual duties, comply with regulatory requirements or meet expected deadlines, and Compugen may experience significant delays in the conduct of its clinical trials as well as significant increased expenditures; Compugen has limited
          experience in the development of therapeutic product candidates, and it may be unable to implement its business strategy. These risks and other risks are more fully discussed in the &#8220;Risk Factors&#8221; section of Compugen&#8217;s most recent Annual Report
          on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen&#8217;s views
          only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Company contact:</div>
      <div style="line-height: 1.25;">Yvonne Naughton, Ph.D.</div>
      <div style="line-height: 1.25;">Head of Investor Relations and Corporate Communications</div>
      <div style="line-height: 1.25;">Email:&#160;ir@cgen.com&#160;&#160;</div>
      <div style="line-height: 1.25;">Tel: +1&#160;(628)&#160;241-0071&#160;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <br>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">COMPUGEN LTD.</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</div>
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except for share and per share amounts)</div>
        <div style="text-align: center; line-height: 1.25;"> <br>
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z14380a51bd014ac182eb93f477a5ff92" class="cfttable">

          <tr>
            <td valign="bottom" style="vertical-align: top;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="6">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Three Months Ended</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="6">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Six Months Ended,</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> June 30,</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">June 30,</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2023</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2022</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2023</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2022</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Unaudited</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Unaudited</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Unaudited</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Unaudited</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Operating expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 52%;">
              <div style="line-height: 1.25;">Research and development expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">7,761</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">6,812</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">15,206</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">13,982</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Marketing and business development expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">49</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">255</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">165</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">478</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">General and administrative expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">2,404</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">2,570</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">4,977</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">5,173</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Total operating expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">10,214</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">9,637</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">20,348</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">19,633</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">Financial and other income, net</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">889</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">493</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">1,697</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">779</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Loss before taxes on income</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">(9,325</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
              <div style="line-height: 1.25; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">(9,144</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
              <div style="line-height: 1.25; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">(18,651</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
              <div style="line-height: 1.25; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">(18,854</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
              <div style="line-height: 1.25; font-weight: bold;">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">Tax benefit</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">49</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">36</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Net loss</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">(9,276</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
              <div style="line-height: 1.25; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">(9,144</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
              <div style="line-height: 1.25; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">(18,615</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
              <div style="line-height: 1.25; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">(18,854</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
              <div style="line-height: 1.25; font-weight: bold;">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 52%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Basic and diluted net loss per ordinary share</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">(0.11</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
              <div style="line-height: 1.25;">)</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">(0.11</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
              <div style="line-height: 1.25;">)</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">(0.21</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
              <div style="line-height: 1.25;">)</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">(0.22</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
              <div style="line-height: 1.25;">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; width: 52%;">
              <div style="line-height: 1.25;">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">87,182,839</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">86,518,714</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">86,903,741</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">86,486,612</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <br>
      <table cellspacing="0" cellpadding="0" id="z523587be7bb04337b0e4b1675ac6dde7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 100%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">COMPUGEN LTD.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">CONDENSED CONSOLIDATED BALANCE SHEETS DATA</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25;">(U.S. dollars, in thousands)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z1968c7801f7345488c5cc1727e1540ad" class="cfttable">

          <tr>
            <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> June 30,</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">December 31,</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2023</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2022</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Unaudited</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">ASSETS</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom;">
              <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Current assets</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25;">Cash, cash equivalents, short-term bank deposits and restricted cash</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">61,983</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">83,708</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Investment in marketable securities</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">4,551</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">Other accounts receivable and prepaid expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">2,865</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">2,417</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Total current assets</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">69,399</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">86,125</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Non-current assets</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25;">Long-term prepaid expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">1,912</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">1,899</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Severance pay fund</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">2,788</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">2,794</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25;">Operating lease right to use asset</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">1,606</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">1,826</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Property and equipment, net</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">1,350</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">1,532</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
              <div style="line-height: 1.25; font-weight: bold;">Total non-current assets</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">7,656</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">8,051</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
              <div style="line-height: 1.25; font-weight: bold;">Total assets</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">77,055</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">94,176</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25; font-weight: bold;">LIABILITIES AND SHAREHOLDERS EQUITY</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25; font-weight: bold;">Current liabilities</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Other accounts payable, accrued expenses and trade payables</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">10,191</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">10,981</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25;">Current maturity of operating lease liability</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">610</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">613</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Short-term deferred participation in R&amp;D expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">325</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
              <div style="line-height: 1.25; font-weight: bold;">Total current liabilities</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">10,801</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">11,919</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25; font-weight: bold;">Non-current liabilities</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Long-term operating lease liability</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">991</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">1,312</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">Accrued severance pay</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">3,262</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">3,265</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Total non-current liabilities</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">4,253</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">4,577</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Total shareholders' equity</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">62,001</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">77,680</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Total liabilities and shareholders' equity</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">77,055</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">94,176</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>exhibit_99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--INTEGIX by Ez-XBRL--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:cgen="http://cgen.com/20230630" xmlns:ecd="http://xbrl.sec.gov/ecd/2023"  ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><title>COMPUGEN LTD - 1119774 - 2023</title></head><body>
        <div style="display:none">
        <ix:header><ix:hidden><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="C_20230630"  id="Fxbrl_20230803123831627" unitRef="usd"  xsi:nil="true"></ix:nonFraction><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="C_20221231"  id="Fxbrl_20230803123835179" unitRef="usd"  xsi:nil="true"></ix:nonFraction><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_20230101to20230630"  id="Fxbrl_20230728034213148" unitRef="usd"  xsi:nil="true"></ix:nonFraction><ix:footnote id="FN20230728034116852" xml:lang="en-US">Represents an amount lower than $1</ix:footnote>
<ix:nonFraction name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"  id="Fxbrl_20220727223450181_xbrl_20220720105058426" unitRef="usd"  xsi:nil="true"></ix:nonFraction><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"  id="Fxbrl_20220727223630806" unitRef="usd"  xsi:nil="true"></ix:nonFraction><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"  id="Fxbrl_20230728042446448_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105006668" unitRef="usd"  xsi:nil="true"></ix:nonFraction><ix:footnote id="FN20230728141130882" xml:lang="en-US">Represents an amount lower than $ 1.</ix:footnote>
<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_20230630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember"  id="Fxbrl_20230728101901825" unitRef="usd"  xsi:nil="true"></ix:nonFraction><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_20230630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember"  id="Fxbrl_20230728101905592" unitRef="usd"  xsi:nil="true"></ix:nonFraction><ix:footnote id="FN20230728102035190" xml:lang="en-US">*   Represents an amount lower than $1</ix:footnote>
<ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20230101to20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"  id="FFact_286"  xsi:nil="true"></ix:nonNumeric></ix:hidden>
<ix:references>
        <link:schemaRef xlink:type="simple" xlink:href="cgen-20230630.xsd"/>
        </ix:references><ix:resources><xbrli:context id="C_20230101to20230630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-06-14</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2018-06-14</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-10-10</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20181001to20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-10-10</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200301to20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-03-01</xbrli:startDate>
        <xbrli:endDate>2020-03-16</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-03-16</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200316_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:UnderwritersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-03-16</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200401to20200414_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:UnderwritersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-04-14</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200401to20200414_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-04-14</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211101to20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-11-01</xbrli:startDate>
        <xbrli:endDate>2021-11-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_srtRangeAxis_srtMaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230630_usgaapAwardTypeAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20230630_usgaapAwardTypeAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_srtRangeAxis_srtMaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230130to20230131_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SalesAgreementWithLeerinkPartnerLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-30</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SalesAgreementWithLeerinkPartnerLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20130801to20130805"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2013-08-01</xbrli:startDate>
        <xbrli:endDate>2013-08-05</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211110"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-11-10</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20130805"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2013-08-05</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180301to20180330"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-03-01</xbrli:startDate>
        <xbrli:endDate>2018-03-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180330"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-03-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_srtRangeAxis_srtMinimumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_srtRangeAxis_srtMaximumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180101to20180105_cgenGovernmentAndOtherGrantsAxis_cgenCommercialLicenseAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:CommercialLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-01-05</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230803_usgaapPlanNameAxis_cgenPlan2010Member_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:Plan2010Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-08-03</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230803_usgaapPlanNameAxis_cgenEmployeeSharePurchasePlanMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:EmployeeSharePurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-08-03</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:unit id="ILSPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:ILS</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<ix:relationship fromRefs="Fxbrl_20230728034213148" toRefs="FN20230728034116852"/><ix:relationship fromRefs="Fxbrl_20220727223630806" toRefs="FN20230728141130882"/><ix:relationship fromRefs="Fxbrl_20230728042446448_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105006668" toRefs="FN20230728141130882"/><ix:relationship fromRefs="Fxbrl_20230728101901825" toRefs="FN20230728102035190"/><ix:relationship fromRefs="Fxbrl_20230728101905592" toRefs="FN20230728102035190"/><ix:relationship fromRefs="FFact_298" toRefs="FN20220720121444312"/><ix:relationship fromRefs="FFact_299" toRefs="FN20220720121444312"/><ix:relationship fromRefs="FFact_300" toRefs="FN20220720121444312"/><ix:relationship fromRefs="FFact_301" toRefs="FN20220720121444312"/></ix:resources></ix:header></div><div><div style=""> <div><div><hr style="border:none;border-bottom:1px solid black;border-top:4px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center" /></div><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0px;margin-bottom:0pt;text-align:right"><span style="text-decoration:underline"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Exhibit 99.2</span></span></span></span></strong></span></p><div><div style="line-height:1.25;font-family:Times New Roman, Times, serif;font-weight:bold;text-align:right">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INTERIM CONSOLIDATED FINANCIAL STATEMENTS</span></span></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">AS OF JUNE 30, 2023</span></span></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. DOLLARS IN THOUSANDS</span></span></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED</span></span></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INDEX</span></span></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><table cellpadding="0" cellspacing="0" style="width:100%"><tr><td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:85%">&#160;</td><td style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;width:15%"><div style="line-height:1.25"><div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Page</span></span></div></div></td></tr><tr><td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:85%">&#160;</td><td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:15%">&#160;</td></tr><tr><td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:85%"><div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#SHEETS_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Condensed Consolidated Balance Sheets</span></span></a></span></span></div></td><td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:15%"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>F-2 - F-3</strong></p></td></tr><tr><td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:85%">&#160;</td><td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:15%">&#160;</td></tr><tr><td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:85%"><div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#LOSS_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Condensed&#160;Consolidated Statements of Comprehensive Loss</span></span></a></span></span></div></td><td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:15%"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>F-4</strong></p></td></tr><tr><td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:85%">&#160;</td><td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:15%">&#160;</td></tr><tr><td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:85%"><div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#EQUITY_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Condensed&#160;Consolidated Statements of Changes in Shareholders' Equity</span></span></a></span></span></div></td><td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:15%"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>F-5</strong></p></td></tr><tr><td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:85%">&#160;</td><td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:15%">&#160;</td></tr><tr><td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:85%"><div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#FLOWS_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Condensed&#160;Consolidated Statements of Cash Flows</span></span></a></span></span></div></td><td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:15%"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>F-6</strong></p></td></tr><tr><td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:85%">&#160;</td><td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:15%">&#160;</td></tr><tr><td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:85%"><div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#NOTES_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Notes to Condensed Consolidated Financial Statements</span></span></a></span></span></div></td><td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:15%"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>F-7 - F-15</strong></p></td></tr></table><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">- - - - - - - - - - - - -</span></span></div><div style="line-height:1.25;font-family:Times New Roman, Times, serif;text-align:right">&#160;</div><div style="clear:both;margin-top:10pt;margin-bottom:0pt"><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div></div></div></div><div style="">
  <div>
    <div>
      <div>
        <div>
          <div style="text-align:right;line-height:1.25;font-family:Times New Roman, Times, serif;font-weight:bold;margin-top:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></div>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25">
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;margin-bottom:5pt"><span id="SHEETS_integixAnchor"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>CONDENSED CONSOLIDATED BALANCE SHEETS</span></span></span></span></span></div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">
            <hr style="height:2px;color:rgb(0, 0, 0);background-color:rgb(0, 0, 0);text-align:center;margin-left:auto;margin-right:auto;border:medium none;text-align:center;margin-top:0pt;margin-bottom:0pt" />
          </div>
        </div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;margin-top:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>U.S. dollars in thousands</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;color:rgb(0, 0, 0);width:100%">

            <tr>
              <td style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom" valign="bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>June 30,</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom" valign="bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>December 31,</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2023</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2022</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Unaudited</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:14.2pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>ASSETS</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>CURRENT ASSETS:</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">
                <div style="margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Cash and cash equivalents</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,071</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_2" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,059</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Restricted cash</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">615</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_4" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">362</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">
                <div style="margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Short-term bank deposits</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_5" name="us-gaap:OtherShortTermInvestments" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,297</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_6" name="us-gaap:OtherShortTermInvestments" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,287</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Investment in marketable securities</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20230728025352671_Fact_5" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,551</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20230728025352671_Fact_6" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom">
                <div style="margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Other accounts receivable and prepaid expenses</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_9" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,865</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_10" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,417</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom">
                <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="text-decoration:underline">Total</span> current assets</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_11" name="us-gaap:AssetsCurrent" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,399</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_12" name="us-gaap:AssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,125</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">
                <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>NON-CURRENT ASSETS:</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Long-term prepaid expenses</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_13" name="us-gaap:PrepaidExpenseNoncurrent" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,912</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_14" name="us-gaap:PrepaidExpenseNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,899</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">
                <div style="margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Severance pay fund</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_15" name="cgen:SeverancePayFundNonCurrent" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,788</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_16" name="cgen:SeverancePayFundNonCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,794</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Operating lease right to use asset</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_17" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,606</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_18" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,826</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom">
                <div style="margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Property and equipment, net</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_19" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,350</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_20" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,532</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom">
                <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="text-decoration:underline">Total</span> non-current assets</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_21" name="us-gaap:AssetsNoncurrent" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,656</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_22" name="us-gaap:AssetsNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,051</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:4px" valign="bottom">
                <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="text-decoration:underline">Total</span> assets</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_23" name="us-gaap:Assets" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,055</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_24" name="us-gaap:Assets" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,176</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25">
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The accompanying notes are an integral part of the condensed consolidated financial statements.</span></span></span></span></div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        </div>
        <div style="clear:both;margin-top:10pt;margin-bottom:4pt">
          <div style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="color:#000000;font-weight:normal;font-style:normal">F - 2</span></span></span></span></span></div>
          <div style="page-break-after:always">
            <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:rgb(0, 0, 0);background-color:rgb(0, 0, 0)" />
          </div>
        </div>
        <div style="text-align:right;font-weight:bold;margin-top:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></div>&#160;<div style="line-height:1.25">
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>CONDENSED CONSOLIDATED BALANCE SHEETS</span></span></span></span></div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">
            <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;margin-top:0pt;margin-bottom:0pt" />
          </div>
        </div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;margin-top:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>U.S. dollars in thousands (except share data)</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;color:rgb(0, 0, 0);width:100%">

            <tr>
              <td style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom" valign="bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>June 30,</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom" valign="bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>December 31,</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2023</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2022</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Unaudited</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:17pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>LIABILITIES AND SHAREHOLDERS' EQUITY</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>CURRENT LIABILITIES:</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">
                <div style="margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Trade payables</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713620_0" name="us-gaap:AccountsPayableCurrent" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,680</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713621_1" name="us-gaap:AccountsPayableCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,773</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Short-term deferred participation in R&#38;D expenses</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713621_2" name="cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713622_3" name="cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">325</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">
                <div style="margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Current maturity of operating lease liability</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713622_4" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">610</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713622_5" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">613</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Other accounts payable and accrued expenses</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713623_6" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,511</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713623_7" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,208</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="text-decoration:underline">Total</span> current liabilities</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713623_8" name="us-gaap:LiabilitiesCurrent" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,801</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713623_9" name="us-gaap:LiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,919</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>NON- CURRENT LIABILITIES:</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">
                <div style="margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Long term operating lease liability</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713624_12" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">991</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713625_13" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,312</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Accrued severance pay</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713625_14" name="us-gaap:PostemploymentBenefitsLiabilityNoncurrent" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,262</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713625_15" name="us-gaap:PostemploymentBenefitsLiabilityNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,265</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="text-decoration:underline">Total</span> non-current liabilities</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713627_16" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,253</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713627_17" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,577</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>COMMITMENTS AND CONTINGENT<span style="-sec-ix-hidden:Fxbrl_20230803123835179"><span style="-sec-ix-hidden:Fxbrl_20230803123831627"> </span></span>LIABILITIES (NOTE 5)</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>SHAREHOLDERS' EQUITY:</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">
                <div style="margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Share capital:</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:25.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Ordinary shares of NIS <ix:nonFraction id="Fxbrl_20220719214834949" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20221231" unitRef="ILSPerShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20220719213713628_18" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20230630" unitRef="ILSPerShare" decimals="INF" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction id="Fxbrl_20220719214917721" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20221231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20220719213713628_20" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20230630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized on June 30, 2023, and December 31, 2022; <ix:nonFraction id="Fxbrl_20220719215055193" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20230630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20220719213713629_22" name="us-gaap:CommonStockSharesIssued" contextRef="C_20230630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">88,233,766</ix:nonFraction></ix:nonFraction> and <ix:nonFraction id="Fxbrl_20220719215111705" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20221231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20220719213713629_24" name="us-gaap:CommonStockSharesIssued" contextRef="C_20221231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,624,643</ix:nonFraction></ix:nonFraction> shares issued and outstanding on June 30, 2023, and December 31, 2022, respectively</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713630_26" name="us-gaap:CommonStockValue" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">244</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713630_27" name="us-gaap:CommonStockValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">240</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">
                <div style="margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Additional paid-in capital</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713630_28" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">536,145</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713631_29" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">533,213</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Accumulated deficit</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="F20220719213713631_30" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">474,388</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="F20220719213713632_31" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">455,773</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="text-decoration:underline">Total</span> shareholders' equity</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713632_32" name="us-gaap:StockholdersEquity" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,001</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713632_33" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,680</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="text-decoration:underline">Total</span> liabilities and shareholders' equity</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713633_34" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,055</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="F20220719213713633_35" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,176</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>

        </table>
        <div>&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The accompanying notes are an integral part of the condensed consolidated financial statements.</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="clear:both;margin-top:10pt;margin-bottom:4pt">
          <div style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="color:#000000;font-weight:normal;font-style:normal">F - 3</span></span></span></span></span></div>
        </div>
      </div>
    </div>
    <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
      </div>
    </div>
  </div>
</div><div style="">
  <div>
    <div>
      <div>
        <div style="line-height:1.25">
          <div style="text-align:right;line-height:1.25;font-family:Times New Roman, Times, serif;font-weight:bold;margin-top:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;margin-bottom:5pt"><span id="LOSS_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></span></span></div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">
            <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;margin-top:0pt;margin-bottom:0pt" />
          </div>
        </div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;margin-top:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands (except share and per share data)</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;color:rgb(0, 0, 0);width:100%">

            <tr>
              <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating expenses:</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
                <div style="margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses, net</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_61" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,206</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_62" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,982</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketing and business development expenses</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_63" name="us-gaap:BusinessDevelopment" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">165</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_64" name="us-gaap:BusinessDevelopment" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">478</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
                <div style="margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative expenses</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_65" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,977</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_66" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,173</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
                <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total operating expenses</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_67" name="us-gaap:OperatingExpenses" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,348</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_68" name="us-gaap:OperatingExpenses" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,633</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
                <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_69" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,697</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_70" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">779</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
                <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss before taxes on income</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_71" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,651</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_72" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,854</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax benefit</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220719215810562_Fact_71" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">36</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220719215810562_Fact_72" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_75" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,615</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_76" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,854</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other comprehensive loss:</span></span></td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in unrealized gains (losses) on marketable securities:</span></span></td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160; &#160; &#160; Unrealized gains (losses) arising during the period, net</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20230728034213148">*</span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728033938209_xbrl_20220719215810562_Fact_72" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total comprehensive loss</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728030537018_Fact_75" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,615</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728030537018_Fact_76" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,854</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted net loss per share</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220719220126329" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20230630" unitRef="USDPerShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_77" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20230630" unitRef="USDPerShare" decimals="INF" format="ixt:num-dot-decimal">0.21</ix:nonFraction></ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220719220147427" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220101to20220630" unitRef="USDPerShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_78" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20220630" unitRef="USDPerShare" decimals="INF" format="ixt:num-dot-decimal">0.22</ix:nonFraction></ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220720012025614" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20230101to20230630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_81" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230101to20230630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,903,741</ix:nonFraction></ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220720012118943" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20220101to20220630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_82" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220101to20220630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,486,612</ix:nonFraction></ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>*&#160; &#160; &#160; &#160; &#160;&#160;</span><span>Represents an amount lower than $1.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></span></div>
        <div>&#160;</div>
        <div style="clear:both;margin-top:10pt;margin-bottom:4pt">
          <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#000000;font-weight:normal;font-style:normal">F - 4</span></span></span></div>
        </div>
      </div>
    </div>
    <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
      </div>
    </div>
  </div>
</div><div style="">
  <div>
    <div>
      <div>
        <div style="text-align:right;line-height:1.25;font-family:Times New Roman, Times, serif;font-weight:bold;margin-top:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
      </div>
      <div style="margin-top:0pt;margin-bottom:0pt;text-align:right">&#160;</div>
      <div style="line-height:1.25">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;margin-bottom:5pt"><span id="EQUITY_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</span></span></span></div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">
          <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;margin-top:0pt;margin-bottom:0pt" />
        </div>
      </div>
      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;margin-top:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands (except share data)</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;color:rgb(0, 0, 0);width:100%">

          <tr>
            <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Ordinary</span>&#160;<span style="font-weight:bold">shares</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional paid-in</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total shareholders&#8217;</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amount</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">capital</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">deficit</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">equity</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of January 1, 2022</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727223132738_Fact_109" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,433,432</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727223132738_Fact_110" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727223132738_Fact_111" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">528,533</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220727223132738_Fact_112" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">422,079</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727223132738_Fact_113" name="us-gaap:StockholdersEquity" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,693</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:40%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options exercised</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222823749_Fact_114" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">33,186</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20220727223630806">*</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222823749_Fact_116" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222823749_xbrl_20220720104943489" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222823749_Fact_117" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:40%" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of ESPP shares</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727223329630_Fact_122" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">158,025</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727223329630_xbrl_20220719224804137" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727223329630_Fact_124" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">248</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727223329630_xbrl_20220720104955752" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727223329630_Fact_125" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">249</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock-based compensation issued to employees, directors and non-employees</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20220727223450181_xbrl_20220720105058426">-</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727223450181_Fact_126" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,189</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727223450181_xbrl_20220720105006668" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727223450181_Fact_127" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,189</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:40%;padding-bottom:2px" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222823775_xbrl_20220720105044504" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222823775_xbrl_20220720105025339" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220727222823775_Fact_128" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,854</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220727222823775_Fact_129" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,854</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:40%;padding-bottom:4px" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of June 30, 2022 (unaudited)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222823781_Fact_130" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,624,643</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222823781_Fact_131" name="us-gaap:StockholdersEquity" contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">240</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222823781_Fact_132" name="us-gaap:StockholdersEquity" contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">531,074</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220727222823781_Fact_133" name="us-gaap:StockholdersEquity" contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">440,933</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222823781_Fact_134" name="us-gaap:StockholdersEquity" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">90,381</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:40%" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of January 1, 2023</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_109" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,624,643</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_110" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">240</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_111" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">533,213</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_112" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">455,773</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_113" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,680</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:40%" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of shares, net</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041429297_xbrl_20220727223504334_Fact_96" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">1,609,123</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041429297_xbrl_20220727223710614" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041429297_xbrl_20220727223504334_Fact_98" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,150</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041429297_xbrl_20220727223504334_xbrl_20220720104851290" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041429297_xbrl_20220727223504334_Fact_99" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,154</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock-based compensation issued to employees, directors and non-employees</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105058426" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041439032_xbrl_20220727223450181_Fact_126" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,782</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105006668" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041439032_xbrl_20220727223450181_Fact_127" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,782</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:40%" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other comprehensive income (loss) from marketable securities, net</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20230728042446448_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105006668">*</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728042446448_xbrl_20230728041439032_xbrl_20220727223450181_Fact_127" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041511128_xbrl_20220727222823775_xbrl_20220720105044504" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041511128_xbrl_20220727222823775_xbrl_20220720105025339" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230728041511128_xbrl_20220727222823775_Fact_128" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,615</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230728041511128_xbrl_20220727222823775_Fact_129" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,615</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:40%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:40%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of June 30, 2023 (unaudited)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_130" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">88,233,766</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_131" name="us-gaap:StockholdersEquity" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">244</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_132" name="us-gaap:StockholdersEquity" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">536,145</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_133" name="us-gaap:StockholdersEquity" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">474,388</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_134" name="us-gaap:StockholdersEquity" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,001</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>*</span>&#160; &#160; &#160; &#160; &#160;&#160;<span>Represents an amount lower than $1.</span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:4pt">
        <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#000000;font-weight:normal;font-style:normal">F - 5</span></span></span></div>
      </div>
    </div>
  </div>
  <div>
    <div>
      <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
        <div style="page-break-after:always">
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:0pt" />
        </div>
      </div>
    </div>
  </div>
</div><div style="">
  <div>
    <div>
      <div>
        <div>
          <div style="text-align:right;line-height:1.25;font-family:Times New Roman, Times, serif;font-weight:bold;margin-top:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></div>
        </div>
        <div style="text-align:justify;line-height:1.25">&#160;</div>
        <div style="line-height:1.25">
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;margin-bottom:5pt"><span id="FLOWS_integixAnchor"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></span></span></span></span></div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">
            <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;margin-top:0pt;margin-bottom:0pt" />
          </div>
        </div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;margin-top:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>U.S. dollars in thousands</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;color:rgb(0, 0, 0);width:100%">

            <tr>
              <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Six months ended</span></span></span></span></div>
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>June 30,</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2023</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2022</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Unaudited</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="text-decoration:underline">Cash flows from operating activities:</span></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">
                <div style="margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Net loss</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20230728044607285" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,615</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20230728044615653" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,854</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">
                <div style="text-indent:-8.8pt;margin-left:25.8pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Adjustments required to reconcile net loss to net cash used in operating activities:</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="text-indent:-8.8pt;margin-left:25.8pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Stock-based compensation</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_137" name="us-gaap:ShareBasedCompensation" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,782</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_138" name="us-gaap:ShareBasedCompensation" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,189</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">
                <div style="margin-left:17pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Depreciation</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_139" name="us-gaap:Depreciation" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">237</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_140" name="us-gaap:Depreciation" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">232</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:17pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Accretion of discount on marketable securities</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20230728052415879_Fact_139" name="cgen:AccretionOfDiscountOnMarketableSecurities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20230728052415879_Fact_140" name="cgen:AccretionOfDiscountOnMarketableSecurities" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">
                <div style="margin-left:17pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Realized gain on sale of marketable securities, net</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20230728052418474_Fact_139" name="us-gaap:MarketableSecuritiesRealizedGainLoss" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20230728052418474_Fact_140" name="us-gaap:MarketableSecuritiesRealizedGainLoss" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Increase (decrease) in severance pay, net</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_141" name="cgen:SeverancePayNet" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20220719231801817" name="cgen:SeverancePayNet" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">24</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">
                <div style="margin-left:17pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Decrease in operating lease right of use asset</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_145" name="cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">290</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_146" name="cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">295</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:17pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Increase in interest receivables from short-term bank deposits</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20220719231852648" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">140</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20230728053007019" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">114</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">
                <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Decrease (increase) in other accounts receivable and prepaid expenses</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20230728053015979" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">448</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719231907400" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">764</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Decrease (increase) in long-term prepaid expenses</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20230728053037345" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_154" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">
                <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Decrease in trade payables</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20220719232044563" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">85</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20230728053025234" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,387</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Increase (decrease) in other accounts payable and accrued expenses</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20230728053044499" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">894</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_158" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">242</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">
                <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Decrease in operating lease liability</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="FFact_159" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">394</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="FFact_160" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">644</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">
                <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Decrease in deferred participation in R&#38;D expenses</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="FFact_161" name="cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">325</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="FFact_162" name="cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,387</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Net cash used in operating activities</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="FFact_163" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,617</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="FFact_164" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">20,683</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="text-decoration:underline">Cash flows from investing activities:</span></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">
                <div style="text-indent:-5.65pt;margin-left:14.15pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Proceeds from maturity of short-term bank deposits</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_165" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,350</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_166" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,945</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="text-indent:-5.65pt;margin-left:14.15pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Investment in short-term bank deposits</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="FFact_167" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,220</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="FFact_168" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,500</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">
                <div style="margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Proceeds from maturity of marketable securities</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20230728052423298_Fact_139" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20230728052423298_Fact_140" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Investment in marketable securities</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20230728052426602_Fact_139" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,536</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20230728052426602_Fact_140" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom">
                <div style="margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Purchase of property and equipment</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="FFact_169" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="FFact_170" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">258</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom">
                <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Net cash provided by investing activities</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_173" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,531</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_174" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,187</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">
                <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="text-decoration:underline">Cash flows from financing activities:</span></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">
                <div style="text-indent:-5.65pt;margin-left:14.15pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Proceeds from issuance of ordinary shares, net</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_175" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,351</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_176" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">249</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="text-indent:-5.65pt;margin-left:14.15pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Proceeds from exercise of options</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_179" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_180" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Net cash provided by financing activities</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_181" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,351</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_182" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Increase (decrease) in cash, cash equivalents and restricted cash</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20220719232250681" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,265</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20230728053102843" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">143</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom">
                <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Cash, cash equivalents and restricted cash at the beginning of the period</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_185" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,421</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_186" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,514</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:4px" valign="bottom">
                <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Cash, cash equivalents and restricted cash at the end of the period</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_187" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,686</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="FFact_188" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,371</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%" valign="bottom">
                <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="text-decoration:underline">Supplemental disclosure of non-cash investing and financing activities:</span></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:4px" valign="bottom">
                <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Purchase of property and equipment</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20230728044639062" name="cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(<ix:nonFraction id="Fxbrl_20230728044646863" name="cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">80</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Right-of-use asset obtained in exchange for operating lease liability</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20230728052431875_Fact_139" name="cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20230728052431875_Fact_140" name="cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:4px" valign="bottom">
                <div style="margin-left:2.85pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Issuance expenses</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20230728052434971_Fact_139" name="cgen:IssuanceExpenses" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">197</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonFraction id="Fxbrl_20230728052434971_Fact_140" name="cgen:IssuanceExpenses" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The accompanying notes are an integral part of the condensed consolidated financial statements.</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="clear:both;margin-top:10pt;margin-bottom:4pt">
          <div style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="color:#000000;font-weight:normal;font-style:normal">F - 6</span></span></span></span></span></div>
        </div>
      </div>
    </div>
    <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:0pt" />
      </div>
    </div>
  </div>
</div><div style="">
  <div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>COMPUGEN LTD. AND ITS SUBSIDIARY</strong></span></span></span></div>
  <div style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</div>
  <div style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">
    <div style="display:inline">
      <div>
        <div style="margin-bottom:5pt"><span id="NOTES_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><strong>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></div>
      </div>
    </div>
  </div>
  <hr style="border-top:2px solid black;margin-top:0pt;margin-bottom:0pt;text-align:center" />
  <div style="margin-top:5pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>U.S. dollars in thousands (except share and per share data)</strong></span></span></span></div>
  <div style="margin:0pt">&#160;</div>
  <ix:nonNumeric id="FFact_200" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="C_20230101to20230630" escape="true">
    <div>
      <div>
        <div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 1:-</span>&#160;</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">GENERAL</span></span></span></td>
                </tr>

            </table>
            <div style="text-align:justify;line-height:1.25">&#160;</div>
            <div style="text-align:justify;line-height:1.25">
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                  <tr>
                    <td style="width:56.7pt">&#160;</td>
                    <td style="width:27.75pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Compugen Ltd. (the &#8220;Company&#8221;) is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Compugen&#8217;s innovative immuno-oncology pipeline consists of three clinical stage programs, targeting immune checkpoints Compugen discovered computationally by COM701, COM902 and rilvegostomig. The Company&#8217;s lead product candidates, COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody are in Phase 1 clinical trials in patients with MSS CRC and platinum resistant ovarian cancer. Rilvegostomig, a novel anti PD-1/TIGIT bispecific antibody with a TIGIT specific component that is derived from Compugen&#8217;s COM902 antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is in a Phase 2 clinical trial in patients with advanced or metastatic non-small cell lung and locally advanced or metastatic gastric cancer. In addition, the Company&#8217;s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. The most advanced preclinical program, COM503, is in IND enabling studies. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 to inhibit cancer growth in the tumor microenvironment.</span></span></div>
                    </td>
                  </tr>

              </table>
            </div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:27.75pt;vertical-align:top">&#160;</td>
                  <td style="width:auto;vertical-align:top;text-align:justify">&#160;</td>
                </tr>
                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:27.75pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company is headquartered in Holon, Israel. Its clinical development activities operate from its U.S. subsidiary in San Francisco, California.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:27.75pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has incurred losses in the amount of $<ix:nonFraction id="Fxbrl_20230802202124242" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,615</ix:nonFraction> during the six months ended June 30, 2023, has an accumulated deficit of $ <ix:nonFraction id="Fxbrl_20230802202128417" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">474,388</ix:nonFraction> as of June 30, 2023, and has an accumulated negative cash flow from operating activities in the amount of $ <ix:nonFraction id="Fxbrl_20230802202134755" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,617</ix:nonFraction> for the six months ended June 30, 2023. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements at the current level of yearly expenditures at least twelve months from the reporting date.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:27.75pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 5, 2013, the Company entered into a Research and Development Collaboration and License Agreement (&#8220;Bayer Agreement&#8221;) with Bayer Pharma AG (&#8220;Bayer&#8221;) for the research, development, and commercialization of antibody-based therapeutics against two novel Compugen-discovered immune checkpoint regulators.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the terms of the Bayer Agreement, the Company received an upfront payment of $<ix:nonFraction id="FFact_193" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="C_20130801to20130805" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction>, and additional aggregate milestone payments of approximately $<ix:nonFraction id="Fxbrl_20230728104443796" name="cgen:ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" contextRef="C_20130805" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,000</ix:nonFraction>.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On November 29, 2022, Bayer notified the Company that it had resolved to terminate, effective as of February 27, 2023, the Bayer Agreement.</span></span></div>
            <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          </div>
        </div>
        <div><ix:exclude>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 7</span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt;margin-bottom:0px"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:0pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:6pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO&#160;</strong></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>CONDENSED</strong></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong> CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
          </div>
          <div style="text-align:justify;line-height:1.25">
            <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>NOTE 1:-</span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>GENERAL (Cont.)</span></strong></span></span></p>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          </div>
        </ix:exclude></div>
        <div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:27.75pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective March 30, 2018, the Company entered into an exclusive license agreement with MedImmune Limited, the global biologics research and development arm of AstraZeneca (&#8220;AstraZeneca&#8221;) to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bi-specific and multi-specific antibody products derived from COM902. AstraZeneca has the right to create multiple products under this license and is solely responsible for all research, development and commercial activities under the agreement. Compugen received a $<ix:nonFraction id="Fxbrl_20230802201751108" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="C_20180301to20180330" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction> upfront payment and $<ix:nonFraction id="Fxbrl_20230802201758034" name="cgen:AccruedMilestonePayment" contextRef="C_20180301to20180330" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,500</ix:nonFraction> milestone payment out of up to $<ix:nonFraction id="Fxbrl_20230802201804474" name="cgen:ResearchAndDevelopmentArrangementPaymentsReceivable" contextRef="C_20180330" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200,000</ix:nonFraction> that the Company is eligible to receive in development, regulatory and commercial milestones for the first product as well as tiered royalties on future product sales. If additional products are developed, additional milestones and royalties would be due to Compugen for each product.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:54pt">&#160;</td>
                  <td style="width:31.5pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#8220;Master Clinical Agreement&#8221;) with Bristol Myers Squibb Company (&#8220;Bristol Myers Squibb&#8221;) to evaluate the safety and tolerability of Compugen&#8217;s COM701 in combination with Bristol Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors.<br />&#160;<br />Pursuant to the Master Clinical Agreement, as amended from time to time, Compugen sponsored the trials, which included the evaluation of the combination of COM701 and Opdivo&#174; &#177; Bristol Myers Squibb investigational anti-TIGIT, BMS-986207. Bristol Myers Squibb and Compugen each supplies its own compound(s) for the studies.<br />&#160;<br />In conjunction with the signing of the Master Clinical Agreement, Bristol Myers Squibb made a $<ix:nonFraction id="FFact_199" name="us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,000</ix:nonFraction> investment in Compugen, see Note 6a.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Among several amendments to the Master Clinical Agreement, on November 10, 2021, the agreement was further amended and in conjunction with the signing of the amendment to the Agreement, Bristol Myers Squibb made a $<ix:nonFraction id="Fxbrl_20220728112859416" name="us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue" contextRef="C_20211110" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction> investment in Compugen, see Note 6a.</span></span></span></div>
            <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>On August 3, 2022, the Company and Bristol Myers Squibb entered into a letter agreement pursuant to which the Master Clinical Agreement, as amended from time to time, was terminated as of such date.</span></span></span></span></span></div>
          </div>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
</div><div style="">
  <ix:nonNumeric id="Fxbrl_20230802203528979" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20230101to20230630" escape="true">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 2:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SIGNIFICANT ACCOUNTING POLICIES</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25;margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2022. The significant accounting policies applied in the annual financial statements of the Company as of December 31, 2022, are applied consistently in these interim consolidated financial statements, except as described below.</span></span></span></span></span></span></span></div>
        <div style="text-align:justify;line-height:1.25;margin-left:56.7pt">&#160;</div>
      </div>
      <div><ix:exclude>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 8</span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt;margin-bottom:0px"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:0pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:6pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO&#160;</strong></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>CONDENSED</strong></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong> CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
        <div style="margin-top:0pt;margin-bottom:0pt">
          <div style="margin-top:0pt;margin-bottom:0pt">
            <div style="margin-top:0pt;margin-bottom:0pt">
              <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;border:0px">

                  <tr style="margin-top:0pt;margin-bottom:0pt">
                    <td style="width:56.7pt;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 2:-</span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">
                      <div style="margin-top:0pt;margin-bottom:0pt;font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></div>
                    </td>
                  </tr>

              </table>
              <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
            </div>
          </div>
        </div>
      </ix:exclude></div>
      <div style="margin-top:0pt;margin-bottom:0pt">
        <div style="margin-top:0pt;margin-bottom:0pt">
          <div style="margin-top:0pt;margin-bottom:0pt">
            <div>
              <div>
                <ix:nonNumeric id="Fxbrl_20230803004059990" name="us-gaap:MarketableSecuritiesPolicy" contextRef="C_20230101to20230630" escape="true">
                  <div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span>Investments in marketable securities:</span></span></span></span></span></span></span></span></span></div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt">&#160;</div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span>The Company accounts for investments in marketable securities in accordance with ASC No. 320, &#8220;Investments - Debt Securities&#8221;.</span></span></span></span></span></span></span></span></span></div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt">&#160;</div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span>Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determinations at each balance sheet date. The Company classifies all of its debt securities as available-for-sale (&#8220;AFS&#8221;). Available-for-sale debt securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income (loss) in shareholders&#8217; equity. Realized gains and losses on sale of investments are included in financial income, net, and are derived using the specific identification method for determining the cost of securities sold.</span></span></span></span></span></span></span></span></span></div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization together with interest on securities is included in financial income, net.</span></span></span></span></span></span></span></div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt">&#160;</div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>At each reporting period, th</span></span></span></span></span></span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">e Company evaluates whethe</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>r declines in fair value below amortized cost are due to expected credit losses, as well as the Company&#8217;s ability and intent to hold the investment until a forecasted recovery occurs in accordance with ASC 326, Financial Instrument- Credit losses. Allowance for credit losses on AFS debt securities are recognized in the Company&#8217;s consolidated statements of income, and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive income (loss) in stockholders&#8217; equity.</span></span></span></span></span></span></span></div>
                  </div>
                </ix:nonNumeric>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
</div><div style="">
  <ix:nonNumeric id="FFact_202" name="cgen:UnauditedInterimConsolidatedFinancialStatementsTextBlock" contextRef="C_20230101to20230630" escape="true">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 3:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. </span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="margin-left:56.7pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:110%">Operating results for the six-month period ended June&#160;30, 2023, are not necessarily indicative of the results that may be expected for the year ended December 31, 2023.</span></span></span></div>
        <div style="margin-left:56.7pt;line-height:1.25;text-align:justify">&#160;</div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 9</span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt;margin-bottom:0px"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:0pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:6pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO&#160;</strong></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>CONDENSED</strong></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong> CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
</div><div style="">
  <div>
    <ix:nonNumeric id="Fxbrl_20230728102752242" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" contextRef="C_20230101to20230630" escape="true">
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>NOTE 4:-</span></span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:110%">MARKETABLE SECURITIES</span></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">&#160;</td>
            </tr>

        </table>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:56pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">The following is a summary of available-for-sale marketable securities as of June 30, 2023:</span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:56pt">&#160;</p>
        <ix:nonNumeric id="Fxbrl_20230728102812931" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" contextRef="C_20230101to20230630" escape="true">
          <div>
            <div>
              <div style="margin-left:56pt">
                <table border="0" cellpadding="0" cellspacing="0" style="width:90%">

                    <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
                      <td style="padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:left" valign="top">
                        <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left">&#160;</p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                      <td colspan="2" style="border-width:2px;border-bottom-style:solid;border-bottom-color:black;padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center" valign="bottom">
                        <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Amortized</strong></span></span></span><br /><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">cost</strong></span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                      <td colspan="2" style="border-width:2px;border-bottom-style:solid;border-bottom-color:black;padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center" valign="bottom">
                        <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Gross</strong></span></span></span><br /><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">unrealized </strong></span></span></span></p>
                        <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">gains</strong></span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                      <td colspan="2" style="border-width:2px;border-bottom-style:solid;border-bottom-color:black;padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center" valign="bottom">
                        <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Gross</strong></span></span></span><br /><strong style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">unrealized</strong></p>
                        <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">losses</strong></span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                      <td colspan="2" style="border-width:2px;border-bottom-style:solid;border-bottom-color:black;padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;vertical-align:bottom" valign="top">
                        <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt"><strong>Fair value</strong></span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                    </tr>
                    <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255);height:15px">
                      <td style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px" valign="top">
                        <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">Available-for-sale &#8211; matures within one year:</span></span></span></p>
                      </td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px">&#160;</td>
                      <td colspan="2" style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td colspan="2" style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td colspan="2" style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td colspan="2" style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                    </tr>
                    <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);height:15px">
                      <td style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;width:52%" valign="top">
                        <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">Governmental bonds</span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:1%">
                        <p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"><span style="font-size:10pt;text-align:left;margin:0px"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">$</span></span></span></p>
                      </td>
                      <td colspan="1" style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:9%" valign="bottom">
                        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20230728101843888" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_20230630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,551</ix:nonFraction></span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:1%">
                        <p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"><span style="font-size:10pt;text-align:left;margin:0px"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">$</span></span></span></p>
                      </td>
                      <td colspan="1" style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:9%" valign="bottom">
                        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><span style="-sec-ix-hidden:Fxbrl_20230728101901825">*</span>&#160;</span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:1%">
                        <p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"><span style="font-size:10pt;text-align:left;margin:0px"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">$</span></span></span></p>
                      </td>
                      <td colspan="1" style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:9%" valign="bottom">
                        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><span style="-sec-ix-hidden:Fxbrl_20230728101905592">*</span></span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:1%">
                        <p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"><span style="font-size:10pt;text-align:left;margin:0px"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">$</span></span></span></p>
                      </td>
                      <td colspan="1" style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:9%" valign="bottom">
                        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20230728101909777" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_20230630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,551</ix:nonFraction></span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                    </tr>

                </table>
              </div>
              <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:56pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">*&#160; &#160; &#160; &#160; &#160; Represents an amount lower than $1</span></span></span></p>
            </div>
          </div>
        </ix:nonNumeric>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:56pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">The Company did not have investments in marketable securities as of June 30, 2022.</span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:56pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">As of June 30, 2023, the Company did not record an allowance for credit losses for its available for sale marketable securities.</span></span></span></p>
      </div>
    </ix:nonNumeric>
    <p style="margin:0pt">&#160;</p>
  </div>
</div><div style="">
  <div>
    <div>
      <ix:nonNumeric id="Fxbrl_20230802221122558" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_20230101to20230630" escape="true">
        <div>
          <div>
            <div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="text-align:right;vertical-align:top;width:56.7pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 5:-</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">COMMITMENTS AND CONTINGENCIES</span></span></span>
                          <p style="margin:0pt">&#160;</p>
                        </div>
                      </td>
                    </tr>

                </table>
              </div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                  <tr>
                    <td style="width:56.7pt">&#160;</td>
                    <td style="width:27.75pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company provided bank guarantees in the amount of $<ix:nonFraction id="Fxbrl_20230802221055283" name="us-gaap:GuaranteeObligationsMaximumExposure" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">284</ix:nonFraction> in favor of its offices in Israel, car leases in Israel and credit card security for its U.S. subsidiary.</span></span>
                        <p style="margin:0pt">&#160;</p>
                      </div>
                    </td>
                  </tr>

              </table>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                  <tr>
                    <td style="width:56.7pt">&#160;</td>
                    <td style="width:27.75pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company received in the past grants from the office of the Israel Innovation Authority of the Israeli Ministry of Industry, Trade and Labor, formerly known as the Office of the Chief Scientist (&#8220;IIA&#8221;). The Company is not obligated to repay any amounts received from the IIA if it does not generate any income from products which incorporate technologies which were funded by such research program(s).</span></span>
                        <p style="margin:0pt">&#160;</p>
                      </div>
                    </td>
                  </tr>

              </table>
              <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">If income is generated from products which incorporate technologies which were funded by a research program, the Company is committed to pay royalties at a rate of between <ix:nonFraction id="Fxbrl_20220720062450451" name="cgen:RoyaltyPercentageBasedOnFutureRevenues" contextRef="C_20230101to20230630_srtRangeAxis_srtMinimumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction>% to <ix:nonFraction id="Fxbrl_20220720062556413" name="cgen:RoyaltyPercentageBasedOnFutureRevenues" contextRef="C_20230101to20230630_srtRangeAxis_srtMaximumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of future revenue generated from products that incorporate technologies that were funded by such research program(s), up to a maximum of <ix:nonFraction id="Fxbrl_20220720062648820" name="cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived" contextRef="C_20230101to20230630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum amount to be repaid is 100% plus interest at LIBOR).</span></span>
                <p style="margin:0pt">&#160;</p>
              </div>
              <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2023, the Company&#8217;s aggregate contingent obligations for payments to IIA, based on royalty-bearing participation received or accrued, net of royalties paid or accrued, totaled $<ix:nonFraction id="Fxbrl_20220720062746091" name="cgen:RoyaltyContingentObligations" contextRef="C_20230630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,800</ix:nonFraction>.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                  <tr>
                    <td style="width:56.7pt">&#160;</td>
                    <td style="width:27.75pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 25, 2012, the Company entered into an Antibodies Discovery Collaboration Agreement (the &#8220;Antibodies Discovery Agreement&#8221;) with a U.S. antibody technology company (&#8220;mAb Technology Company&#8221;), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement, the mAb Technology Company is entitled to certain royalties that could be eliminated upon payment of certain one-time fees (all milestone and royalties payments referred together as &#8220;Contingent Fees&#8221;). For the six-month periods ended June 30, 2023 and 2022, the Company did not incur Contingent Fees.</span></span></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="text-align:justify;margin-left:84pt;line-height:1.25;font-family:Times New Roman, Times, serif">&#160;</div>
          <div><ix:exclude>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 10</span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt;margin-bottom:0px"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:0pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:6pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO&#160;</strong></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>CONDENSED</strong></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong> CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </div>
            </div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 5:-</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">COMMITMENTS AND CONTINGENCIES </span><strong><span>(Cont.)</span></strong></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          </ix:exclude></div>
          <div>
            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                  <tr>
                    <td style="vertical-align:top;width:56.7pt">&#160;</td>
                    <td style="vertical-align:top;width:27.75pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
                    <td style="vertical-align:top;text-align:justify;width:auto">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On <ix:nonNumeric id="Fxbrl_20230802220955963" name="cgen:AgreementStartDate" contextRef="C_20230101to20230630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember" format="ixt:date-monthname-day-year-en">May 9, 2012</ix:nonNumeric>, the Company entered into agreement (the &#8220;May 2012 Agreement&#8221;) with a U.S. Business Development Strategic Advisor (&#8220;Advisor&#8221;) for the purpose of entering into transactions with pharma companies related to selected pipeline program candidates. Under the agreement, the Advisor was to be entitled to <ix:nonFraction id="Fxbrl_20230802221007541" name="cgen:ParticipationRights" contextRef="C_20230101to20230630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction>% of the cash considerations that may be received under such transactions. <ix:nonNumeric id="Fxbrl_20230802221014450" name="cgen:AgreementTerminationDescription" contextRef="C_20230101to20230630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember">In 2014, the May 2012 Agreement was terminated, except with respect to certain payments arising from the Bayer Agreement which survive termination of the May 2012 Agreement until August 5, 2025.</ix:nonNumeric></span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif">
                <p style="margin:0pt">&#160;</p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Bayer Agreement was terminated effective February 27, 2023 and no further payments to the Advisor are expected under the May 2012 Agreement.<br />&#160;<br />For the six months ended June 30, 2023 and 2022, the Company had not paid nor accrued any expenses related to the May 2012 Agreement.</span></span>
                <p style="margin:0pt">&#160;</p>
              </div>
              <div style="text-align:justify;line-height:1.25">
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                    <tr>
                      <td style="width:56.7pt">&#160;</td>
                      <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify">
                        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective as of January 5, 2018, the Company entered into a Commercial License Agreement (&#8220;CLA&#8221;) with a European cell line development company. Under the agreement the Company is required to pay an annual maintenance fee, certain amounts upon the occurrence of specified milestones events, and <ix:nonFraction id="Fxbrl_20230802221025410" name="cgen:PercentageOfRoyaltiesOnNetSales" contextRef="C_20180101to20180105_cgenGovernmentAndOtherGrantsAxis_cgenCommercialLicenseAgreementMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction>% royalties on annual net sales with respect to each commercialized product manufactured using the company&#8217;s cell line. Royalties due under the CLA are creditable against the annual maintenance fee. In addition, the Company may at any time prior to the occurrence of a specific milestone event buy-out the royalty payment obligations in a single fixed amount. For the six-month periods ended June 30, 2023 and 2022, the Company did not incur milestone payments.</span></span>
                          <p style="margin:0pt">&#160;</p>
                        </div>
                      </td>
                    </tr>

                </table>
              </div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                  <tr>
                    <td style="width:56.7pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective as of October 28, 2020, the Company entered into a collaboration agreement with a U.S. antibody discovery and optimization company for generation and optimization of therapeutic antibodies for the Company. Under the agreement, the Company is required to pay service fees per services performed and certain amounts upon the occurrence of specified milestones events, and single-digit percent royalties on annual net sales with respect to each product sold that comprises or contains one or more antibodies so generated or optimized. The royalty rate is dependent upon the product type and any third-party contribution. For the six-month periods ended June 30, 2023 and 2022 the Company did not incur milestone payments.</span></span></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
      </ix:nonNumeric>
    </div>
  </div>
  <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
</div><div style="">
  <ix:nonNumeric id="FFact_289" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" contextRef="C_20230101to20230630" escape="true">
    <div>
      <div>
        <div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>NOTE 6:-</span></span></span></span></span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>SHAREHOLDERS' EQUITY</span></span></span></span></span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>a.</span></span></span></span></span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>Issuance of Shares:</span></span></span></span></span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>On June 14, 2018, the Company entered into an agreement in connection with a registered direct offering (the &#8220;Offering&#8221;) of an aggregate of <ix:nonFraction id="FFact_223" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">5,316,457</ix:nonFraction> Ordinary Shares (the &#8220;RD Shares&#8221;) of the Company at a purchase price of $<ix:nonFraction id="FFact_224" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember" unitRef="USDPerShare" decimals="INF" format="ixt:num-dot-decimal">3.95</ix:nonFraction> per RD Share. In connection with the issuance of the RD Shares, the Company also issued warrants to purchase an aggregate of up to <ix:nonFraction id="FFact_225" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">4,253,165</ix:nonFraction> additional Ordinary Shares (the &#8220;Warrants&#8221;). The Warrants were exercisable at a price of $<ix:nonFraction id="FFact_226" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember" unitRef="USDPerShare" decimals="INF" format="ixt:num-dot-decimal">4.74</ix:nonFraction> per Ordinary Share and had a term of <ix:nonNumeric id="FFact_227" name="cgen:ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" contextRef="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric> from the date of issuance. The Offering was made pursuant to the Company&#8217;s Registration Statement. Proceeds from the Offering were $<ix:nonFraction id="FFact_228" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,767</ix:nonFraction> (net of $<ix:nonFraction id="FFact_229" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,233</ix:nonFraction> issuance expenses).</span></span></span></span></span></span></span></span></div>
            <div><ix:exclude>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
              <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                <div>
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 11</span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt;margin-bottom:0px"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:0pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:6pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO&#160;</strong></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>CONDENSED</strong></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong> CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
                </div>
              </div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                  <tr>
                    <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>NOTE 6:-</span></span></span></span></span></span></span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>SHAREHOLDERS&#8217; EQUITY (Cont.)</span></span></span></span></span></span></span></span></div>
                    </td>
                  </tr>

              </table>
            </ix:exclude></div>
          </div>
        </div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div>
          <div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>During the period from January 1, 2021 through June 30, 2023, warrants to purchase an aggregate of <ix:nonFraction id="Fxbrl_20230728024501070" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20230630_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">3,955,696</ix:nonFraction> Ordinary Shares were exercised with proceeds of approximately $<ix:nonFraction id="Fxbrl_20230728024514846" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_20210101to20230630_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,750</ix:nonFraction>, and the remaining warrants to purchase up to <ix:nonFraction id="Fxbrl_20230728024526061" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_20230630_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">297,469</ix:nonFraction> Ordinary Shares expired in June 2023.<br />&#160;</span></span></span></span></span></span></span></div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement with Bristol Myers Squibb to evaluate the safety and tolerability of the Company&#8217;s COM701 in combination with Bristol Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors. In conjunction with the Master Clinical Agreement, Bristol Myers Squibb made a $<ix:nonFraction id="FFact_235" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,000</ix:nonFraction> equity investment in the Company.</span></span></span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Under the terms of the securities purchase agreement, Bristol Myers Squibb purchased <ix:nonFraction id="FFact_236" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20181001to20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">2,424,243</ix:nonFraction> ordinary shares of the Company at a purchase price of $<ix:nonFraction id="FFact_237" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="USDPerShare" decimals="INF" format="ixt:num-dot-decimal">4.95</ix:nonFraction> per share. The share price represented a <ix:nonFraction id="FFact_238" name="cgen:PercentageOfClosingPrice" contextRef="C_20181001to20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">33</ix:nonFraction>% premium over the average closing price of the Company&#8217;s ordinary shares for twenty (20) Nasdaq trading days prior to the execution of the securities purchase agreement. The investment closed on October 12, 2018.</span></span></span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The premium over the fair market value in the amount of $<ix:nonFraction id="FFact_239" name="cgen:RelativeFairValueOfDeferredParticipation" contextRef="C_20230630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,121</ix:nonFraction> represents the relative fair value of deferred participation of Bristol Myers Squibb in R&#38;D expenses which are amortized over the period of the clinical trial based on the progress in the R&#38;D, in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221; and $<ix:nonFraction id="FFact_240" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" contextRef="C_20230101to20230630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,788</ix:nonFraction> (net of $<ix:nonFraction id="FFact_241" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20230101to20230630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction> issuance expenses) were considered equity investment.</span></span></span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In conjunction with the signing of the amendment to the Master Clinical Agreement in November 2021, Bristol Myers Squibb made a $<ix:nonFraction id="Fxbrl_20220720034631668" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction> investment in the Company, purchasing <ix:nonFraction id="Fxbrl_20220720034743180" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20211101to20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">2,332,815</ix:nonFraction> ordinary shares of the Company at a purchase price of $<ix:nonFraction id="Fxbrl_20220720034904580" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="USDPerShare" scale="0" decimals="5" format="ixt:num-dot-decimal">8.57333</ix:nonFraction> per share. The share price represented a <ix:nonFraction id="Fxbrl_20220720034949299" name="cgen:PercentageOfClosingPrice" contextRef="C_20211101to20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">33</ix:nonFraction>% premium over the closing price of Company&#8217;s ordinary shares on the last Nasdaq trading day immediately prior to the execution of the securities purchase agreement.</span></span></span></span></span></span></div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The premium over the fair market value in the amount of $<ix:nonFraction id="Fxbrl_20220720035100582" name="cgen:RelativeFairValueOfDeferredParticipation" contextRef="C_20230630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction> represents the relative fair value of deferred participation of Bristol Myers Squibb in R&#38;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&#38;D, in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221;) and $<ix:nonFraction id="Fxbrl_20220720035407188" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" contextRef="C_20230101to20230630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,958</ix:nonFraction> (net of $<ix:nonFraction id="Fxbrl_20220720035509163" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20230101to20230630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction> issuance expenses) were considered equity investment.</span></span></span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In March 2020, the Company entered into an underwriting agreement with SVB Leerink LLC and Stifel, Nicolaus &#38; Company, Incorporated, as representatives of the several underwriters relating to the issuance and sale in a public offering of <ix:nonFraction id="FFact_242" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20200301to20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">8,333,334</ix:nonFraction> of the Company&#8217;s ordinary shares at a price to the public of $<ix:nonFraction id="FFact_243" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="USDPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.00</ix:nonFraction> per share (and a price of $<ix:nonFraction id="FFact_244" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20200316_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="USDPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.46</ix:nonFraction> per share to the underwriters). Such shares were issued on March 16, 2020. In addition, the Company granted the underwriters a 30-day option to purchase additional ordinary shares at the price set forth above. On April 14, 2020, the Company issued and sold, pursuant to that underwriting agreement an additional <ix:nonFraction id="FFact_245" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20200401to20200414_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">483,005</ix:nonFraction> ordinary shares pursuant to the underwriters&#8217; option specified above. The Company sold a total of <ix:nonFraction id="FFact_246" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20200401to20200414_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">8,816,339</ix:nonFraction> ordinary shares in the offering with proceeds of $<ix:nonFraction id="FFact_247" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_20200401to20200414_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,147</ix:nonFraction> (net of $<ix:nonFraction id="FFact_248" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20200401to20200414_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,200</ix:nonFraction> issuance expenses).</span></span></span></span></span></span></div>
            <div><ix:exclude>
              <div style="line-height:1.25">&#160;</div>
              <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                <div>
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 12</span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt;margin-bottom:0px"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:0pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:6pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO&#160;</strong></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>CONDENSED</strong></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong> CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
                </div>
              </div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                  <tr>
                    <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>NOTE 6:-</span></span></span></span></span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>SHAREHOLDERS&#8217; EQUITY (Cont.)</span></span></span></span></span></span></div>
                    </td>
                  </tr>

              </table>
            </ix:exclude></div>
          </div>
        </div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div>
          <div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On January 31, 2023, the Company entered into a Sales Agreement with Leerink Partners LLC (previously known as SVB Securities LLC) (&#8220;Leerink Partners&#8221;), as sales agent, pursuant to which the Company may offer and sell, from time to time through Leerink Partners, its ordinary shares through an &#8220;at the market offering&#8221; (ATM). The offer and sale of our ordinary shares, if any, will be made pursuant to the Company&#8217;s shelf registration statement on Form F-3, as supplemented by a prospectus supplement. Pursuant to the applicable prospectus supplement, the Company may offer and sell up to $<ix:nonFraction id="Fxbrl_20230728031246595" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" contextRef="C_20230130to20230131_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,000</ix:nonFraction> of its ordinary shares. As of June 30, 2023, <ix:nonFraction id="Fxbrl_20230728031257218" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20230101to20230630_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">1,609,123</ix:nonFraction> shares were issued and sold through the ATM, with proceeds of approximately $<ix:nonFraction id="Fxbrl_20230728031311578" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_20230101to20230630_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,154</ix:nonFraction> (net of $<ix:nonFraction id="Fxbrl_20230728031320267" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20230101to20230630_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">458</ix:nonFraction> issuance expenses).</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>b.</span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share option plan:</span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>During the six-month period ended June 30, 2023, the Company&#8217;s Board of Directors granted <ix:nonFraction id="Fxbrl_20220720040533152" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="C_20230101to20230630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">19,500</ix:nonFraction> options to purchase ordinary shares of the Company to employees. The exercise prices for such options range from $<ix:nonFraction id="Fxbrl_20220720040558485" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="C_20230101to20230630" unitRef="USDPerShare" decimals="INF" format="ixt:num-dot-decimal">0.67</ix:nonFraction> to $<ix:nonFraction id="FFact_251" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="C_20230101to20230630" unitRef="USDPerShare" decimals="INF" format="ixt:num-dot-decimal">1.06</ix:nonFraction> per share, with vesting to occur in up to <ix:nonNumeric id="FFact_252" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20230101to20230630" format="ixt-sec:durwordsen">four years</ix:nonNumeric>.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The following table presents the assumptions used to estimate the fair value of the options granted in the periods presented:</span></span></span></span></div>
          </div>
        </div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="margin-left:84.45pt">
          <ix:nonNumeric id="Fxbrl_20220728002533924" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_20230101to20230630" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>Six months ended</span></span></span></span></span></span></span></span></span></span></div>
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>June 30,</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>2023</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>2022</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>Unaudited</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>Volatility</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><ix:nonFraction id="Fxbrl_20220727222002683" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_20230101to20230630" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">75.9</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20220727222015231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_20230101to20230630" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">76.4</ix:nonFraction></span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>%</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><ix:nonFraction id="Fxbrl_20220727222026940" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_20220101to20220630" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">69.4</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20220727222103489" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_20220101to20220630" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">72.0</ix:nonFraction></span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>%</span></span></span></span></span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>Risk-free interest rate</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><ix:nonFraction id="Fxbrl_20220727222244528" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_20230101to20230630" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.3</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20220727233307366" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_20230101to20230630" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>%</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><ix:nonFraction id="Fxbrl_20220727233317706" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_20220101to20220630" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.5</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20220727235651276" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_20220101to20220630" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>%</span></span></span></span></span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>Dividend yield</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><ix:nonFraction id="Fxbrl_20220727235701651" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20230101to20230630" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>%</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><ix:nonFraction id="Fxbrl_20220727235716123" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20220101to20220630" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>%</span></span></span></span></span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>Expected life (years)</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><ix:nonNumeric id="Fxbrl_20220727235725275" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20230101to20230630_srtRangeAxis_srtMinimumMember" format="ixt-sec:duryear">5.0</ix:nonNumeric>-<ix:nonNumeric id="Fxbrl_20220727235734670" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20230101to20230630_srtRangeAxis_srtMaximumMember" format="ixt-sec:duryear">5.1</ix:nonNumeric></span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><ix:nonNumeric id="Fxbrl_20230728030223347" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20220630_srtRangeAxis_srtMinimumMember" format="ixt-sec:duryear">5.0</ix:nonNumeric>-<ix:nonNumeric id="Fxbrl_20230728030231097" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20220630_srtRangeAxis_srtMaximumMember" format="ixt-sec:duryear">5.4</ix:nonNumeric></span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
      </div>
    </div>
    <div>
      <div>
        <div>
          <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div>
            <div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="color:rgb(0, 0, 0)">Weighted average fair value of options granted during the six-month periods ended June 30, 2023 and 2022 were $</span><ix:nonFraction id="FFact_267" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20230101to20230630" unitRef="USDPerShare" decimals="INF" format="ixt:num-dot-decimal">0.53</ix:nonFraction><span style="color:rgb(0, 0, 0)"> and $<ix:nonFraction id="FFact_268" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20220101to20220630" unitRef="USDPerShare" decimals="INF" format="ixt:num-dot-decimal">1.94</ix:nonFraction>, respectively.</span></span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="color:rgb(0, 0, 0)">During the six-month periods ended June 30, 2023 and 2022, the Company recorded share based compensation related to stock options in a total amount of $</span><ix:nonFraction id="FFact_269" name="us-gaap:StockOptionPlanExpense" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,782</ix:nonFraction><span style="color:rgb(0, 0, 0)"> and $<ix:nonFraction id="FFact_270" name="us-gaap:StockOptionPlanExpense" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,092</ix:nonFraction>, respectively.</span></span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="color:rgb(0, 0, 0)">As of June 30, 2023, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date was $</span><ix:nonFraction id="FFact_271" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,267</ix:nonFraction><span style="color:rgb(0, 0, 0)"> which is expected to be recognized over a weighted average period of approximately</span><span style="font-weight:bold;color:rgb(0, 0, 0)">&#160;</span><ix:nonNumeric id="FFact_272" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_20230101to20230630" format="ixt-sec:duryear">2.08</ix:nonNumeric><span style="color:rgb(0, 0, 0)"> years.</span></span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>For the six months ended June 30, 2023 and 2022, the total weighted average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were <ix:nonFraction id="Fxbrl_20220720041818515" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20230101to20230630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">7,460,568</ix:nonFraction><span style="color:rgb(0, 0, 0)">&#160;</span>and <ix:nonFraction id="FFact_274" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20220101to20220630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">8,504,958</ix:nonFraction>, respectively.</span></span></span></span></div>
              <div><ix:exclude>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
                <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                  <div>
                    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 13</span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt;margin-bottom:0px"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:0pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:6pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO&#160;</strong></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>CONDENSED</strong></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong> CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
                  </div>
                </div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                    <tr>
                      <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>NOTE 6:-</span></span></span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify">
                        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>SHAREHOLDERS&#8217; EQUITY (Cont.)</span></span></span></span></div>
                      </td>
                    </tr>

                </table>
              </ix:exclude></div>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                  <tr>
                    <td style="width:56.7pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>c.</span></span></span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Employee Stock Purchase Plan:</span></span></span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company selected the Black-Scholes-Merton option-pricing model as the most appropriate fair value method for its share-option awards and Employee Share Purchase Plan (&#8220;ESPP&#8221;).</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>As of<span style="color:rgb(0, 0, 0)"> June 30, 2023 and </span>since its adoption<span style="color:rgb(0, 0, 0)">, </span><ix:nonFraction id="FFact_275" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="C_20230101to20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">275,854</ix:nonFraction><span style="color:rgb(0, 0, 0)"> Ordinary Shares had been purchased under the ESPP and </span><ix:nonFraction id="FFact_276" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">324,146</ix:nonFraction><span style="color:rgb(0, 0, 0)"> Ordinary Shares were available for future issuance under the ESPP.</span></span></span></span></span></span></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">&#160;</div>
            </div>
          </div>
          <div>
            <div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The following table presents the assumptions used to estimate the fair value of ESPP granted in the periods presented:</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="margin-left:81pt">
                <ix:nonNumeric id="Fxbrl_20220728002557752" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_20230101to20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" escape="true">
                  <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                          <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Six months ended</span></span></span></span></div>
                          <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>June 30,</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                          <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                          <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                          <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Unaudited</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:middle" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:middle" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                          <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Volatility</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_277" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_20230101to20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220720042810087" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">65</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20220720042816078" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">70</ix:nonFraction></span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%" valign="bottom">
                          <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Risk-free interest rate</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_280" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_20230101to20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220720042753766" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.1</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20220720042801271" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                          <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Dividend yield</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_283" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20230101to20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220720042946790" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%" valign="bottom">
                          <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected life (years)</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="-sec-ix-hidden:FFact_286">-</span></span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="Fxbrl_20220720042714542" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" format="ixt-sec:duryear">0.5</ix:nonNumeric></span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                      </tr>

                  </table>
                </ix:nonNumeric>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="color:rgb(0, 0, 0)">During the six-month periods ended June 30, 2023 and 2022, the Company recorded ESPP compensation in a total amount of $</span><ix:nonFraction id="Fxbrl_20220720043008949" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" contextRef="C_20230101to20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction><span style="color:rgb(0, 0, 0)"> and $<ix:nonFraction id="FFact_288" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">97</ix:nonFraction>.</span></span></span></span></span></div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
</div><div style="">
  <div>
    <div>
      <ix:nonNumeric id="Fxbrl_20220727231501241" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" contextRef="C_20230101to20230630" escape="true">
        <div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 7:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">FINANCIAL AND OTHER INCOME, NET</span></p>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;</span></span></span></div>
          <div>
            <div style="margin-left:56pt">
              <ix:nonNumeric id="Fxbrl_20220727231515518" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" contextRef="C_20230101to20230630" escape="true">
                <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                        <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest income</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_290" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,671</ix:nonFraction></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_291" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">463</ix:nonFraction></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:2px;width:76%" valign="bottom">
                        <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exchange rate differences and other</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220720002002984" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_293" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">316</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:4px;width:76%" valign="bottom">
                        <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_294" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,697</ix:nonFraction></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_295" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">779</ix:nonFraction></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>

                </table>
              </ix:nonNumeric>
            </div>
          </div>
        </div>
      </ix:nonNumeric>
      <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 14</span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt;margin-bottom:0px"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:0pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:6pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO&#160;</strong></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>CONDENSED</strong></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong> CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
    </div>
  </div>
</div><div style="">
      <div>
        <div>
          <ix:nonNumeric id="Fxbrl_20220727224715083" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_20230101to20230630" escape="true">
            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 8:-</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>RELATED PARTY BALANCES AND TRANSACTIONS</strong></span></p>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <ix:nonNumeric id="Fxbrl_20220728112628625" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" contextRef="C_20230101to20230630" escape="true">
                <div>
                  <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-left:56.7pt"><span style="font-family:Times New Roman,Times,serif"><span>Balances with related parties:</span></span></span></div>
                  <div>
                    <div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                      <div style="margin-left:56.7pt">
                        <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                            <tr>
                              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                                <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span>June 30,</span></strong></span></span></span></span></div>
                                <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span>2023</span></strong></span></span></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                                <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span>December&#160;31,</span></strong></span></span></span></span></div>
                                <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span>2022</span></strong></span></span></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                            </tr>
                            <tr>
                              <td rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" rowspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;border-bottom:2px solid black" valign="bottom">
                                <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>Unaudited</span></strong></span></span></div>
                              </td>
                              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                            </tr>
                            <tr>
                              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                            </tr>
                            <tr>
                              <td style="vertical-align:top;font-family:Times New Roman, Times, serif;padding-bottom:4px;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Trade and other payables (a)</span></span></span></div>
                              </td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                              </td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_298" name="cgen:TradeAndOtherPayablesRelatedParties" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></span></span></div>
                              </td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                <div style="line-height:1.25;font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                <div style="line-height:1.25;font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_299" name="cgen:TradeAndOtherPayablesRelatedParties" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">83</ix:nonFraction></span></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                            </tr>

                        </table>
                      </div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
                      <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-left:56.7pt"><span style="font-family:Times New Roman,Times,serif"><span>Related parties' expenses:</span></span></span></div>
                      <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                      <div style="margin-left:56.7pt">
                        <div>
                          <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                              <tr>
                                <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>Six months ended</span></strong></span></span></div>
                                  <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>June 30,</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>2023</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>2022</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>Unaudited</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
                                  <div style="line-height:1.25;text-indent:-8.5pt;margin-left:11.35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Amounts charged to:</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:top;font-family:Times New Roman, Times, serif;padding-bottom:4px;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                                  <div style="line-height:1.25;text-indent:-8.5pt;margin-left:11.35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Research and development expenses (a)</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_300" name="us-gaap:CostsAndExpensesRelatedParty" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_301" name="us-gaap:CostsAndExpensesRelatedParty" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">114</ix:nonFraction></span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                              </tr>

                          </table>
                        </div>
                      </div>
                    </div>
                  </div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;width:56.7pt">&#160;</td>
                        <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:27.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(a)</span></span></span></td>
                        <td style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, serif;width:auto">
                          <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:footnote id="FN20220720121444312" xml:lang="en-US">The Company incurred expenses for research and development services provided by related party for cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies.</ix:footnote></span></span></span></div>
                        </td>
                      </tr>

                  </table>
                </div>
              </ix:nonNumeric>
            </div>
          </ix:nonNumeric>
          <p style="margin:0pt">&#160;</p>
        </div>
      </div>
    </div><div style="">
  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">
    <ix:nonNumeric id="Fxbrl_20220728193545297" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_20230101to20230630" escape="true">
      <div>
        <div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 9:-</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SUBSEQUENT EVENTS</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 3, 2023, following recommendation of the compensation committee, the Company&#8217;s board of directors reduced the total number of shares reserved for issuance under the Company&#8217;s 2010 Plan by <ix:nonFraction id="Fxbrl_20230728015337735" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_20230803_usgaapPlanNameAxis_cgenPlan2010Member_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">500,000</ix:nonFraction> and the total number of shares reserved for issuance under the ESPP by <ix:nonFraction id="Fxbrl_20230728015343566" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_20230803_usgaapPlanNameAxis_cgenEmployeeSharePurchasePlanMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">210,000</ix:nonFraction>.</span></span></div>
          </div>
        </div>
      </div>
    </ix:nonNumeric>
    <div style="text-align:justify;margin-left:56.9pt;line-height:1.25">&#160;</div>
  </div>
  <div style="text-align:center;margin-top:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span style="color:rgb(0, 0, 0);font-weight:normal;font-style:normal">F - 15</span></span></span></span></span></span>
    <hr style="border:none;border-bottom:4px solid black;border-top:1px solid black;height:10px;width:100%;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center" />
  </div>
</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>4
<FILENAME>exhibit_99-3.htm
<DESCRIPTION>EXHIBIT 99.3
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="margin-left: 5.4pt; line-height: 1.25;"><img width="745" height="3" src="image0.jpg"></div>
    <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 99.3</font></u><br>
    </div>
    <div style="line-height: 1.25"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">FINANCIAL CONDITION</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="margin-left: 5.35pt; line-height: 1.25; font-weight: bold;">RESULTS OF OPERATIONS</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="margin-left: 5.35pt; line-height: 1.25; font-style: italic; font-weight: bold;">Six months ended June 30, 2023 and 2022</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="margin-right: 5.2pt; margin-left: 5.35pt; line-height: 1.25;"><font style="font-style: italic;">Research and Development Expenses</font>. Research and development, or R&amp;D expenses increased by approximately 9% to approximately $15.2
      million for the first six months of 2023 from approximately $14.0 million for the comparable period of 2022. The increase is mainly due to lower amortization of the deferred participation in R&amp;D expenses following the termination of the agreement
      with Bristol Myers Squibb in the third quarter of 2022 and an increase in preclinical and CMC activities associated with COM503, offset by a decrease in clinical trial expenses, in headcount and by currency exchange effect. R&amp;D expenses, as a
      percentage of total operating expenses, increased to 75% for the first six months of 2023 from 71% for the comparable period of 2022.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="margin-right: 9.2pt; margin-left: 5.35pt; line-height: 1.25;"><font style="font-style: italic;">Marketing and Business Development Expenses</font>. Marketing and business development expenses decreased by approximately 65% to approximately
      $0.2 million for the first six months of 2023 from approximately $0.5 million for the comparable period of 2022. The decrease is mainly due to headcount reduction. Marketing and business development expenses, as a percentage of total operating
      expenses, decreased to 1% for the first six months of 2023 from 2% for the comparable period of 2022.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="margin-right: 5.2pt; margin-left: 5.35pt; line-height: 1.25;"><font style="font-style: italic;">General and Administrative Expenses</font>. General and administrative expenses decreased by approximately 4% to approximately $5.0 million for
      the first six months of 2023 from approximately $5.2 million for the comparable period of 2022. The decrease is mainly due to a reduction in the cost of our D&amp;O insurance premium and currency exchange effects. General and administrative expenses,
      as a percentage of total operating expenses, decreased to 24% for the first six months of 2023 from 26% for the comparable period of 2022.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="margin-right: 5.2pt; margin-left: 5.4pt; line-height: 1.25;"><font style="font-style: italic;">Financial and other Income, Net</font>. Financial and other income, net, were approximately $1.7 million for the first six months of 2023
      compared with approximately $0.8 million for the comparable period of 2022. The increase is mainly due to increased interest income due to higher interest rates in the market, offset by a lower level of cash and deposit balances and by currency
      exchange effects.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="line-height: 1.25"> <br>
    </div>
    <div style="margin-left: 5.35pt; line-height: 1.25; font-weight: bold;">LIQUIDITY AND CAPITAL RESOURCES</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="margin-left: 5.35pt; line-height: 1.25;"><font style="font-style: italic;">Net Cash Used in Operating Activities. </font>Net cash used in operating activities was approximately $18.6 million in the first six months of 2023 compared with
      approximately $20.7 million in the comparable period of 2022. The lower net cash used in operating activities during the first six months of 2023 is mainly due to the lower level of cash expenses related to clinical, other R&amp;D activities and
      headcount compared to the first six months of 2022.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="margin-right: 9.2pt; margin-left: 5.35pt; line-height: 1.25;"><font style="font-style: italic;">Net Cash Provided by Investing Activities. </font>Net cash provided by investing activities during the first six months of 2023 was
      approximately $23.5 million compared with approximately $20.2 million in the comparable period of 2022. Changes in net cash provided by investing activities is mainly due to changes in the level of cash deposited or withdrawn from bank deposits and
      due to investments in marketable securities. Net cash provided by investing activities is dependent on capital raising, cash needs to fund our operating activities and changes in the level of the Company&#8217;s cash and cash equivalents.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="margin-left: 5.35pt; line-height: 1.25;"><font style="font-style: italic;">Net Cash Provided by Financing Activities. </font>Net cash provided by financing activities was $1.4 million in the first six months of 2023 compared with $0.4
      million in the comparable period of 2022. The net cash provided in the first six months of 2023 is due to net proceeds received from sales of ordinary shares in the first six months of 2023 under the Company&#8217;s existing at the market offering facility
      pursuant to a sales agreement with Leerink Partners, compared to proceeds received from exercise of employee share options and ESPP shares in the comparable period of 2022.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="margin-left: 5.4pt; line-height: 1.25;"><font style="font-style: italic;">Net Liquidity. </font>Liquidity refers to liquid financial assets available to fund the Company&#8217;s business operations and pay for near-term obligations. These liquid
      financial assets mostly consist of cash and cash equivalents, as well as short-term bank deposits and investment in marketable securities. As of June 30, 2023, the Company had total cash, cash equivalents, restricted cash, short-term bank deposits
      and investment in marketable securities of approximately $66.5 million.</div>
    <div style="margin-left: 5.4pt; line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25">
      <div></div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cgen-20230630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:cgen="http://cgen.com/20230630" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" targetNamespace="http://cgen.com/20230630" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
  <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://cgen.com/role/cgen-daei1" id="cgen-daei1">
        <link:definition>0001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-cbs" id="cgen-cbs">
        <link:definition>0002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-cbsp" id="cgen-cbsp">
        <link:definition>0003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-csocl" id="cgen-csocl">
        <link:definition>0004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-socise1" id="cgen-socise1">
        <link:definition>0005 - Statement - CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>0006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-g" id="cgen-g">
        <link:definition>0007 - Disclosure - GENERAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sap1" id="cgen-sap1">
        <link:definition>0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/UnauditedInterimConsolidatedFinancialStatements" id="UnauditedInterimConsolidatedFinancialStatements">
        <link:definition>0009 - Disclosure - UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/MARKETABLESECURITIES" id="MARKETABLESECURITIES">
        <link:definition>0010 - Disclosure - MARKETABLE SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-cac" id="cgen-cac">
        <link:definition>0011 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-se1" id="cgen-se1">
        <link:definition>0012 - Disclosure - SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-fin" id="cgen-fin">
        <link:definition>0013 - Disclosure - FINANCIAL AND OTHER INCOME, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-rpbat" id="cgen-rpbat">
        <link:definition>0014 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/SUBSEQUENTEVENTS" id="SUBSEQUENTEVENTS">
        <link:definition>0015 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies" id="Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/MARKETABLESECURITIESTables" id="MARKETABLESECURITIESTables">
        <link:definition>0017 - Disclosure - MARKETABLE SECURITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-set" id="cgen-set">
        <link:definition>0018 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-fint" id="cgen-fint">
        <link:definition>0019 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables" id="RelatedPartyBalancesAndTransactionsTables">
        <link:definition>0020 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-gd1" id="cgen-gd1">
        <link:definition>0021 - Disclosure - GENERAL (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/MARKETABLESECURITIESDetails" id="MARKETABLESECURITIESDetails">
        <link:definition>0022 - Disclosure - MARKETABLE SECURITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>0023 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails" id="ShareholdersEquityIssuanceOfSharesDetails">
        <link:definition>0024 - Disclosure - SHAREHOLDERS' EQUITY (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails" id="ShareholdersEquityScheduleOfStock-basedCompensationDetails">
        <link:definition>0025 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of fair value assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-find" id="cgen-find">
        <link:definition>0026 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-rpbatd" id="cgen-rpbatd">
        <link:definition>0027 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails" id="SUBSEQUENTEVENTSNarrativeDetails">
        <link:definition>0028 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AccretionOfDiscountOnMarketableSecurities" id="cgen_AccretionOfDiscountOnMarketableSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AccruedMilestonePayment" id="cgen_AccruedMilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AgreementMember" id="cgen_AgreementMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgreementStartDate" id="cgen_AgreementStartDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgreementTerminationDescription" id="cgen_AgreementTerminationDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmountIncurredMilestonePayments" id="cgen_AmountIncurredMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AtMarketOfferingProgramMember" id="cgen_AtMarketOfferingProgramMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" id="cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CollaborationAgreementWithUSAntibodyCompanyMember" id="cgen_CollaborationAgreementWithUSAntibodyCompanyMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CollaborativeArrangementsMember" id="cgen_CollaborativeArrangementsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CollaborativeArrangementsTwoMember" id="cgen_CollaborativeArrangementsTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommercialLicenseAgreementMember" id="cgen_CommercialLicenseAgreementMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ContingentFees" id="cgen_ContingentFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredParticipationOfBmsInRdExpenses" id="cgen_DeferredParticipationOfBmsInRdExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DevelopmentRegulatoryAndCommercialMilestonesCompensation" id="cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DocumentAndEntityInformationAbstract" id="cgen_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmployeeSharePurchasePlanMember" id="cgen_EmployeeSharePurchasePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FinancialIncomeExpenseNet" id="cgen_FinancialIncomeExpenseNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="GovernmentAndOtherGrantsAxis" id="cgen_GovernmentAndOtherGrantsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="GovernmentAndOtherGrantsDomain" id="cgen_GovernmentAndOtherGrantsDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GovernmentAndOtherGrantsLineItems" id="cgen_GovernmentAndOtherGrantsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GovernmentAndOtherGrantsMember" id="cgen_GovernmentAndOtherGrantsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GovernmentAndOtherGrantsTable" id="cgen_GovernmentAndOtherGrantsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" id="cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" id="cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IssuanceExpenses" id="cgen_IssuanceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LongTermDeferredParticipationinResearchAndDevelopmentExpenses" id="cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MasterClinicalAgreementMember" id="cgen_MasterClinicalAgreementMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MaximumAuthorizedProceedsFromIssuanceOfCommonStock" id="cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MaximumRoyaltyRepaidAsPercentageOfGrantReceived" id="cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="May2012AgreementMember" id="cgen_May2012AgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" id="cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsExercised" id="cgen_NumberOfWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ParticipationRights" id="cgen_ParticipationRights" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfClosingPrice" id="cgen_PercentageOfClosingPrice" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfRoyaltiesOnNetSales" id="cgen_PercentageOfRoyaltiesOnNetSales" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Plan2010Member" id="cgen_Plan2010Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PurchaseOfPropertyAndEquipmentAsNonCashTransaction" id="cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ReceivablesOnAccountOfShares" id="cgen_ReceivablesOnAccountOfShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RegisteredDirectOfferingMember" id="cgen_RegisteredDirectOfferingMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RelatedPartyBalancesAndTransactionsAbstract" id="cgen_RelatedPartyBalancesAndTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RelativeFairValueOfDeferredParticipation" id="cgen_RelativeFairValueOfDeferredParticipation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable" id="cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentArrangementPaymentsReceivable" id="cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" id="cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" id="cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentGrantOneMember" id="cgen_ResearchAndDevelopmentGrantOneMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RetainerFee" id="cgen_RetainerFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RoyaltyContingentObligations" id="cgen_RoyaltyContingentObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RoyaltyPercentageBasedOnFutureRevenues" id="cgen_RoyaltyPercentageBasedOnFutureRevenues" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SalesAgreementWithLeerinkPartnerLlcMember" id="cgen_SalesAgreementWithLeerinkPartnerLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeverancePayFundNonCurrent" id="cgen_SeverancePayFundNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SeverancePayNet" id="cgen_SeverancePayNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" id="cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" id="cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueWarrantsExercised" id="cgen_StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="SupplementalRightOfUseAssetAndOperatingLeaseLiability" id="cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SvbLeerinkLlcAndStifelNicolausAndCompanyMember" id="cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TradeAndOtherPayablesRelatedParties" id="cgen_TradeAndOtherPayablesRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="UnauditedInterimConsolidatedFinancialStatementsAbstract" id="cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnauditedInterimConsolidatedFinancialStatementsTextBlock" id="cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnderwritersMember" id="cgen_UnderwritersMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>cgen-20230630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#cgen-cbs" roleURI="http://cgen.com/role/cgen-cbs"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#cgen-csocl" roleURI="http://cgen.com/role/cgen-csocl"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://cgen.com/role/ConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#cgen-find" roleURI="http://cgen.com/role/cgen-find"/>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-cbs">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_8"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SeverancePayFundNonCurrent" xlink:label="loc_cgen_SeverancePayFundNonCurrent_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_25"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_OtherShortTermInvestments_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsNoncurrent_8" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_8" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8" xlink:to="loc_cgen_SeverancePayFundNonCurrent_9" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_10" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_11" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_13" xlink:to="loc_us-gaap_LiabilitiesCurrent_14" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_14" xlink:to="loc_us-gaap_AccountsPayableCurrent_14" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_14" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_15" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_14" xlink:to="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_16" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_14" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_17" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_13" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_19" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_19" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_19" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_19" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_20" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_19" xlink:to="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_21" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_13" xlink:to="loc_us-gaap_StockholdersEquity_23" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_23" xlink:to="loc_us-gaap_CommonStockValue_23" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_23" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_24" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_23" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_25" order="20" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-csocl">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaap_BusinessDevelopment_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xlink:to="loc_us-gaap_OperatingExpenses_2" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2" xlink:to="loc_us-gaap_BusinessDevelopment_3" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xlink:to="loc_cgen_FinancialIncomeExpenseNet_6" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AccretionOfDiscountOnMarketableSecurities" xlink:label="loc_cgen_AccretionOfDiscountOnMarketableSecurities_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_25"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ShareBasedCompensation_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_AccretionOfDiscountOnMarketableSecurities_3" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_4" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_Depreciation_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_SeverancePayNet_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_7" order="60" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8" order="70" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9" order="80" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_10" order="90" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_11" order="100" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_12" order="110" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_13" order="120" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_14" order="130" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_15" order="140" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_17" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_18" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_19" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_20" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_21" order="40" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_23" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_23" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_23" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_23" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_24" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_23" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_25" order="20" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-find">
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cgen_FinancialIncomeExpenseNet_0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cgen_FinancialIncomeExpenseNet_0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2" order="10" use="optional" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>cgen-20230630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#cgen-socise1" roleURI="http://cgen.com/role/cgen-socise1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#cgen-set" roleURI="http://cgen.com/role/cgen-set"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#CommitmentsAndContingenciesDetails" roleURI="http://cgen.com/role/CommitmentsAndContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#ShareholdersEquityIssuanceOfSharesDetails" roleURI="http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#ShareholdersEquityScheduleOfStock-basedCompensationDetails" roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#SUBSEQUENTEVENTSNarrativeDetails" roleURI="http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#MARKETABLESECURITIESDetails" roleURI="http://cgen.com/role/MARKETABLESECURITIESDetails"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-socise1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_20"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_RetainedEarningsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_12" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_NumberOfWarrantsExercised_13" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_14" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_15" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_16" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_17" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_18" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_19" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_20" order="130" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-set">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_us-gaap_EmployeeStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_GovernmentAndOtherGrantsLineItems" xlink:label="loc_cgen_GovernmentAndOtherGrantsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_GovernmentAndOtherGrantsTable" xlink:label="loc_cgen_GovernmentAndOtherGrantsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyLeaseGuaranteeMember" xlink:label="loc_us-gaap_PropertyLeaseGuaranteeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IL" xlink:label="loc_country_IL_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_GovernmentAndOtherGrantsMember" xlink:label="loc_cgen_GovernmentAndOtherGrantsMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="loc_cgen_GovernmentAndOtherGrantsDomain_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_CommercialLicenseAgreementMember" xlink:label="loc_cgen_CommercialLicenseAgreementMember_19"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="loc_cgen_GovernmentAndOtherGrantsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="loc_us-gaap_SupplyCommitmentAxis_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_23"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_CollaborationAgreementWithUSAntibodyCompanyMember" xlink:label="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_28"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_29"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_30"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_31"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_32"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_33"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_35"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_36"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_37"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_PercentageOfRoyaltiesOnNetSales" xlink:label="loc_cgen_PercentageOfRoyaltiesOnNetSales_38"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AmountIncurredMilestonePayments" xlink:label="loc_cgen_AmountIncurredMilestonePayments_39"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_GovernmentAndOtherGrantsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_1" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_1" xlink:to="loc_us-gaap_PropertyLeaseGuaranteeMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_1" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_srt_StatementGeographicalAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5" xlink:to="loc_srt_SegmentGeographicalDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5" xlink:to="loc_country_IL_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5" xlink:to="loc_srt_SegmentGeographicalDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_9" xlink:to="loc_us-gaap_GainContingencyNatureDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingencyNatureDomain_9" xlink:to="loc_cgen_GovernmentAndOtherGrantsMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_9" xlink:to="loc_us-gaap_GainContingencyNatureDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_srt_RangeAxis_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_13" xlink:to="loc_srt_RangeMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_13" xlink:to="loc_srt_MinimumMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_13" xlink:to="loc_srt_MaximumMember_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_13" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsAxis_18" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_18" xlink:to="loc_cgen_GovernmentAndOtherGrantsDomain_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_18" xlink:to="loc_cgen_May2012AgreementMember_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_18" xlink:to="loc_cgen_CommercialLicenseAgreementMember_19" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_18" xlink:to="loc_cgen_GovernmentAndOtherGrantsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_us-gaap_SupplyCommitmentAxis_23" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SupplyCommitmentAxis_23" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_23" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_23" xlink:to="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_23" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SupplyCommitmentAxis_23" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_28" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_29" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_30" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_RoyaltyContingentObligations_31" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_ContingentFees_32" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_ParticipationRights_33" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_RetainerFee_34" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_35" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_AgreementStartDate_36" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_AgreementTerminationDescription_37" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_PercentageOfRoyaltiesOnNetSales_38" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_AmountIncurredMilestonePayments_39" order="120" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AtMarketOfferingProgramMember" xlink:label="loc_cgen_AtMarketOfferingProgramMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AgreementMember" xlink:label="loc_cgen_AgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SalesAgreementWithLeerinkPartnerLlcMember" xlink:label="loc_cgen_SalesAgreementWithLeerinkPartnerLlcMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_22"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_30"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_32"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_33"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_DeferredParticipationOfBmsInRdExpenses" xlink:label="loc_cgen_DeferredParticipationOfBmsInRdExpenses_34"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RelativeFairValueOfDeferredParticipation" xlink:label="loc_cgen_RelativeFairValueOfDeferredParticipation_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_51"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_52"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_AtMarketOfferingProgramMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_AgreementMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_MasterClinicalAgreementMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_CollaborativeArrangementsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_CollaborativeArrangementsTwoMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_SalesAgreementWithLeerinkPartnerLlcMember_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_cgen_RegisteredDirectOfferingMember_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_cgen_UnderwritersMember_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_us-gaap_WarrantMember_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_17" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_17" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_17" xlink:to="loc_us-gaap_EmployeeStockMember_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_17" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_22" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_23" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_24" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_25" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_26" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_27" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_28" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_29" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_30" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_31" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_32" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_PercentageOfClosingPrice_33" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_DeferredParticipationOfBmsInRdExpenses_34" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_RelativeFairValueOfDeferredParticipation_35" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_36" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_37" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_38" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_39" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_40" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_41" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_42" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_43" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_44" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockOptionPlanExpense_45" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_46" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_47" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_48" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_49" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_50" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_51" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_52" order="310" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_17"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_us-gaap_EmployeeStockMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_14" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_15" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_16" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_17" order="70" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_Plan2010Member" xlink:label="loc_cgen_Plan2010Member_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_EmployeeSharePurchasePlanMember" xlink:label="loc_cgen_EmployeeSharePurchasePlanMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_PlanNameAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5" xlink:to="loc_cgen_Plan2010Member_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5" xlink:to="loc_cgen_EmployeeSharePurchasePlanMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_11" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/MARKETABLESECURITIESDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9" order="40" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>cgen-20230630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AccretionOfDiscountOnMarketableSecurities" xlink:label="loc_cgen_AccretionOfDiscountOnMarketableSecurities_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AccretionOfDiscountOnMarketableSecurities" xlink:label="loc_cgen_AccretionOfDiscountOnMarketableSecurities_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AccretionOfDiscountOnMarketableSecurities" xlink:label="loc_cgen_AccretionOfDiscountOnMarketableSecurities_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AccruedMilestonePayment" xlink:label="loc_cgen_AccruedMilestonePayment_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AccruedMilestonePayment" xlink:label="loc_cgen_AccruedMilestonePayment_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AccruedMilestonePayment" xlink:label="loc_cgen_AccruedMilestonePayment_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AgreementMember" xlink:label="loc_cgen_AgreementMember_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AgreementMember" xlink:label="loc_cgen_AgreementMember_8"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AmountIncurredMilestonePayments" xlink:label="loc_cgen_AmountIncurredMilestonePayments_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AmountIncurredMilestonePayments" xlink:label="loc_cgen_AmountIncurredMilestonePayments_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AtMarketOfferingProgramMember" xlink:label="loc_cgen_AtMarketOfferingProgramMember_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AtMarketOfferingProgramMember" xlink:label="loc_cgen_AtMarketOfferingProgramMember_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AtMarketOfferingProgramMember" xlink:label="loc_cgen_AtMarketOfferingProgramMember_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_19"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_21"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_CollaborationAgreementWithUSAntibodyCompanyMember" xlink:label="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_22"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_CollaborationAgreementWithUSAntibodyCompanyMember" xlink:label="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_23"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_24"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_25"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_26"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_27"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_CommercialLicenseAgreementMember" xlink:label="loc_cgen_CommercialLicenseAgreementMember_28"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_CommercialLicenseAgreementMember" xlink:label="loc_cgen_CommercialLicenseAgreementMember_29"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_30"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_31"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_32"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_DeferredParticipationOfBmsInRdExpenses" xlink:label="loc_cgen_DeferredParticipationOfBmsInRdExpenses_33"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_DeferredParticipationOfBmsInRdExpenses" xlink:label="loc_cgen_DeferredParticipationOfBmsInRdExpenses_34"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_DeferredParticipationOfBmsInRdExpenses" xlink:label="loc_cgen_DeferredParticipationOfBmsInRdExpenses_35"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation" xlink:label="loc_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_36"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation" xlink:label="loc_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_37"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_DocumentAndEntityInformationAbstract" xlink:label="loc_cgen_DocumentAndEntityInformationAbstract_38"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_DocumentAndEntityInformationAbstract" xlink:label="loc_cgen_DocumentAndEntityInformationAbstract_39"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_EmployeeSharePurchasePlanMember" xlink:label="loc_cgen_EmployeeSharePurchasePlanMember_40"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_EmployeeSharePurchasePlanMember" xlink:label="loc_cgen_EmployeeSharePurchasePlanMember_41"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_42"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_43"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_44"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_45"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_46"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_47"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_48"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_GovernmentAndOtherGrantsLineItems" xlink:label="loc_cgen_GovernmentAndOtherGrantsLineItems_49"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_GovernmentAndOtherGrantsLineItems" xlink:label="loc_cgen_GovernmentAndOtherGrantsLineItems_50"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_GovernmentAndOtherGrantsMember" xlink:label="loc_cgen_GovernmentAndOtherGrantsMember_51"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_GovernmentAndOtherGrantsMember" xlink:label="loc_cgen_GovernmentAndOtherGrantsMember_52"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_GovernmentAndOtherGrantsTable" xlink:label="loc_cgen_GovernmentAndOtherGrantsTable_53"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_GovernmentAndOtherGrantsTable" xlink:label="loc_cgen_GovernmentAndOtherGrantsTable_54"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_55"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_56"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_57"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_58"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_59"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_60"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_IssuanceExpenses" xlink:label="loc_cgen_IssuanceExpenses_61"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_IssuanceExpenses" xlink:label="loc_cgen_IssuanceExpenses_62"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_IssuanceExpenses" xlink:label="loc_cgen_IssuanceExpenses_63"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_64"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_65"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_66"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_67"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_68"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_69"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_70"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_71"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_72"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_73"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_74"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_75"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_76"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_77"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_78"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_79"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_80"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_81"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_82"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_83"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_84"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_85"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_86"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_87"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_PercentageOfRoyaltiesOnNetSales" xlink:label="loc_cgen_PercentageOfRoyaltiesOnNetSales_88"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_PercentageOfRoyaltiesOnNetSales" xlink:label="loc_cgen_PercentageOfRoyaltiesOnNetSales_89"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_Plan2010Member" xlink:label="loc_cgen_Plan2010Member_90"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_Plan2010Member" xlink:label="loc_cgen_Plan2010Member_91"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_92"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_93"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_94"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_95"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ReceivablesOnAccountOfShares" xlink:label="loc_cgen_ReceivablesOnAccountOfShares_96"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ReceivablesOnAccountOfShares" xlink:label="loc_cgen_ReceivablesOnAccountOfShares_97"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ReceivablesOnAccountOfShares" xlink:label="loc_cgen_ReceivablesOnAccountOfShares_98"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_99"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_100"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RelativeFairValueOfDeferredParticipation" xlink:label="loc_cgen_RelativeFairValueOfDeferredParticipation_101"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RelativeFairValueOfDeferredParticipation" xlink:label="loc_cgen_RelativeFairValueOfDeferredParticipation_102"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RelativeFairValueOfDeferredParticipation" xlink:label="loc_cgen_RelativeFairValueOfDeferredParticipation_103"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_104"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_105"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_106"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_107"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_108"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_109"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_110"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_111"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_112"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_113"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_114"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_115"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_116"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_117"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_118"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_119"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_120"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_121"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_122"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_123"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_124"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_125"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_126"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SalesAgreementWithLeerinkPartnerLlcMember" xlink:label="loc_cgen_SalesAgreementWithLeerinkPartnerLlcMember_127"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SalesAgreementWithLeerinkPartnerLlcMember" xlink:label="loc_cgen_SalesAgreementWithLeerinkPartnerLlcMember_128"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SalesAgreementWithLeerinkPartnerLlcMember" xlink:label="loc_cgen_SalesAgreementWithLeerinkPartnerLlcMember_129"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SeverancePayFundNonCurrent" xlink:label="loc_cgen_SeverancePayFundNonCurrent_130"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SeverancePayFundNonCurrent" xlink:label="loc_cgen_SeverancePayFundNonCurrent_131"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SeverancePayFundNonCurrent" xlink:label="loc_cgen_SeverancePayFundNonCurrent_132"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_133"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_134"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_135"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_136"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_137"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_138"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_139"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_140"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_141"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_142"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_143"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_144"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_145"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" xlink:label="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_146"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" xlink:label="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_147"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" xlink:label="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_148"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_149"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_150"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_151"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_TradeAndOtherPayablesRelatedParties" xlink:label="loc_cgen_TradeAndOtherPayablesRelatedParties_152"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_TradeAndOtherPayablesRelatedParties" xlink:label="loc_cgen_TradeAndOtherPayablesRelatedParties_153"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_TradeAndOtherPayablesRelatedParties" xlink:label="loc_cgen_TradeAndOtherPayablesRelatedParties_154"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock" xlink:label="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_155"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock" xlink:label="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_156"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock" xlink:label="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_157"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_158"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_159"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaap_BusinessDevelopment_160"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaap_BusinessDevelopment_161"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_162"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_163"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_164"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_165"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_166"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_167"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_168"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_169"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_170"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_171"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_172"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_173"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_174"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_175"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_176"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_177"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_178"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_179"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_180"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_181"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_182"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_183"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_184"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_185"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_186"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_187"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_188"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_189"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_190"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_191"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_192"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_193"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_194"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_195"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_196"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_197"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_198"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_199"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_200"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_201"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_202"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_203"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_204"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_205"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_206"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_207"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_208"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_209"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_210"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_211"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_212"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_213"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_214"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_215"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_216"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_217"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_218"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_219"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_220"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_221"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="loc_cgen_GovernmentAndOtherGrantsDomain_222"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RelatedPartyBalancesAndTransactionsAbstract" xlink:label="loc_cgen_RelatedPartyBalancesAndTransactionsAbstract_223"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract" xlink:label="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract_224"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IL" xlink:label="loc_country_IL_225"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_226"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_227"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_228"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_229"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_230"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_231"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_232"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_233"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_234"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_235"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_236"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_237"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_238"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_239"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_240"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_241"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_242"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_243"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_244"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_245"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_246"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_247"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_248"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_249"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_250"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_251"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_252"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_253"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_254"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_255"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_256"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_257"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_258"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_259"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_260"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_261"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_262"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_263"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_264"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_265"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_266"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_267"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_268"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_269"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_270"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_271"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_272"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_273"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_274"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_275"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_276"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_277"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_278"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_279"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_280"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_281"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_282"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_283"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_284"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_285"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_286"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_287"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_288"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_289"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_290"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_291"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_292"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_293"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_294"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_295"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_296"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_297"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_298"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_299"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_300"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_301"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_302"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_303"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_304"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_305"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_306"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_307"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_308"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_309"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_310"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_311"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_312"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_313"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_314"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_315"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_316"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_317"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_318"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_319"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_320"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_321"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_322"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_323"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_324"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_325"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_326"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_327"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_328"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_329"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_330"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_331"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_332"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncomeTableTextBlock" xlink:label="loc_us-gaap_InterestAndOtherIncomeTableTextBlock_333"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:label="loc_us-gaap_InterestIncomeDepositsWithFinancialInstitutions_334"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_335"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_336"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_337"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:label="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_338"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_339"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_340"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_341"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_342"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_343"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_344"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_345"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_346"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_347"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_348"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_349"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_350"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_351"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_352"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_353"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_354"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_355"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_356"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_357"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_358"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_359"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_360"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_361"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_362"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_363"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_364"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_365"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_366"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_367"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_368"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_369"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_370"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_371"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_372"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_373"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_374"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_375"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_376"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_377"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_378"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_379"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_380"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_381"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_382"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_383"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_384"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_385"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_386"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_387"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_388"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_389"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_390"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_391"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_392"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_393"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_394"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_395"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_396"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_397"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_398"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_399"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_400"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_401"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_402"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_403"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_404"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_405"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_406"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_407"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_408"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_409"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_410"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_411"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_412"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_413"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_414"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_415"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_416"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_417"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_418"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_419"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_420"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_421"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyLeaseGuaranteeMember" xlink:label="loc_us-gaap_PropertyLeaseGuaranteeMember_422"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_423"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_424"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_425"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_426"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_427"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_428"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_429"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_430"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_431"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_432"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_433"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_434"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_435"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_436"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_437"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_438"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_439"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_440"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_441"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_442"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_443"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_444"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_445"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_446"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_447"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_448"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_449"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_450"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_451"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_452"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_453"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_454"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_455"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_456"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_457"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_458"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_459"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_460"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_461"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_462"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_463"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_464"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_465"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_466"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_467"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_468"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_469"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_470"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_471"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_472"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_473"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_474"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_475"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_476"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_477"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_478"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_479"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_480"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_481"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_482"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_483"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_484"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_485"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense_486"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_487"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_488"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_489"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_490"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_491"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_492"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_493"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_494"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_495"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="loc_us-gaap_SupplyCommitmentAxis_496"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_497"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_498"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_499"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_500"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_501"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_502"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_503"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_504"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AccretionOfDiscountOnMarketableSecurities_0" xml:lang="en-US">Represent the amount of Accretion of discount on marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_AccretionOfDiscountOnMarketableSecurities_1" xml:lang="en-US">Accretion of discount on marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AccretionOfDiscountOnMarketableSecurities_2" xml:lang="en-US">Accretion Of Discount On Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AccruedMilestonePayment_0" xml:lang="en-US">Represents the amount of accrued milestone payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AccruedMilestonePayment_1" xml:lang="en-US">Accrued Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AccruedMilestonePayment_2" xml:lang="en-US">Accrued milestone payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AgreementMember_0" xml:lang="en-US">Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AgreementMember_1" xml:lang="en-US">Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AgreementStartDate_0" xml:lang="en-US">Start date of the agreement, in CCYY-MM-DD format.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AgreementStartDate_1" xml:lang="en-US">Agreement, start date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AgreementTerminationDescription_0" xml:lang="en-US">Agreement termination description.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AgreementTerminationDescription_1" xml:lang="en-US">Agreement termination description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AgreementTerminationDescription_2" xml:lang="en-US">Agreement termination description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AmountIncurredMilestonePayments_0" xml:lang="en-US">Amount incurred milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AmountIncurredMilestonePayments_1" xml:lang="en-US">Amount incurred milestone payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AtMarketOfferingProgramMember_0" xml:lang="en-US">At The Market Offering Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AtMarketOfferingProgramMember_1" xml:lang="en-US">At Market Offering Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AtMarketOfferingProgramMember_2" xml:lang="en-US">At The Market Offering Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_0" xml:lang="en-US">Expiration period of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_1" xml:lang="en-US">Class Of Warrant Or Righst Period From Which Warrants Or Rights Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_2" xml:lang="en-US">Expiration period of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_0" xml:lang="en-US">Collaboration Agreement With U.S. Antibody Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_1" xml:lang="en-US">Collaboration Agreement With U.S. Antibody Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CollaborativeArrangementsMember_0" xml:lang="en-US">Collaborative Arrangements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CollaborativeArrangementsMember_1" xml:lang="en-US">Collaborative Arrangements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CollaborativeArrangementsTwoMember_0" xml:lang="en-US">Collaborative Arrangements Two Member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CollaborativeArrangementsTwoMember_1" xml:lang="en-US">Collaborative Arrangements Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CommercialLicenseAgreementMember_0" xml:lang="en-US">Commercial License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CommercialLicenseAgreementMember_1" xml:lang="en-US">Commercial License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ContingentFees_0" xml:lang="en-US">Contingent fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ContingentFees_1" xml:lang="en-US">Contingent fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ContingentFees_2" xml:lang="en-US">Contingent fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DeferredParticipationOfBmsInRdExpenses_0" xml:lang="en-US">Deferred participation of BMS in R&amp;amp;D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DeferredParticipationOfBmsInRdExpenses_1" xml:lang="en-US">Deferred Participation Of Bms In Rd Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DeferredParticipationOfBmsInRdExpenses_2" xml:lang="en-US">Deferred participation of BMS in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_0" xml:lang="en-US">Development, regulatory and commercial milestones compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_1" xml:lang="en-US">Development, regulatory and commercial milestones compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DocumentAndEntityInformationAbstract_0" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DocumentAndEntityInformationAbstract_1" xml:lang="en-US">Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_EmployeeSharePurchasePlanMember_0" xml:lang="en-US">Information about the Employee Share Purchase Plan member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_EmployeeSharePurchasePlanMember_1" xml:lang="en-US">Employee Share Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_FinancialIncomeExpenseNet_0" xml:lang="en-US">The aggregate of financial and other income net of expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_FinancialIncomeExpenseNet_1" xml:lang="en-US">Financial and other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_FinancialIncomeExpenseNet_2" xml:lang="en-US">Financial Income Expense Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_cgen_FinancialIncomeExpenseNet_3" xml:lang="en-US">Financial and other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_FinancialIncomeExpenseNet_4" xml:lang="en-US">Financial and other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_GovernmentAndOtherGrantsAxis_0" xml:lang="en-US">Government and Other Grants [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GovernmentAndOtherGrantsAxis_1" xml:lang="en-US">Government and Other Grants [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_GovernmentAndOtherGrantsLineItems_0" xml:lang="en-US">Government And Other Grants [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GovernmentAndOtherGrantsLineItems_1" xml:lang="en-US">Government and Other Grants [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_GovernmentAndOtherGrantsMember_0" xml:lang="en-US">Government and Other Grants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GovernmentAndOtherGrantsMember_1" xml:lang="en-US">Government and Other Grants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_GovernmentAndOtherGrantsTable_0" xml:lang="en-US">Government And Other Grants [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GovernmentAndOtherGrantsTable_1" xml:lang="en-US">Government and Other Grants [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_0" xml:lang="en-US">Increase (decrease) in deferred participation in R&amp;amp;D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_1" xml:lang="en-US">Increase Decrease In Deferred Participation In Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_2" xml:lang="en-US">Decrease in deferred participation in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Decrease in operating lease right of use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_1" xml:lang="en-US">Decrease in operating lease right of use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_2" xml:lang="en-US">Increase Decrease In Operating Lease Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IssuanceExpenses_0" xml:lang="en-US">Represent the amount of Issuance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IssuanceExpenses_1" xml:lang="en-US">Issuance Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_IssuanceExpenses_2" xml:lang="en-US">Issuance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_0" xml:lang="en-US">Long term deferred participation in R&amp;amp;D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_1" xml:lang="en-US">Long Term Deferred Participationin Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_2" xml:lang="en-US">Long-term deferred participation in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MasterClinicalAgreementMember_0" xml:lang="en-US">Master Clinical Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MasterClinicalAgreementMember_1" xml:lang="en-US">Master Clinical Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Maximum authorized proceeds from issuance of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_1" xml:lang="en-US">Maximum Authorized Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_2" xml:lang="en-US">Proceeds from issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_0" xml:lang="en-US">Maximum Royalty Repaid As Percentage Of Grant Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_1" xml:lang="en-US">Maximum royalty repaid as percentage of grant received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_2" xml:lang="en-US">Maximum royalty repaid as percentage of grant received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_May2012AgreementMember_0" xml:lang="en-US">Information pertaining to the May 2012 Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_May2012AgreementMember_1" xml:lang="en-US">May 2012 Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_May2012AgreementMember_2" xml:lang="en-US">May 2012 Agreement With Advisor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_0" xml:lang="en-US">Disclosure of accounting policy pertaining to new accounting pronouncements not yet adopted, that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_1" xml:lang="en-US">New Accounting Pronouncements Not Yet Adopted Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_2" xml:lang="en-US">Recently issued accounting pronouncements, not yet adopted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_NumberOfWarrantsExercised_0" xml:lang="en-US">Number of warrants exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_NumberOfWarrantsExercised_1" xml:lang="en-US">Number Of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_NumberOfWarrantsExercised_2" xml:lang="en-US">Warrants exercised, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ParticipationRights_0" xml:lang="en-US">Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to advisor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ParticipationRights_1" xml:lang="en-US">Participation Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PercentageOfClosingPrice_0" xml:lang="en-US">Percentage of closing price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PercentageOfClosingPrice_1" xml:lang="en-US">Percentage of closing price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PercentageOfRoyaltiesOnNetSales_0" xml:lang="en-US">Percentage of royalties on net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PercentageOfRoyaltiesOnNetSales_1" xml:lang="en-US">Percentage of royalties on net sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_Plan2010Member_0" xml:lang="en-US">Information about the plan 2010 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_Plan2010Member_1" xml:lang="en-US">Plan 2010 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_0" xml:lang="en-US">The amount of purchase property and equipment as non cash transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_1" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_2" xml:lang="en-US">Purchase Of Property And Equipment As Non Cash Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_3" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ReceivablesOnAccountOfShares_0" xml:lang="en-US">Receivables on account of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ReceivablesOnAccountOfShares_1" xml:lang="en-US">Receivables On Account Of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ReceivablesOnAccountOfShares_2" xml:lang="en-US">Receivables on account of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RegisteredDirectOfferingMember_0" xml:lang="en-US">Registered direct offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RegisteredDirectOfferingMember_1" xml:lang="en-US">Registered direct offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RelativeFairValueOfDeferredParticipation_0" xml:lang="en-US">Relative fair value of deferred participation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RelativeFairValueOfDeferredParticipation_1" xml:lang="en-US">Relative Fair Value Of Deferred Participation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_RelativeFairValueOfDeferredParticipation_2" xml:lang="en-US">Relative fair value of deferred participation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_0" xml:lang="en-US">Addition Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_1" xml:lang="en-US">Research And Development Arrangement Additional Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_0" xml:lang="en-US">Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_1" xml:lang="en-US">Research And Development Arrangement Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_2" xml:lang="en-US">Potential milestone compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_0" xml:lang="en-US">Potential milestone compensation company is now eligible for.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_1" xml:lang="en-US">Research And Development Arrangement Payments Receivable On Remaining Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_2" xml:lang="en-US">Potential milestone compensation company is now eligible for</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_0" xml:lang="en-US">Potential milestone revenue for preclinical stages of research from arrangements for research and development, including collaboration and licenses agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_1" xml:lang="en-US">Research And Development Arrangement Preclinical Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_2" xml:lang="en-US">Preclinical milestone compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentGrantOneMember_0" xml:lang="en-US">Represents Research and development grant one member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentGrantOneMember_1" xml:lang="en-US">Research And Development Grant One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentGrantOneMember_2" xml:lang="en-US">Research And Development Grant One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RetainerFee_0" xml:lang="en-US">Retainer fee per month.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RetainerFee_1" xml:lang="en-US">Retainer Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_RetainerFee_2" xml:lang="en-US">Retainer fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RoyaltyContingentObligations_0" xml:lang="en-US">The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RoyaltyContingentObligations_1" xml:lang="en-US">Royalty Contingent Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_RoyaltyContingentObligations_2" xml:lang="en-US">Contingent royalty obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_0" xml:lang="en-US">Royalty Percentage Based On Future Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_1" xml:lang="en-US">Royalty percentage based on future revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_2" xml:lang="en-US">Royalty percentage based on future revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SalesAgreementWithLeerinkPartnerLlcMember_0" xml:lang="en-US">Information about the Sales Agreement with Leerink Partner LLC member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SalesAgreementWithLeerinkPartnerLlcMember_1" xml:lang="en-US">Sales Agreement With Leerink Partner Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SalesAgreementWithLeerinkPartnerLlcMember_2" xml:lang="en-US">Sales Agreement With Leerink Partner LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SeverancePayFundNonCurrent_0" xml:lang="en-US">Monthly deposits in externally managed funds which primarily cover Israeli law severance pay liability of one month's salary for each year of employment upon the retirement or death of an employee or termination of employment without a valid legal reason.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SeverancePayFundNonCurrent_1" xml:lang="en-US">Severance Pay Fund Non Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SeverancePayFundNonCurrent_2" xml:lang="en-US">Severance pay fund</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SeverancePayNet_0" xml:lang="en-US">Severance pay, net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SeverancePayNet_1" xml:lang="en-US">Severance Pay Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SeverancePayNet_2" xml:lang="en-US">Increase (decrease) in severance pay, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_0" xml:lang="en-US">Short term deferred participation in R&amp;amp;D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_1" xml:lang="en-US">Short Term Deferred Participation In Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_2" xml:lang="en-US">Short-term deferred participation in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_0" xml:lang="en-US">Stock-based compensation relating to options issued to employees and directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_1" xml:lang="en-US">Stock Based Compensation Relating To Options Issued To Employees And Directors Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_2" xml:lang="en-US">Stock-based compensation issued to employees, directors and non-employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_3" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_0" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_1" xml:lang="en-US">Stock Issued During Period Value Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_2" xml:lang="en-US">Warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_0" xml:lang="en-US">Represent the Right-of-use asset obtained in exchange for operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_1" xml:lang="en-US">Supplemental Right Of Use Asset And Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_2" xml:lang="en-US">Right-of-use asset obtained in exchange for operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_0" xml:lang="en-US">SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_1" xml:lang="en-US">Svb Leerink Llc And Stifel Nicolaus And Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_2" xml:lang="en-US">SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_TradeAndOtherPayablesRelatedParties_0" xml:lang="en-US">Trade and other payables related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_TradeAndOtherPayablesRelatedParties_1" xml:lang="en-US">Trade And Other Payables Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_TradeAndOtherPayablesRelatedParties_2" xml:lang="en-US">Trade and other payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_0" xml:lang="en-US">The entire disclosure of unaudited interim consolidated financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_1" xml:lang="en-US">Unaudited Interim Consolidated Financial Statements [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_2" xml:lang="en-US">UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_UnderwritersMember_0" xml:lang="en-US">Underwriters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_UnderwritersMember_1" xml:lang="en-US">Underwriters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_BusinessDevelopment_0" xml:lang="en-US">Marketing and business development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessDevelopment_1" xml:lang="en-US">Marketing and business development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_1" xml:lang="en-US">General and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0" xml:lang="en-US">Tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/negativeTerseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1" xml:lang="en-US">Tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_3" xml:lang="en-US">Tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_0" xml:lang="en-US">Decrease (increase) in other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_1" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0" xml:lang="en-US">Decrease in other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_0" xml:lang="en-US">Increase in interest receivables from short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_1" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0" xml:lang="en-US">Decrease (increase) in long-term prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_0" xml:lang="en-US">Decrease (increase) in long-term prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_1" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_0" xml:lang="en-US">Realized gain on sale of marketable securities, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_1" xml:lang="en-US">Marketable Securities, Realized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetIncomeLoss_0" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_1" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss_2" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_3" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_4" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingExpenses_0" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_OperatingExpenses_1" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses_2" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses_3" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_0" xml:lang="en-US">Investment in marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_1" xml:lang="en-US">Payments to Acquire Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_0" xml:lang="en-US">Investment in short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_1" xml:lang="en-US">Payments to Acquire Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development expenses, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_1" xml:lang="en-US">Research and development expenses, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_0" xml:lang="en-US">Total comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_1" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_2" xml:lang="en-US">Total comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xml:lang="en-US">Loss before taxes on income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xml:lang="en-US">Loss before taxes on income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">Cash, cash equivalents and restricted cash at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">Cash, cash equivalents and restricted cash at the beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0" xml:lang="en-US">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1" xml:lang="en-US">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_2" xml:lang="en-US">Ordinary shares, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity_0" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity_1" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity_2" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity_3" xml:lang="en-US">Total shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GovernmentAndOtherGrantsDomain_0" xml:lang="en-US">Government And Other Grants [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RelatedPartyBalancesAndTransactionsAbstract_0" xml:lang="en-US">Related Party Balances And Transactions Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract_0" xml:lang="en-US">Unaudited Interim Consolidated Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_IL_0" xml:lang="en-US">Israel [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract_0" xml:lang="en-US">Cover [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1_0" xml:lang="en-US">Entity Address, Address Line One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2_0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine3_0" xml:lang="en-US">Entity Address, Address Line Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown_0" xml:lang="en-US">Entity Address, City or Town</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry_0" xml:lang="en-US">Entity Address Country</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode_0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber_0" xml:lang="en-US">Entity File Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode_0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember_0" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember_0" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis_0" xml:lang="en-US">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_RangeAxis_1" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember_0" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis_0" xml:lang="en-US">Statement Geographical [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_StatementGeographicalAxis_1" xml:lang="en-US">Geographical [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis_0" xml:lang="en-US">Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_1" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent_0" xml:lang="en-US">Trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_0" xml:lang="en-US">Trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0" xml:lang="en-US">Additional paid-in capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0" xml:lang="en-US">Stock-based compensation issued to employees, directors and non-employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0" xml:lang="en-US">Total weighted average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets_0" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets_1" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent_0" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent_1" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0" xml:lang="en-US">CURRENT ASSETS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrent_0" xml:lang="en-US">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsNoncurrent_1" xml:lang="en-US">Total non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract_0" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1" xml:lang="en-US">Gross unrealized gains</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1" xml:lang="en-US">Gross unrealized losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1" xml:lang="en-US">Amortized cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0" xml:lang="en-US">Debt Securities, Available-for-Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1" xml:lang="en-US">Fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis_0" xml:lang="en-US">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1" xml:lang="en-US">Increase (decrease) in cash, cash equivalents and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0" xml:lang="en-US">Exercise price of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0" xml:lang="en-US">Warrants purchase to ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0" xml:lang="en-US">Warrants purchase to ordinary shares remain outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES (NOTE 4)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies_1" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES (NOTE 5)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1" xml:lang="en-US">Number of shares reserved for issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember_0" xml:lang="en-US">Ordinary shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_0" xml:lang="en-US">Ordinary shares, par value per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_1" xml:lang="en-US">Ordinary shares, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0" xml:lang="en-US">Ordinary shares, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued_0" xml:lang="en-US">Ordinary shares, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue_0" xml:lang="en-US">Ordinary shares of NIS 0.01 par value per share: 200,000,000 shares authorized on June 30, 2021 and December 31, 2020; 83,917,929 and 83,675,856 shares issued and outstanding on June 30, 2021 and December 31, 2020, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue_1" xml:lang="en-US">Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized on June 30, 2023, and December 31, 2022; 88,233,766 and 86,624,643 shares issued and outstanding on June 30, 2023, and December 31, 2022, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_0" xml:lang="en-US">Concentration of credit risks</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_0" xml:lang="en-US">Corporate Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_1" xml:lang="en-US">Governmental bonds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty_0" xml:lang="en-US">Related parties' expenses amounts charged to research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty_1" xml:lang="en-US">Research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_0" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_0" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1" xml:lang="en-US">Schedule of available-for-sale marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation_0" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic_0" xml:lang="en-US">Basic and diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_1" xml:lang="en-US">Basic net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted_0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_1" xml:lang="en-US">Diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_0" xml:lang="en-US">Basic and diluted loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0" xml:lang="en-US">Unrecognized compensation cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0" xml:lang="en-US">Period over which compensation expense will be recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1" xml:lang="en-US">Unrecognized estimated compensation cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockMember_0" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_0" xml:lang="en-US">Share based compensation ESPP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost_0" xml:lang="en-US">Equity investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis_0" xml:lang="en-US">Financial Instrument [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainContingenciesByNatureAxis_0" xml:lang="en-US">Gain Contingencies, Nature [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GuaranteeObligationsByNatureAxis_0" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure_0" xml:lang="en-US">Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure_1" xml:lang="en-US">Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract_0" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_0" xml:lang="en-US">TAXES ON INCOME [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_0" xml:lang="en-US">TAXES ON INCOME</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0" xml:lang="en-US">Increase in other accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" xml:lang="en-US">Increase (decrease) in other accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0" xml:lang="en-US">Increase in trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1" xml:lang="en-US">Decrease in trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0" xml:lang="en-US">Decrease in operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestAndOtherIncomeTableTextBlock_0" xml:lang="en-US">Schedule of Financial And Other Income, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeDepositsWithFinancialInstitutions_0" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest_0" xml:lang="en-US">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest_1" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest_2" xml:lang="en-US">Interest Income, Deposits with Financial Institutions, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_0" xml:lang="en-US">Amount of investment in Compugen</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1" xml:lang="en-US">MARKETABLE SECURITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US">Total liabilities and shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent_0" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_1" xml:lang="en-US">Total non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_0" xml:lang="en-US">NON- CURRENT LIABILITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent_0" xml:lang="en-US">Marketable Securities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent_1" xml:lang="en-US">Investment in marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_0" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_1" xml:lang="en-US">Investments in marketable securities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_0" xml:lang="en-US">Marketable Security, Unrealized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_1" xml:lang="en-US">Other comprehensive income (loss) from marketable securities, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_2" xml:lang="en-US">Change in unrealized gains (losses) on marketable securities: Unrealized gains (losses) arising during the period, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">Cash flows from financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US">Net cash provided by investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0" xml:lang="en-US">Cash flows from investing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Cash flows from operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xml:lang="en-US">Recently adopted accounting pronouncements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0" xml:lang="en-US">Operating expenses:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_0" xml:lang="en-US">Current maturity of operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0" xml:lang="en-US">Long term operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Operating lease right to use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xml:lang="en-US">GENERAL [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0" xml:lang="en-US">GENERAL</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_0" xml:lang="en-US">Other accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_0" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1" xml:lang="en-US">Other comprehensive loss:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_1" xml:lang="en-US">Other comprehensive income (loss) from marketable securities, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_2" xml:lang="en-US">Change in unrealized gains (losses) on marketable securities: Unrealized gains (losses) arising during the period, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_0" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_1" xml:lang="en-US">Other comprehensive income (loss) from marketable securities, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_2" xml:lang="en-US">Change in unrealized gains (losses) on marketable securities: Unrealized gains (losses) arising during the period, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1" xml:lang="en-US">Other comprehensive income (loss) from marketable securities, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2" xml:lang="en-US">Change in unrealized gains (losses) on marketable securities: Unrealized gains (losses) arising during the period, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract_0" xml:lang="en-US">FINANCIAL AND OTHER INCOME, NET [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract_1" xml:lang="en-US">Other Income and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_0" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_1" xml:lang="en-US">FINANCIAL AND OTHER INCOME, NET</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_0" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_1" xml:lang="en-US">Exchange rate differences and other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherShortTermInvestments_0" xml:lang="en-US">Short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_0" xml:lang="en-US">Issuance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_1" xml:lang="en-US">Issuance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis_0" xml:lang="en-US">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain_0" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_0" xml:lang="en-US">Accrued severance pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xml:lang="en-US">Other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent_0" xml:lang="en-US">Long-term prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0" xml:lang="en-US">Proceeds from ordinary shares in offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Proceeds from issuance of ordinary shares, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_0" xml:lang="en-US">Proceeds from maturity of short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_0" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_1" xml:lang="en-US">Proceeds from maturity of short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_0" xml:lang="en-US">Proceeds from Sale and Maturity of Held-to-Maturity Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_1" xml:lang="en-US">Proceeds from Sale and Maturity of Held-to-Maturity Securities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_2" xml:lang="en-US">Proceeds from Maturity of marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_0" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_1" xml:lang="en-US">Proceeds from Maturity of marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1" xml:lang="en-US">Proceeds from maturity of short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_2" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_0" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_1" xml:lang="en-US">Proceeds from equity investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_0" xml:lang="en-US">Proceeds from Sale of Held-to-Maturity Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_1" xml:lang="en-US">Proceeds from Sale and Maturity of Held-to-Maturity Securities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_2" xml:lang="en-US">Proceeds from maturity of marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_0" xml:lang="en-US">Proceeds from exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_0" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_1" xml:lang="en-US">Proceeds from warrant exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyLeaseGuaranteeMember_0" xml:lang="en-US">Office leases [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_0" xml:lang="en-US">RELATED PARTY BALANCES AND TRANSACTIONS [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_1" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0" xml:lang="en-US">RELATED PARTY BALANCES AND TRANSACTIONS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0" xml:lang="en-US">Upfront payment received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_0" xml:lang="en-US">Percentage of workforce reduction from restructuring activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember_0" xml:lang="en-US">Accumulated deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0" xml:lang="en-US">Revenue recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0" xml:lang="en-US">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_0" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1" xml:lang="en-US">Schedule of financial and other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" xml:lang="en-US">Schedule of related party balances and transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0" xml:lang="en-US">Schedule of Weighted-average Assumptions Used to Estimate Fair Value of Options Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xml:lang="en-US">Schedule of weighted-average assumptions used to estimate fair value of options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation_0" xml:lang="en-US">Stock-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0" xml:lang="en-US">Vesting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0" xml:lang="en-US">Expected dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0" xml:lang="en-US">Expected life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xml:lang="en-US">Expected life (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0" xml:lang="en-US">Expected volatility, maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_0" xml:lang="en-US">Expected volatility, minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xml:lang="en-US">Expected risk free interest rates range</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0" xml:lang="en-US">Expected risk free interest rate range, maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0" xml:lang="en-US">Expected risk free interest rates range, minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0" xml:lang="en-US">Ordinary shares available for issuance | shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_0" xml:lang="en-US">Options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Weighted average fair value of options granted during period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_1" xml:lang="en-US">Number of shares purchased for ESPP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xml:lang="en-US">Award Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Stock options granted, exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xml:lang="en-US">Stock-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_0" xml:lang="en-US">Stock options granted, exercise price, minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_0" xml:lang="en-US">Stock options granted, exercise price, maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_0" xml:lang="en-US">SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_0" xml:lang="en-US">Offering price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems_0" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable_0" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0" xml:lang="en-US">SHAREHOLDERS' EQUITY:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_0" xml:lang="en-US">SHAREHOLDERS' EQUITY [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0" xml:lang="en-US">Issuance of ordinary shares pursuant to the ESPP, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1" xml:lang="en-US">Issuance of ESPP shares, (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US">Issuance of shares, net, (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2" xml:lang="en-US">Ordinary shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0" xml:lang="en-US">Options exercised, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0" xml:lang="en-US">Issuance of ordinary shares pursuant to the ESPP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1" xml:lang="en-US">Issuance of ESPP shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1" xml:lang="en-US">Issuance of shares, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_2" xml:lang="en-US">Value of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockOptionPlanExpense_0" xml:lang="en-US">Share based compensation stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems_0" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember_0" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_1" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable_0" xml:lang="en-US">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_0" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_0" xml:lang="en-US">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplyCommitmentAxis_0" xml:lang="en-US">Supply Commitment [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xml:lang="en-US">Financial Instruments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember_0" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US">Weighted average number of ordinary shares used in computing diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xml:lang="en-US">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xml:lang="en-US">Weighted average number of ordinary shares used in computing basic net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract_0" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccretionOfDiscountOnMarketableSecurities_1" xlink:to="lab_cgen_AccretionOfDiscountOnMarketableSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccretionOfDiscountOnMarketableSecurities_2" xlink:to="lab_cgen_AccretionOfDiscountOnMarketableSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccretionOfDiscountOnMarketableSecurities_3" xlink:to="lab_cgen_AccretionOfDiscountOnMarketableSecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccruedMilestonePayment_4" xlink:to="lab_cgen_AccruedMilestonePayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccruedMilestonePayment_5" xlink:to="lab_cgen_AccruedMilestonePayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccruedMilestonePayment_6" xlink:to="lab_cgen_AccruedMilestonePayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementMember_7" xlink:to="lab_cgen_AgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementMember_8" xlink:to="lab_cgen_AgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementStartDate_9" xlink:to="lab_cgen_AgreementStartDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementStartDate_10" xlink:to="lab_cgen_AgreementStartDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementTerminationDescription_11" xlink:to="lab_cgen_AgreementTerminationDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementTerminationDescription_12" xlink:to="lab_cgen_AgreementTerminationDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementTerminationDescription_13" xlink:to="lab_cgen_AgreementTerminationDescription_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmountIncurredMilestonePayments_14" xlink:to="lab_cgen_AmountIncurredMilestonePayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmountIncurredMilestonePayments_15" xlink:to="lab_cgen_AmountIncurredMilestonePayments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AtMarketOfferingProgramMember_16" xlink:to="lab_cgen_AtMarketOfferingProgramMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AtMarketOfferingProgramMember_17" xlink:to="lab_cgen_AtMarketOfferingProgramMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AtMarketOfferingProgramMember_18" xlink:to="lab_cgen_AtMarketOfferingProgramMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_19" xlink:to="lab_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_20" xlink:to="lab_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_21" xlink:to="lab_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_22" xlink:to="lab_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_23" xlink:to="lab_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsMember_24" xlink:to="lab_cgen_CollaborativeArrangementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsMember_25" xlink:to="lab_cgen_CollaborativeArrangementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsTwoMember_26" xlink:to="lab_cgen_CollaborativeArrangementsTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsTwoMember_27" xlink:to="lab_cgen_CollaborativeArrangementsTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CommercialLicenseAgreementMember_28" xlink:to="lab_cgen_CommercialLicenseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CommercialLicenseAgreementMember_29" xlink:to="lab_cgen_CommercialLicenseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ContingentFees_30" xlink:to="lab_cgen_ContingentFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ContingentFees_31" xlink:to="lab_cgen_ContingentFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ContingentFees_32" xlink:to="lab_cgen_ContingentFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredParticipationOfBmsInRdExpenses_33" xlink:to="lab_cgen_DeferredParticipationOfBmsInRdExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredParticipationOfBmsInRdExpenses_34" xlink:to="lab_cgen_DeferredParticipationOfBmsInRdExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredParticipationOfBmsInRdExpenses_35" xlink:to="lab_cgen_DeferredParticipationOfBmsInRdExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_36" xlink:to="lab_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_37" xlink:to="lab_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DocumentAndEntityInformationAbstract_38" xlink:to="lab_cgen_DocumentAndEntityInformationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DocumentAndEntityInformationAbstract_39" xlink:to="lab_cgen_DocumentAndEntityInformationAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeeSharePurchasePlanMember_40" xlink:to="lab_cgen_EmployeeSharePurchasePlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeeSharePurchasePlanMember_41" xlink:to="lab_cgen_EmployeeSharePurchasePlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_42" xlink:to="lab_cgen_FinancialIncomeExpenseNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_43" xlink:to="lab_cgen_FinancialIncomeExpenseNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_44" xlink:to="lab_cgen_FinancialIncomeExpenseNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_45" xlink:to="lab_cgen_FinancialIncomeExpenseNet_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_46" xlink:to="lab_cgen_FinancialIncomeExpenseNet_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_47" xlink:to="lab_cgen_GovernmentAndOtherGrantsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_48" xlink:to="lab_cgen_GovernmentAndOtherGrantsAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_49" xlink:to="lab_cgen_GovernmentAndOtherGrantsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_50" xlink:to="lab_cgen_GovernmentAndOtherGrantsLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsMember_51" xlink:to="lab_cgen_GovernmentAndOtherGrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsMember_52" xlink:to="lab_cgen_GovernmentAndOtherGrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_53" xlink:to="lab_cgen_GovernmentAndOtherGrantsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_54" xlink:to="lab_cgen_GovernmentAndOtherGrantsTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_55" xlink:to="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_56" xlink:to="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_57" xlink:to="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_58" xlink:to="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_59" xlink:to="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_60" xlink:to="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceExpenses_61" xlink:to="lab_cgen_IssuanceExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceExpenses_62" xlink:to="lab_cgen_IssuanceExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceExpenses_63" xlink:to="lab_cgen_IssuanceExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_64" xlink:to="lab_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_65" xlink:to="lab_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_66" xlink:to="lab_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementMember_67" xlink:to="lab_cgen_MasterClinicalAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementMember_68" xlink:to="lab_cgen_MasterClinicalAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_69" xlink:to="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_70" xlink:to="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_71" xlink:to="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_72" xlink:to="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_73" xlink:to="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_74" xlink:to="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_May2012AgreementMember_75" xlink:to="lab_cgen_May2012AgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_May2012AgreementMember_76" xlink:to="lab_cgen_May2012AgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_May2012AgreementMember_77" xlink:to="lab_cgen_May2012AgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_78" xlink:to="lab_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_79" xlink:to="lab_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_80" xlink:to="lab_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfWarrantsExercised_81" xlink:to="lab_cgen_NumberOfWarrantsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfWarrantsExercised_82" xlink:to="lab_cgen_NumberOfWarrantsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfWarrantsExercised_83" xlink:to="lab_cgen_NumberOfWarrantsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ParticipationRights_84" xlink:to="lab_cgen_ParticipationRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ParticipationRights_85" xlink:to="lab_cgen_ParticipationRights_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfClosingPrice_86" xlink:to="lab_cgen_PercentageOfClosingPrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfClosingPrice_87" xlink:to="lab_cgen_PercentageOfClosingPrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfRoyaltiesOnNetSales_88" xlink:to="lab_cgen_PercentageOfRoyaltiesOnNetSales_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfRoyaltiesOnNetSales_89" xlink:to="lab_cgen_PercentageOfRoyaltiesOnNetSales_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_Plan2010Member_90" xlink:to="lab_cgen_Plan2010Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_Plan2010Member_91" xlink:to="lab_cgen_Plan2010Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_92" xlink:to="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_93" xlink:to="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_94" xlink:to="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_95" xlink:to="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReceivablesOnAccountOfShares_96" xlink:to="lab_cgen_ReceivablesOnAccountOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReceivablesOnAccountOfShares_97" xlink:to="lab_cgen_ReceivablesOnAccountOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReceivablesOnAccountOfShares_98" xlink:to="lab_cgen_ReceivablesOnAccountOfShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RegisteredDirectOfferingMember_99" xlink:to="lab_cgen_RegisteredDirectOfferingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RegisteredDirectOfferingMember_100" xlink:to="lab_cgen_RegisteredDirectOfferingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RelativeFairValueOfDeferredParticipation_101" xlink:to="lab_cgen_RelativeFairValueOfDeferredParticipation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RelativeFairValueOfDeferredParticipation_102" xlink:to="lab_cgen_RelativeFairValueOfDeferredParticipation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RelativeFairValueOfDeferredParticipation_103" xlink:to="lab_cgen_RelativeFairValueOfDeferredParticipation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_104" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_105" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_106" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_107" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_108" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_109" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_110" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_111" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_112" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_113" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_114" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentGrantOneMember_115" xlink:to="lab_cgen_ResearchAndDevelopmentGrantOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentGrantOneMember_116" xlink:to="lab_cgen_ResearchAndDevelopmentGrantOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentGrantOneMember_117" xlink:to="lab_cgen_ResearchAndDevelopmentGrantOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RetainerFee_118" xlink:to="lab_cgen_RetainerFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RetainerFee_119" xlink:to="lab_cgen_RetainerFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RetainerFee_120" xlink:to="lab_cgen_RetainerFee_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyContingentObligations_121" xlink:to="lab_cgen_RoyaltyContingentObligations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyContingentObligations_122" xlink:to="lab_cgen_RoyaltyContingentObligations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyContingentObligations_123" xlink:to="lab_cgen_RoyaltyContingentObligations_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_124" xlink:to="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_125" xlink:to="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_126" xlink:to="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SalesAgreementWithLeerinkPartnerLlcMember_127" xlink:to="lab_cgen_SalesAgreementWithLeerinkPartnerLlcMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SalesAgreementWithLeerinkPartnerLlcMember_128" xlink:to="lab_cgen_SalesAgreementWithLeerinkPartnerLlcMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SalesAgreementWithLeerinkPartnerLlcMember_129" xlink:to="lab_cgen_SalesAgreementWithLeerinkPartnerLlcMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayFundNonCurrent_130" xlink:to="lab_cgen_SeverancePayFundNonCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayFundNonCurrent_131" xlink:to="lab_cgen_SeverancePayFundNonCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayFundNonCurrent_132" xlink:to="lab_cgen_SeverancePayFundNonCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayNet_133" xlink:to="lab_cgen_SeverancePayNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayNet_134" xlink:to="lab_cgen_SeverancePayNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayNet_135" xlink:to="lab_cgen_SeverancePayNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_136" xlink:to="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_137" xlink:to="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_138" xlink:to="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_139" xlink:to="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_140" xlink:to="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_141" xlink:to="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_142" xlink:to="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_143" xlink:to="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_144" xlink:to="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_145" xlink:to="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_146" xlink:to="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_147" xlink:to="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_148" xlink:to="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_149" xlink:to="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_150" xlink:to="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_151" xlink:to="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TradeAndOtherPayablesRelatedParties_152" xlink:to="lab_cgen_TradeAndOtherPayablesRelatedParties_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TradeAndOtherPayablesRelatedParties_153" xlink:to="lab_cgen_TradeAndOtherPayablesRelatedParties_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TradeAndOtherPayablesRelatedParties_154" xlink:to="lab_cgen_TradeAndOtherPayablesRelatedParties_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_155" xlink:to="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_156" xlink:to="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_157" xlink:to="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnderwritersMember_158" xlink:to="lab_cgen_UnderwritersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnderwritersMember_159" xlink:to="lab_cgen_UnderwritersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDevelopment_160" xlink:to="lab_us-gaap_BusinessDevelopment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDevelopment_161" xlink:to="lab_us-gaap_BusinessDevelopment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_162" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_163" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_164" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_165" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_166" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_167" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_168" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_169" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_170" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_171" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_172" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_173" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_174" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_175" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_176" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_177" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_178" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_179" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_180" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_181" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_182" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_183" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_184" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_185" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_186" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_187" xlink:to="lab_us-gaap_NetIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_188" xlink:to="lab_us-gaap_NetIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_189" xlink:to="lab_us-gaap_NetIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_190" xlink:to="lab_us-gaap_NetIncomeLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_191" xlink:to="lab_us-gaap_NetIncomeLoss_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_192" xlink:to="lab_us-gaap_OperatingExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_193" xlink:to="lab_us-gaap_OperatingExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_194" xlink:to="lab_us-gaap_OperatingExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_195" xlink:to="lab_us-gaap_OperatingExpenses_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_196" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_197" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_198" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_199" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments_200" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments_201" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_202" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_203" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_204" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_205" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_206" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_207" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_208" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_209" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_210" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_211" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_212" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_213" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_214" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_215" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_216" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_217" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_218" xlink:to="lab_us-gaap_StockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_219" xlink:to="lab_us-gaap_StockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_220" xlink:to="lab_us-gaap_StockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_221" xlink:to="lab_us-gaap_StockholdersEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_222" xlink:to="lab_cgen_GovernmentAndOtherGrantsDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RelatedPartyBalancesAndTransactionsAbstract_223" xlink:to="lab_cgen_RelatedPartyBalancesAndTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract_224" xlink:to="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IL_225" xlink:to="lab_country_IL_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_226" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_227" xlink:to="lab_dei_CoverAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_228" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_229" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_230" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_231" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_232" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_233" xlink:to="lab_dei_EntityAddressAddressLine1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_234" xlink:to="lab_dei_EntityAddressAddressLine2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine3_235" xlink:to="lab_dei_EntityAddressAddressLine3_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_236" xlink:to="lab_dei_EntityAddressCityOrTown_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry_237" xlink:to="lab_dei_EntityAddressCountry_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_238" xlink:to="lab_dei_EntityAddressPostalZipCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_239" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_240" xlink:to="lab_dei_EntityFileNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_241" xlink:to="lab_dei_EntityIncorporationStateCountryCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_242" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_243" xlink:to="lab_srt_MaximumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_244" xlink:to="lab_srt_MinimumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_245" xlink:to="lab_srt_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_246" xlink:to="lab_srt_RangeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_247" xlink:to="lab_srt_RangeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_248" xlink:to="lab_srt_StatementGeographicalAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_249" xlink:to="lab_srt_StatementGeographicalAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis_250" xlink:to="lab_srt_StatementScenarioAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_251" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_252" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_253" xlink:to="lab_us-gaap_AccountsPayableCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_254" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_255" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_256" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_257" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_258" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_259" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_260" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_261" xlink:to="lab_us-gaap_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_262" xlink:to="lab_us-gaap_Assets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_263" xlink:to="lab_us-gaap_AssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_264" xlink:to="lab_us-gaap_AssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_265" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_266" xlink:to="lab_us-gaap_AssetsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_267" xlink:to="lab_us-gaap_AssetsNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_268" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_269" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_270" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_271" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_272" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_273" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_274" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_275" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_276" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_277" xlink:to="lab_us-gaap_AwardTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_278" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_279" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_280" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_281" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_282" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_283" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_284" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_285" xlink:to="lab_us-gaap_CommitmentsAndContingencies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_286" xlink:to="lab_us-gaap_CommitmentsAndContingencies_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_287" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_288" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_289" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_290" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_291" xlink:to="lab_us-gaap_CommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_292" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_293" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_294" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_295" xlink:to="lab_us-gaap_CommonStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_296" xlink:to="lab_us-gaap_CommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_297" xlink:to="lab_us-gaap_CommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_298" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_299" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_300" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesRelatedParty_301" xlink:to="lab_us-gaap_CostsAndExpensesRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesRelatedParty_302" xlink:to="lab_us-gaap_CostsAndExpensesRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_303" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_304" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_305" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_306" xlink:to="lab_us-gaap_Depreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_307" xlink:to="lab_us-gaap_EarningsPerShareBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_308" xlink:to="lab_us-gaap_EarningsPerShareBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_309" xlink:to="lab_us-gaap_EarningsPerShareDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_310" xlink:to="lab_us-gaap_EarningsPerShareDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_311" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_312" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_313" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_314" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_315" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_316" xlink:to="lab_us-gaap_EmployeeStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_317" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost_318" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfAssetsAcquired_319" xlink:to="lab_us-gaap_FairValueOfAssetsAcquired_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_320" xlink:to="lab_us-gaap_FinancialInstrumentAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_321" xlink:to="lab_us-gaap_GainContingenciesByNatureAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_322" xlink:to="lab_us-gaap_GuaranteeObligationsByNatureAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsMaximumExposure_323" xlink:to="lab_us-gaap_GuaranteeObligationsMaximumExposure_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsMaximumExposure_324" xlink:to="lab_us-gaap_GuaranteeObligationsMaximumExposure_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_325" xlink:to="lab_us-gaap_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_326" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_327" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_328" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_329" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_330" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_331" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_332" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncomeTableTextBlock_333" xlink:to="lab_us-gaap_InterestAndOtherIncomeTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeDepositsWithFinancialInstitutions_334" xlink:to="lab_us-gaap_InterestIncomeDepositsWithFinancialInstitutions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_335" xlink:to="lab_us-gaap_InvestmentIncomeInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_336" xlink:to="lab_us-gaap_InvestmentIncomeInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_337" xlink:to="lab_us-gaap_InvestmentIncomeInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_338" xlink:to="lab_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_339" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_340" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_341" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_342" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_343" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_344" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_345" xlink:to="lab_us-gaap_LiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_346" xlink:to="lab_us-gaap_LiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_347" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_348" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_349" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_350" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent_351" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent_352" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy_353" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy_354" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_355" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_356" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_357" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_358" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_359" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_360" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_361" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_362" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_363" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_364" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_365" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_366" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_367" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_368" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_369" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_370" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_371" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_372" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_373" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_374" xlink:to="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_375" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_376" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_377" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_378" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_379" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_380" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_381" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_382" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_383" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_384" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_385" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_386" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_387" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_388" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_389" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_390" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_391" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermInvestments_392" xlink:to="lab_us-gaap_OtherShortTermInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_393" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_394" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_395" xlink:to="lab_us-gaap_PlanNameAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_396" xlink:to="lab_us-gaap_PlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_397" xlink:to="lab_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_398" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrent_399" xlink:to="lab_us-gaap_PrepaidExpenseNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_400" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_401" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_402" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_403" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_404" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_405" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_406" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_407" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_408" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_409" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_410" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_411" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_412" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_413" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_414" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_415" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_416" xlink:to="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_417" xlink:to="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_418" xlink:to="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_419" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_420" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_421" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyLeaseGuaranteeMember_422" xlink:to="lab_us-gaap_PropertyLeaseGuaranteeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_423" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_424" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_425" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_426" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_427" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_428" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_429" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_430" xlink:to="lab_us-gaap_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_431" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_432" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_433" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_434" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_435" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_436" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_437" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_438" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_439" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_440" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_441" xlink:to="lab_us-gaap_ShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_442" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_443" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_444" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_445" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_446" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_447" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_448" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_449" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_450" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_451" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_452" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_453" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_454" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_455" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_456" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_457" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_458" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_459" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_460" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_461" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_462" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_463" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_464" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_465" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_466" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_467" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_468" xlink:to="lab_us-gaap_StatementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_469" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_470" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_471" xlink:to="lab_us-gaap_StatementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_472" xlink:to="lab_us-gaap_StockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_473" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_474" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_475" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_476" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_477" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_478" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_479" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_480" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_481" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_482" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_483" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_484" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_485" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionPlanExpense_486" xlink:to="lab_us-gaap_StockOptionPlanExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_487" xlink:to="lab_us-gaap_SubsequentEventLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_488" xlink:to="lab_us-gaap_SubsequentEventMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_489" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_490" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_491" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_492" xlink:to="lab_us-gaap_SubsequentEventTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_493" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_494" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_495" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentAxis_496" xlink:to="lab_us-gaap_SupplyCommitmentAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_497" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_498" xlink:to="lab_us-gaap_TypeOfArrangementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_499" xlink:to="lab_us-gaap_WarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_500" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_501" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_502" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_503" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_504" xlink:to="lab_us-gaap_AssetsAbstract_0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>cgen-20230630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#cgen-daei1" roleURI="http://cgen.com/role/cgen-daei1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#cgen-cbs" roleURI="http://cgen.com/role/cgen-cbs"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#cgen-cbsp" roleURI="http://cgen.com/role/cgen-cbsp"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#cgen-csocl" roleURI="http://cgen.com/role/cgen-csocl"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#cgen-socise1" roleURI="http://cgen.com/role/cgen-socise1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://cgen.com/role/ConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#cgen-g" roleURI="http://cgen.com/role/cgen-g"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#cgen-sap1" roleURI="http://cgen.com/role/cgen-sap1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#UnauditedInterimConsolidatedFinancialStatements" roleURI="http://cgen.com/role/UnauditedInterimConsolidatedFinancialStatements"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#cgen-cac" roleURI="http://cgen.com/role/cgen-cac"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#cgen-se1" roleURI="http://cgen.com/role/cgen-se1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#cgen-fin" roleURI="http://cgen.com/role/cgen-fin"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#cgen-rpbat" roleURI="http://cgen.com/role/cgen-rpbat"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#cgen-set" roleURI="http://cgen.com/role/cgen-set"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#cgen-fint" roleURI="http://cgen.com/role/cgen-fint"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#RelatedPartyBalancesAndTransactionsTables" roleURI="http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#cgen-gd1" roleURI="http://cgen.com/role/cgen-gd1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#CommitmentsAndContingenciesDetails" roleURI="http://cgen.com/role/CommitmentsAndContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#ShareholdersEquityIssuanceOfSharesDetails" roleURI="http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#ShareholdersEquityScheduleOfStock-basedCompensationDetails" roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#cgen-find" roleURI="http://cgen.com/role/cgen-find"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#cgen-rpbatd" roleURI="http://cgen.com/role/cgen-rpbatd"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#SUBSEQUENTEVENTS" roleURI="http://cgen.com/role/SUBSEQUENTEVENTS"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#SUBSEQUENTEVENTSNarrativeDetails" roleURI="http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#MARKETABLESECURITIES" roleURI="http://cgen.com/role/MARKETABLESECURITIES"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#MARKETABLESECURITIESTables" roleURI="http://cgen.com/role/MARKETABLESECURITIESTables"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20230630.xsd#MARKETABLESECURITIESDetails" roleURI="http://cgen.com/role/MARKETABLESECURITIESDetails"/>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-daei1">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_16"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentType_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_AmendmentFlag_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityFileNumber_9" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_10" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressAddressLine1_11" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressAddressLine2_12" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressAddressLine3_13" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressCityOrTown_14" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressCountry_15" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressPostalZipCode_16" order="150" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-cbs">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SeverancePayFundNonCurrent" xlink:label="loc_cgen_SeverancePayFundNonCurrent_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_23"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_34"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_OtherShortTermInvestments_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AssetsCurrent_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_9" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_9" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_9" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_9" xlink:to="loc_cgen_SeverancePayFundNonCurrent_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_11" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_12" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_9" xlink:to="loc_us-gaap_AssetsNoncurrent_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_17" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_AccountsPayableCurrent_17" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_19" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_20" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_LiabilitiesCurrent_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_23" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_23" xlink:to="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_23" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_24" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_23" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_25" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_23" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_CommitmentsAndContingencies_28" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_StockholdersEquityAbstract_29" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_CommonStockValue_29" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_30" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_31" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_StockholdersEquity_32" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_34" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-cbsp">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4" order="30" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-csocl">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaap_BusinessDevelopment_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_16"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_BusinessDevelopment_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_OperatingExpenses_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_cgen_FinancialIncomeExpenseNet_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_10" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_10" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasic_13" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_14" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_15" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_16" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-socise1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_20"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_RetainedEarningsMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockholdersEquity_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_cgen_NumberOfWarrantsExercised_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_13" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_14" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_15" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_16" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_17" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_NetIncomeLoss_18" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockholdersEquity_19" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_20" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AccretionOfDiscountOnMarketableSecurities" xlink:label="loc_cgen_AccretionOfDiscountOnMarketableSecurities_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_34"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" xlink:label="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_35"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_IssuanceExpenses" xlink:label="loc_cgen_IssuanceExpenses_36"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_ShareBasedCompensation_2" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_Depreciation_3" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_AccretionOfDiscountOnMarketableSecurities_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_SeverancePayNet_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_9" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_10" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_11" order="90" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_12" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_13" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_14" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_15" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_16" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_26" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_26" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_26" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_26" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_27" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_26" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_28" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_26" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_31" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_33" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_34" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_35" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_cgen_IssuanceExpenses_36" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-g">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sap1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/UnauditedInterimConsolidatedFinancialStatements">
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract" xlink:label="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock" xlink:label="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract_0" xlink:to="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-cac">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-se1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-fin">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-rpbat">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_7" order="60" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-set">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_us-gaap_EmployeeStockMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-fint">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables">
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RelatedPartyBalancesAndTransactionsAbstract" xlink:label="loc_cgen_RelatedPartyBalancesAndTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_RelatedPartyBalancesAndTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-gd1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AccruedMilestonePayment" xlink:label="loc_cgen_AccruedMilestonePayment_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:label="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_AccruedMilestonePayment_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_7" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_GovernmentAndOtherGrantsTable" xlink:label="loc_cgen_GovernmentAndOtherGrantsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyLeaseGuaranteeMember" xlink:label="loc_us-gaap_PropertyLeaseGuaranteeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IL" xlink:label="loc_country_IL_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_GovernmentAndOtherGrantsMember" xlink:label="loc_cgen_GovernmentAndOtherGrantsMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="loc_cgen_GovernmentAndOtherGrantsDomain_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_CommercialLicenseAgreementMember" xlink:label="loc_cgen_CommercialLicenseAgreementMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="loc_us-gaap_SupplyCommitmentAxis_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_CollaborationAgreementWithUSAntibodyCompanyMember" xlink:label="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_GovernmentAndOtherGrantsLineItems" xlink:label="loc_cgen_GovernmentAndOtherGrantsLineItems_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_21"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_22"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_23"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_24"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_25"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_26"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_28"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_29"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_30"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_PercentageOfRoyaltiesOnNetSales" xlink:label="loc_cgen_PercentageOfRoyaltiesOnNetSales_31"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AmountIncurredMilestonePayments" xlink:label="loc_cgen_AmountIncurredMilestonePayments_32"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_cgen_GovernmentAndOtherGrantsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_1" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_1" xlink:to="loc_us-gaap_PropertyLeaseGuaranteeMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_srt_StatementGeographicalAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4" xlink:to="loc_srt_SegmentGeographicalDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4" xlink:to="loc_country_IL_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_7" xlink:to="loc_us-gaap_GainContingencyNatureDomain_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingencyNatureDomain_7" xlink:to="loc_cgen_GovernmentAndOtherGrantsMember_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_srt_RangeAxis_10" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_10" xlink:to="loc_srt_RangeMember_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_10" xlink:to="loc_srt_MinimumMember_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_10" xlink:to="loc_srt_MaximumMember_11" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsAxis_14" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_14" xlink:to="loc_cgen_GovernmentAndOtherGrantsDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_14" xlink:to="loc_cgen_May2012AgreementMember_14" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_14" xlink:to="loc_cgen_CommercialLicenseAgreementMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_us-gaap_SupplyCommitmentAxis_18" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentAxis_18" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_18" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_18" xlink:to="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_18" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsLineItems_21" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_RoyaltyContingentObligations_24" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_ContingentFees_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_ParticipationRights_26" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_RetainerFee_27" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_28" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_AgreementStartDate_29" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_AgreementTerminationDescription_30" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_PercentageOfRoyaltiesOnNetSales_31" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_AmountIncurredMilestonePayments_32" order="110" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AtMarketOfferingProgramMember" xlink:label="loc_cgen_AtMarketOfferingProgramMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_AgreementMember" xlink:label="loc_cgen_AgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_SalesAgreementWithLeerinkPartnerLlcMember" xlink:label="loc_cgen_SalesAgreementWithLeerinkPartnerLlcMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_26"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_28"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_29"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_DeferredParticipationOfBmsInRdExpenses" xlink:label="loc_cgen_DeferredParticipationOfBmsInRdExpenses_30"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_RelativeFairValueOfDeferredParticipation" xlink:label="loc_cgen_RelativeFairValueOfDeferredParticipation_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_48"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_AtMarketOfferingProgramMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_AgreementMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_MasterClinicalAgreementMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_CollaborativeArrangementsMember_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_CollaborativeArrangementsTwoMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_SalesAgreementWithLeerinkPartnerLlcMember_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_10" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_cgen_RegisteredDirectOfferingMember_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_cgen_UnderwritersMember_11" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_us-gaap_WarrantMember_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_15" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_15" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15" xlink:to="loc_us-gaap_EmployeeStockMember_15" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_18" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_22" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_23" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_24" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_25" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_26" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_27" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_28" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_cgen_PercentageOfClosingPrice_29" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_cgen_DeferredParticipationOfBmsInRdExpenses_30" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_cgen_RelativeFairValueOfDeferredParticipation_31" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_32" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_33" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_34" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_35" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_36" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_37" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_38" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_39" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_StockOptionPlanExpense_41" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_42" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_43" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_44" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_45" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_46" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_47" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_48" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_us-gaap_EmployeeStockMember_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_12" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_13" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-find">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_cgen_FinancialIncomeExpenseNet_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-rpbatd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_TradeAndOtherPayablesRelatedParties" xlink:label="loc_cgen_TradeAndOtherPayablesRelatedParties_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_cgen_TradeAndOtherPayablesRelatedParties_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/SUBSEQUENTEVENTS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_Plan2010Member" xlink:label="loc_cgen_Plan2010Member_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20230630.xsd#cgen_EmployeeSharePurchasePlanMember" xlink:label="loc_cgen_EmployeeSharePurchasePlanMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_PlanNameAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4" xlink:to="loc_us-gaap_PlanNameDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4" xlink:to="loc_cgen_Plan2010Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4" xlink:to="loc_cgen_EmployeeSharePurchasePlanMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/MARKETABLESECURITIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/MARKETABLESECURITIESTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/MARKETABLESECURITIESDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0" !8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
6*** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image00001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ =P!2  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !O 1L# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% $<F_RG\H+YF#MW=,]L^U>>OH?Q49V9?%^D("?NC3P0/;D9KLM?
MT*T\1Z/-I=\9A;S%2YAD*-P0PY'N*\2N+3X-6=S+;7&N:U%-$Q1T9KK*D=1]
MR@#NO[!^*W_0Y:3_ ."X?X4?V#\5O^ARTG_P7#_"N V?!3_H8=8_[[NO_B*-
MGP4_Z&'6/^^[K_XB@#LM6A^(NA:9-J6I^.]&MK.''F2OIPPN2 .@SR2!7E6J
MI'K.HS7][\6[5IY3EMD5PBCV"@  >PK<O(_@N;*;R]8U2Y<(2D+R7*K(1T&2
MAQD]ZXC^UOAW_P!"=K'_ (-/_L* +W]CV/\ T5FW_P"^;K_"OIWPI;QVGA'1
MX(KO[9&EG%MN02?.^4?/SSSU_&OE3^UOAW_T)VL?^#3_ .PKVGX6_%#P]J45
MOX9BM[C3&MXQ'9K>7'F>:.?E#8'(X 'ITZ4 >MT444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !56],\=G
M,]G;13W*J3''(^Q7;T+8./KBK5% 'GO_  E7Q _Z)DO_ (.H/\*/^$J^('_1
M,E_\'4'^%;GC#1KS5+6"6T\476@>03OEBV['!QPVX@9SC!_QKCO^$:U7_HL-
MQ^47_P 70!J_\)5\0/\ HF2_^#J#_"L?7M:^+%_!&-&\'+I4RMEV:_MKA7'I
M@@8/N#3_ /A&M5_Z+#<?E%_\71_PC6J_]%AN/RB_^+H YE]2^.2.4>+3T8=5
M9[,$?^/4W^U?CA_<TW_O[9__ !50>,OAWH312:[XC^(SW3(%C:1+9))",X P
MK9/6N&_X1_X9_P#0\ZA_X*6_QH ]\^'^N^-)GDLO&5A;*Q.Z&\@N8#D_W&1&
M)SZ$#ZUZ'7R38:1\.K+4+6[M_'6HB>"5)(\:2_W@01W]:^M1R : %HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ***Y#6;SQ]]O9=#TG1?LB\![VZ?>_OA1A?S- &;XT\5^$)FFT#7;#4-0B1
ME:5(+25XPPZ#<N,D>U<5GX0?]"=JG_@#<?\ Q5=M]L^+'_0)\+?^!$U'VSXL
M?] GPM_X$34 <3GX0?\ 0G:I_P" -Q_\51GX0?\ 0G:I_P" -Q_\571ZAXP\
M=Z3,(=2D\"V4Q&1'<ZD\;$>N&(K"UOQCXTU2R^S6OBGP+IC$_--;:LI<CT!;
M./PYH Y?Q+?>"[62!/#GPWGO5*DS/=1W$>/0  Y/U^E8/]L6/_1)K?\ [ZNO
M\:Z#S_B#_P!%2\/?^#J/_P")K>T3PU\5M7DMYQX\M7TV1L/<VEV)_E'7;A0"
M?QH RO -C9>*/$\%N_PTM+"VB/FS74DEP!&!TQN."2>@_P *^C:IZ=9M8:?#
M:O=7%VT:@-/</NDD/J>WY"KE !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% &?J6MZ3HJHVJ:G9V*R$A#<SK&&^FXC-
M<IXA\0^'M;MUM[;XBV>E(#\[6=[ ';_@3$X'TKG]7\8Z;JMZ9-0^%6O:BT>8
MXYI](#DKGMN&0#UQ5'^W/#G_ $175/\ P11_X4 6?L.A_P#1:M0_\&\%'V'0
M_P#HM6H?^#>"JW]N>'/^B*ZI_P""*/\ PH_MSPY_T175/_!%'_A0!'JLOA_2
M=/DO)/C#K5P$Z16FH1S2,?0*O\SQ7''XA: PP?&/Q$P1C[\'_P 74USJ_BC[
M5*;7X.:4MN7/E"7P[(7"YX#$<9QZ5%_:_C#_ *([HW_A.2_XT <S+_PK&>5I
M9KWQE)(QRSO#;DD_7=6QX<\'>"O%=Y]FT6#QI<MGYY/(MA''_O,6P*]+^'_A
M_4?$.Z\\2^!?"VE6*DJD/]D;+B0^N&)VK[D<_K7JUCI]EIEJMMI]I!:P*<B*
M",(H_ <4 >;:!\!O"6BWHNKG[3JC+]R*\*F,?50!G\>*]0C1(HUCC5411A54
M8 %/HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQEC7MU% 'Q3_ ,*V\:_]"OJG_@.U?8F@:>ND>'=-TY5VBUM8X< =U4 UI44
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165163084064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COMPUGEN LTD.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001119774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">26 Harokmim Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Holon<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">5885849<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165164528896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 17,071<span></span>
</td>
<td class="nump">$ 11,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">615<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term bank deposits</a></td>
<td class="nump">44,297<span></span>
</td>
<td class="nump">72,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investment in marketable securities</a></td>
<td class="nump">4,551<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other accounts receivable and prepaid expenses</a></td>
<td class="nump">2,865<span></span>
</td>
<td class="nump">2,417<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">69,399<span></span>
</td>
<td class="nump">86,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Long-term prepaid expenses</a></td>
<td class="nump">1,912<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SeverancePayFundNonCurrent', window );">Severance pay fund</a></td>
<td class="nump">2,788<span></span>
</td>
<td class="nump">2,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right to use asset</a></td>
<td class="nump">1,606<span></span>
</td>
<td class="nump">1,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,350<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">7,656<span></span>
</td>
<td class="nump">8,051<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">77,055<span></span>
</td>
<td class="nump">94,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade payables</a></td>
<td class="nump">1,680<span></span>
</td>
<td class="nump">1,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses', window );">Short-term deferred participation in R&amp;D expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturity of operating lease liability</a></td>
<td class="nump">610<span></span>
</td>
<td class="nump">613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Other accounts payable and accrued expenses</a></td>
<td class="nump">8,511<span></span>
</td>
<td class="nump">9,208<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,801<span></span>
</td>
<td class="nump">11,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON- CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long term operating lease liability</a></td>
<td class="nump">991<span></span>
</td>
<td class="nump">1,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsLiabilityNoncurrent', window );">Accrued severance pay</a></td>
<td class="nump">3,262<span></span>
</td>
<td class="nump">3,265<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">4,253<span></span>
</td>
<td class="nump">4,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENT LIABILITIES (NOTE 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized on June 30, 2023, and December 31, 2022; 88,233,766 and 86,624,643 shares issued and outstanding on June 30, 2023, and December 31, 2022, respectively</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">536,145<span></span>
</td>
<td class="nump">533,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(474,388)<span></span>
</td>
<td class="num">(455,773)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">62,001<span></span>
</td>
<td class="nump">77,680<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 77,055<span></span>
</td>
<td class="nump">$ 94,176<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SeverancePayFundNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monthly deposits in externally managed funds which primarily cover Israeli law severance pay liability of one month's salary for each year of employment upon the retirement or death of an employee or termination of employment without a valid legal reason.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SeverancePayFundNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term deferred participation in R&amp;amp;D expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 712<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481179/712-10-25-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 712<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481179/712-10-25-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165162457680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value per share</a></td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">88,233,766<span></span>
</td>
<td class="nump">86,624,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">88,233,766<span></span>
</td>
<td class="nump">86,624,643<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165164489728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses, net</a></td>
<td class="nump">$ 15,206<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 13,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDevelopment', window );">Marketing and business development expenses</a></td>
<td class="nump">165<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">4,977<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,173<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">20,348<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_FinancialIncomeExpenseNet', window );">Financial and other income, net</a></td>
<td class="nump">1,697<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">779<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes on income</a></td>
<td class="nump">18,651<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="nump">36<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">18,615<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gains (losses) on marketable securities: Unrealized gains (losses) arising during the period, net</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="nump">$ 18,615<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 18,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share</a></td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of ordinary shares used in computing basic net loss per share</a></td>
<td class="nump">86,903,741<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">86,486,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of ordinary shares used in computing diluted net loss per share</a></td>
<td class="nump">86,903,741<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">86,486,612<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents an amount lower than $1</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_FinancialIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of financial and other income net of expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_FinancialIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165158685616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Ordinary shares [Member]</div></th>
<th class="th"><div>Additional paid-in capital [Member]</div></th>
<th class="th" colspan="2"><div>Accumulated deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 239<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 528,533<span></span>
</td>
<td class="num">$ (422,079)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 106,693<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">86,433,432<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">104<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, shares</a></td>
<td class="nump">33,186<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of ESPP shares</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">248<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of ESPP shares, (in shares)</a></td>
<td class="nump">158,025<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue', window );">Stock-based compensation issued to employees, directors and non-employees</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,189<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="num">(18,854)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(18,854)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">531,074<span></span>
</td>
<td class="num">(440,933)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">90,381<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Jun. 30, 2022</a></td>
<td class="nump">86,624,643<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">533,213<span></span>
</td>
<td class="num">(455,773)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 77,680<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">86,624,643<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">86,624,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares, net</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,150<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, net, (in shares)</a></td>
<td class="nump">1,609,123<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue', window );">Stock-based compensation issued to employees, directors and non-employees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,782<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Other comprehensive income (loss) from marketable securities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="num">(18,615)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(18,615)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 244<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 536,145<span></span>
</td>
<td class="num">$ (474,388)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 62,001<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Jun. 30, 2023</a></td>
<td class="nump">88,233,766<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">88,233,766<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents an amount lower than $ 1.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation relating to options issued to employees and directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165158717376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,615)<span></span>
</td>
<td class="num">$ (18,854)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,782<span></span>
</td>
<td class="nump">2,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AccretionOfDiscountOnMarketableSecurities', window );">Accretion of discount on marketable securities</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Realized gain on sale of marketable securities, net</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SeverancePayNet', window );">Increase (decrease) in severance pay, net</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Decrease in operating lease right of use asset</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Increase in interest receivables from short-term bank deposits</a></td>
<td class="num">(140)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Decrease (increase) in other accounts receivable and prepaid expenses</a></td>
<td class="num">(448)<span></span>
</td>
<td class="nump">764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Decrease (increase) in long-term prepaid expenses</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Decrease in trade payables</a></td>
<td class="num">(85)<span></span>
</td>
<td class="num">(2,387)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in other accounts payable and accrued expenses</a></td>
<td class="num">(894)<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Decrease in operating lease liability</a></td>
<td class="num">(394)<span></span>
</td>
<td class="num">(644)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses', window );">Decrease in deferred participation in R&amp;D expenses</a></td>
<td class="num">(325)<span></span>
</td>
<td class="num">(2,387)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(18,617)<span></span>
</td>
<td class="num">(20,683)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturity of short-term bank deposits</a></td>
<td class="nump">51,350<span></span>
</td>
<td class="nump">58,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Investment in short-term bank deposits</a></td>
<td class="num">(23,220)<span></span>
</td>
<td class="num">(38,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities', window );">Proceeds from maturity of marketable securities</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Investment in marketable securities</a></td>
<td class="num">(5,536)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(258)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">23,531<span></span>
</td>
<td class="nump">20,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares, net</a></td>
<td class="nump">1,351<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,351<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">6,265<span></span>
</td>
<td class="num">(143)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the period</a></td>
<td class="nump">11,421<span></span>
</td>
<td class="nump">8,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of the period</a></td>
<td class="nump">17,686<span></span>
</td>
<td class="nump">8,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction', window );">Purchase of property and equipment</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IssuanceExpenses', window );">Issuance expenses</a></td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AccretionOfDiscountOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of Accretion of discount on marketable securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AccretionOfDiscountOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in deferred participation in R&amp;amp;D expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in operating lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IssuanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of Issuance expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IssuanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchase property and equipment as non cash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SeverancePayNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Severance pay, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SeverancePayNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the Right-of-use asset obtained in exchange for operating lease liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165166677408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>GENERAL [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">GENERAL</a></td>
<td class="text">
    <div>
      <div>
        <div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 1:-</span>&#160;</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">GENERAL</span></span></span></td>
                </tr>

            </table>
            <div style="text-align:justify;line-height:1.25">&#160;</div>
            <div style="text-align:justify;line-height:1.25">
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                  <tr>
                    <td style="width:56.7pt">&#160;</td>
                    <td style="width:27.75pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Compugen Ltd. (the &#8220;Company&#8221;) is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Compugen&#8217;s innovative immuno-oncology pipeline consists of three clinical stage programs, targeting immune checkpoints Compugen discovered computationally by COM701, COM902 and rilvegostomig. The Company&#8217;s lead product candidates, COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody are in Phase 1 clinical trials in patients with MSS CRC and platinum resistant ovarian cancer. Rilvegostomig, a novel anti PD-1/TIGIT bispecific antibody with a TIGIT specific component that is derived from Compugen&#8217;s COM902 antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is in a Phase 2 clinical trial in patients with advanced or metastatic non-small cell lung and locally advanced or metastatic gastric cancer. In addition, the Company&#8217;s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. The most advanced preclinical program, COM503, is in IND enabling studies. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 to inhibit cancer growth in the tumor microenvironment.</span></span></div>
                    </td>
                  </tr>

              </table>
            </div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:27.75pt;vertical-align:top">&#160;</td>
                  <td style="width:auto;vertical-align:top;text-align:justify">&#160;</td>
                </tr>
                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:27.75pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company is headquartered in Holon, Israel. Its clinical development activities operate from its U.S. subsidiary in San Francisco, California.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:27.75pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has incurred losses in the amount of $18,615 during the six months ended June 30, 2023, has an accumulated deficit of $ 474,388 as of June 30, 2023, and has an accumulated negative cash flow from operating activities in the amount of $ 18,617 for the six months ended June 30, 2023. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements at the current level of yearly expenditures at least twelve months from the reporting date.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:27.75pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 5, 2013, the Company entered into a Research and Development Collaboration and License Agreement (&#8220;Bayer Agreement&#8221;) with Bayer Pharma AG (&#8220;Bayer&#8221;) for the research, development, and commercialization of antibody-based therapeutics against two novel Compugen-discovered immune checkpoint regulators.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the terms of the Bayer Agreement, the Company received an upfront payment of $10,000, and additional aggregate milestone payments of approximately $23,000.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On November 29, 2022, Bayer notified the Company that it had resolved to terminate, effective as of February 27, 2023, the Bayer Agreement.</span></span></div>
            <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          </div>
        </div>
        <div></div>
        <div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:27.75pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective March 30, 2018, the Company entered into an exclusive license agreement with MedImmune Limited, the global biologics research and development arm of AstraZeneca (&#8220;AstraZeneca&#8221;) to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bi-specific and multi-specific antibody products derived from COM902. AstraZeneca has the right to create multiple products under this license and is solely responsible for all research, development and commercial activities under the agreement. Compugen received a $10,000 upfront payment and $15,500 milestone payment out of up to $200,000 that the Company is eligible to receive in development, regulatory and commercial milestones for the first product as well as tiered royalties on future product sales. If additional products are developed, additional milestones and royalties would be due to Compugen for each product.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:54pt">&#160;</td>
                  <td style="width:31.5pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#8220;Master Clinical Agreement&#8221;) with Bristol Myers Squibb Company (&#8220;Bristol Myers Squibb&#8221;) to evaluate the safety and tolerability of Compugen&#8217;s COM701 in combination with Bristol Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors.<br/>&#160;<br/>Pursuant to the Master Clinical Agreement, as amended from time to time, Compugen sponsored the trials, which included the evaluation of the combination of COM701 and Opdivo&#174; &#177; Bristol Myers Squibb investigational anti-TIGIT, BMS-986207. Bristol Myers Squibb and Compugen each supplies its own compound(s) for the studies.<br/>&#160;<br/>In conjunction with the signing of the Master Clinical Agreement, Bristol Myers Squibb made a $12,000 investment in Compugen, see Note 6a.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Among several amendments to the Master Clinical Agreement, on November 10, 2021, the agreement was further amended and in conjunction with the signing of the amendment to the Agreement, Bristol Myers Squibb made a $20,000 investment in Compugen, see Note 6a.</span></span></span></div>
            <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>On August 3, 2022, the Company and Bristol Myers Squibb entered into a letter agreement pursuant to which the Master Clinical Agreement, as amended from time to time, was terminated as of such date.</span></span></span></span></span></div>
          </div>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165165413808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 2:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SIGNIFICANT ACCOUNTING POLICIES</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25;margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2022. The significant accounting policies applied in the annual financial statements of the Company as of December 31, 2022, are applied consistently in these interim consolidated financial statements, except as described below.</span></span></span></span></span></span></span></div>
        <div style="text-align:justify;line-height:1.25;margin-left:56.7pt">&#160;</div>
      </div>
      <div></div>
      <div style="margin-top:0pt;margin-bottom:0pt">
        <div style="margin-top:0pt;margin-bottom:0pt">
          <div style="margin-top:0pt;margin-bottom:0pt">
            <div>
              <div>

                  <div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span>Investments in marketable securities:</span></span></span></span></span></span></span></span></span></div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt">&#160;</div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span>The Company accounts for investments in marketable securities in accordance with ASC No. 320, &#8220;Investments - Debt Securities&#8221;.</span></span></span></span></span></span></span></span></span></div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt">&#160;</div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span>Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determinations at each balance sheet date. The Company classifies all of its debt securities as available-for-sale (&#8220;AFS&#8221;). Available-for-sale debt securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income (loss) in shareholders&#8217; equity. Realized gains and losses on sale of investments are included in financial income, net, and are derived using the specific identification method for determining the cost of securities sold.</span></span></span></span></span></span></span></span></span></div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization together with interest on securities is included in financial income, net.</span></span></span></span></span></span></span></div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt">&#160;</div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>At each reporting period, th</span></span></span></span></span></span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">e Company evaluates whethe</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>r declines in fair value below amortized cost are due to expected credit losses, as well as the Company&#8217;s ability and intent to hold the investment until a forecasted recovery occurs in accordance with ASC 326, Financial Instrument- Credit losses. Allowance for credit losses on AFS debt securities are recognized in the Company&#8217;s consolidated statements of income, and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive income (loss) in stockholders&#8217; equity.</span></span></span></span></span></span></span></div>
                  </div>

              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165166629888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract', window );"><strong>Unaudited Interim Consolidated Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock', window );">UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</a></td>
<td class="text">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 3:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. </span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="margin-left:56.7pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:110%">Operating results for the six-month period ended June&#160;30, 2023, are not necessarily indicative of the results that may be expected for the year ended December 31, 2023.</span></span></span></div>
        <div style="margin-left:56.7pt;line-height:1.25;text-align:justify">&#160;</div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of unaudited interim consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165166436672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">MARKETABLE SECURITIES</a></td>
<td class="text">
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>NOTE 4:-</span></span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:110%">MARKETABLE SECURITIES</span></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">&#160;</td>
            </tr>

        </table>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:56pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">The following is a summary of available-for-sale marketable securities as of June 30, 2023:</span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:56pt">&#160;</p>

          <div>
            <div>
              <div style="margin-left:56pt">
                <table border="0" cellpadding="0" cellspacing="0" style="width:90%">

                    <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
                      <td style="padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:left" valign="top">
                        <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left">&#160;</p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                      <td colspan="2" style="border-width:2px;border-bottom-style:solid;border-bottom-color:black;padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center" valign="bottom">
                        <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Amortized</strong></span></span></span><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">cost</strong></span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                      <td colspan="2" style="border-width:2px;border-bottom-style:solid;border-bottom-color:black;padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center" valign="bottom">
                        <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Gross</strong></span></span></span><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">unrealized </strong></span></span></span></p>
                        <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">gains</strong></span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                      <td colspan="2" style="border-width:2px;border-bottom-style:solid;border-bottom-color:black;padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center" valign="bottom">
                        <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Gross</strong></span></span></span><br/><strong style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">unrealized</strong></p>
                        <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">losses</strong></span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                      <td colspan="2" style="border-width:2px;border-bottom-style:solid;border-bottom-color:black;padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;vertical-align:bottom" valign="top">
                        <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt"><strong>Fair value</strong></span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                    </tr>
                    <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255);height:15px">
                      <td style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px" valign="top">
                        <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">Available-for-sale &#8211; matures within one year:</span></span></span></p>
                      </td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px">&#160;</td>
                      <td colspan="2" style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td colspan="2" style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td colspan="2" style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td colspan="2" style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                    </tr>
                    <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);height:15px">
                      <td style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;width:52%" valign="top">
                        <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">Governmental bonds</span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:1%">
                        <p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"><span style="font-size:10pt;text-align:left;margin:0px"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">$</span></span></span></p>
                      </td>
                      <td colspan="1" style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:9%" valign="bottom">
                        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">4,551</span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:1%">
                        <p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"><span style="font-size:10pt;text-align:left;margin:0px"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">$</span></span></span></p>
                      </td>
                      <td colspan="1" style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:9%" valign="bottom">
                        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><span style="-sec-ix-hidden:Fxbrl_20230728101901825">*</span>&#160;</span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:1%">
                        <p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"><span style="font-size:10pt;text-align:left;margin:0px"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">$</span></span></span></p>
                      </td>
                      <td colspan="1" style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:9%" valign="bottom">
                        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><span style="-sec-ix-hidden:Fxbrl_20230728101905592">*</span></span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:1%">
                        <p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"><span style="font-size:10pt;text-align:left;margin:0px"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">$</span></span></span></p>
                      </td>
                      <td colspan="1" style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:9%" valign="bottom">
                        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">4,551</span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                    </tr>

                </table>
              </div>
              <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:56pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">*&#160; &#160; &#160; &#160; &#160; Represents an amount lower than $1</span></span></span></p>
            </div>
          </div>

        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:56pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">The Company did not have investments in marketable securities as of June 30, 2022.</span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:56pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">As of June 30, 2023, the Company did not record an allowance for credit losses for its available for sale marketable securities.</span></span></span></p>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165258051232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">
        <div>
          <div>
            <div>
              <div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                    <tr style="vertical-align:top">
                      <td style="text-align:right;vertical-align:top;width:56.7pt">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 5:-</span></span></span></div>
                      </td>
                      <td style="text-align:left;vertical-align:top;width:auto">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">COMMITMENTS AND CONTINGENCIES</span></span></span>
                          <p style="margin:0pt">&#160;</p>
                        </div>
                      </td>
                    </tr>

                </table>
              </div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                  <tr>
                    <td style="width:56.7pt">&#160;</td>
                    <td style="width:27.75pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company provided bank guarantees in the amount of $284 in favor of its offices in Israel, car leases in Israel and credit card security for its U.S. subsidiary.</span></span>
                        <p style="margin:0pt">&#160;</p>
                      </div>
                    </td>
                  </tr>

              </table>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                  <tr>
                    <td style="width:56.7pt">&#160;</td>
                    <td style="width:27.75pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company received in the past grants from the office of the Israel Innovation Authority of the Israeli Ministry of Industry, Trade and Labor, formerly known as the Office of the Chief Scientist (&#8220;IIA&#8221;). The Company is not obligated to repay any amounts received from the IIA if it does not generate any income from products which incorporate technologies which were funded by such research program(s).</span></span>
                        <p style="margin:0pt">&#160;</p>
                      </div>
                    </td>
                  </tr>

              </table>
              <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">If income is generated from products which incorporate technologies which were funded by a research program, the Company is committed to pay royalties at a rate of between 3% to 5% of future revenue generated from products that incorporate technologies that were funded by such research program(s), up to a maximum of 100% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum amount to be repaid is 100% plus interest at LIBOR).</span></span>
                <p style="margin:0pt">&#160;</p>
              </div>
              <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2023, the Company&#8217;s aggregate contingent obligations for payments to IIA, based on royalty-bearing participation received or accrued, net of royalties paid or accrued, totaled $9,800.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                  <tr>
                    <td style="width:56.7pt">&#160;</td>
                    <td style="width:27.75pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 25, 2012, the Company entered into an Antibodies Discovery Collaboration Agreement (the &#8220;Antibodies Discovery Agreement&#8221;) with a U.S. antibody technology company (&#8220;mAb Technology Company&#8221;), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement, the mAb Technology Company is entitled to certain royalties that could be eliminated upon payment of certain one-time fees (all milestone and royalties payments referred together as &#8220;Contingent Fees&#8221;). For the six-month periods ended June 30, 2023 and 2022, the Company did not incur Contingent Fees.</span></span></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="text-align:justify;margin-left:84pt;line-height:1.25;font-family:Times New Roman, Times, serif">&#160;</div>
          <div></div>
          <div>
            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                  <tr>
                    <td style="vertical-align:top;width:56.7pt">&#160;</td>
                    <td style="vertical-align:top;width:27.75pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
                    <td style="vertical-align:top;text-align:justify;width:auto">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 9, 2012, the Company entered into agreement (the &#8220;May 2012 Agreement&#8221;) with a U.S. Business Development Strategic Advisor (&#8220;Advisor&#8221;) for the purpose of entering into transactions with pharma companies related to selected pipeline program candidates. Under the agreement, the Advisor was to be entitled to 4% of the cash considerations that may be received under such transactions. In 2014, the May 2012 Agreement was terminated, except with respect to certain payments arising from the Bayer Agreement which survive termination of the May 2012 Agreement until August 5, 2025.</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif">
                <p style="margin:0pt">&#160;</p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Bayer Agreement was terminated effective February 27, 2023 and no further payments to the Advisor are expected under the May 2012 Agreement.<br/>&#160;<br/>For the six months ended June 30, 2023 and 2022, the Company had not paid nor accrued any expenses related to the May 2012 Agreement.</span></span>
                <p style="margin:0pt">&#160;</p>
              </div>
              <div style="text-align:justify;line-height:1.25">
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                    <tr>
                      <td style="width:56.7pt">&#160;</td>
                      <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify">
                        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective as of January 5, 2018, the Company entered into a Commercial License Agreement (&#8220;CLA&#8221;) with a European cell line development company. Under the agreement the Company is required to pay an annual maintenance fee, certain amounts upon the occurrence of specified milestones events, and 1% royalties on annual net sales with respect to each commercialized product manufactured using the company&#8217;s cell line. Royalties due under the CLA are creditable against the annual maintenance fee. In addition, the Company may at any time prior to the occurrence of a specific milestone event buy-out the royalty payment obligations in a single fixed amount. For the six-month periods ended June 30, 2023 and 2022, the Company did not incur milestone payments.</span></span>
                          <p style="margin:0pt">&#160;</p>
                        </div>
                      </td>
                    </tr>

                </table>
              </div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                  <tr>
                    <td style="width:56.7pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective as of October 28, 2020, the Company entered into a collaboration agreement with a U.S. antibody discovery and optimization company for generation and optimization of therapeutic antibodies for the Company. Under the agreement, the Company is required to pay service fees per services performed and certain amounts upon the occurrence of specified milestones events, and single-digit percent royalties on annual net sales with respect to each product sold that comprises or contains one or more antibodies so generated or optimized. The royalty rate is dependent upon the product type and any third-party contribution. For the six-month periods ended June 30, 2023 and 2022 the Company did not incur milestone payments.</span></span></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165165622240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>SHAREHOLDERS' EQUITY [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">SHAREHOLDERS' EQUITY</a></td>
<td class="text">
    <div>
      <div>
        <div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>NOTE 6:-</span></span></span></span></span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>SHAREHOLDERS' EQUITY</span></span></span></span></span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>a.</span></span></span></span></span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>Issuance of Shares:</span></span></span></span></span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>On June 14, 2018, the Company entered into an agreement in connection with a registered direct offering (the &#8220;Offering&#8221;) of an aggregate of 5,316,457 Ordinary Shares (the &#8220;RD Shares&#8221;) of the Company at a purchase price of $3.95 per RD Share. In connection with the issuance of the RD Shares, the Company also issued warrants to purchase an aggregate of up to 4,253,165 additional Ordinary Shares (the &#8220;Warrants&#8221;). The Warrants were exercisable at a price of $4.74 per Ordinary Share and had a term of five years from the date of issuance. The Offering was made pursuant to the Company&#8217;s Registration Statement. Proceeds from the Offering were $19,767 (net of $1,233 issuance expenses).</span></span></span></span></span></span></span></span></div>
            <div></div>
          </div>
        </div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div>
          <div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>During the period from January 1, 2021 through June 30, 2023, warrants to purchase an aggregate of 3,955,696 Ordinary Shares were exercised with proceeds of approximately $18,750, and the remaining warrants to purchase up to 297,469 Ordinary Shares expired in June 2023.<br/>&#160;</span></span></span></span></span></span></span></div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement with Bristol Myers Squibb to evaluate the safety and tolerability of the Company&#8217;s COM701 in combination with Bristol Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors. In conjunction with the Master Clinical Agreement, Bristol Myers Squibb made a $12,000 equity investment in the Company.</span></span></span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Under the terms of the securities purchase agreement, Bristol Myers Squibb purchased 2,424,243 ordinary shares of the Company at a purchase price of $4.95 per share. The share price represented a 33% premium over the average closing price of the Company&#8217;s ordinary shares for twenty (20) Nasdaq trading days prior to the execution of the securities purchase agreement. The investment closed on October 12, 2018.</span></span></span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The premium over the fair market value in the amount of $4,121 represents the relative fair value of deferred participation of Bristol Myers Squibb in R&amp;D expenses which are amortized over the period of the clinical trial based on the progress in the R&amp;D, in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221; and $7,788 (net of $91 issuance expenses) were considered equity investment.</span></span></span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In conjunction with the signing of the amendment to the Master Clinical Agreement in November 2021, Bristol Myers Squibb made a $20,000 investment in the Company, purchasing 2,332,815 ordinary shares of the Company at a purchase price of $8.57333 per share. The share price represented a 33% premium over the closing price of Company&#8217;s ordinary shares on the last Nasdaq trading day immediately prior to the execution of the securities purchase agreement.</span></span></span></span></span></span></div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The premium over the fair market value in the amount of $5,000 represents the relative fair value of deferred participation of Bristol Myers Squibb in R&amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;D, in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221;) and $14,958 (net of $42 issuance expenses) were considered equity investment.</span></span></span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In March 2020, the Company entered into an underwriting agreement with SVB Leerink LLC and Stifel, Nicolaus &amp; Company, Incorporated, as representatives of the several underwriters relating to the issuance and sale in a public offering of 8,333,334 of the Company&#8217;s ordinary shares at a price to the public of $9.00 per share (and a price of $8.46 per share to the underwriters). Such shares were issued on March 16, 2020. In addition, the Company granted the underwriters a 30-day option to purchase additional ordinary shares at the price set forth above. On April 14, 2020, the Company issued and sold, pursuant to that underwriting agreement an additional 483,005 ordinary shares pursuant to the underwriters&#8217; option specified above. The Company sold a total of 8,816,339 ordinary shares in the offering with proceeds of $74,147 (net of $5,200 issuance expenses).</span></span></span></span></span></span></div>
            <div></div>
          </div>
        </div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div>
          <div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On January 31, 2023, the Company entered into a Sales Agreement with Leerink Partners LLC (previously known as SVB Securities LLC) (&#8220;Leerink Partners&#8221;), as sales agent, pursuant to which the Company may offer and sell, from time to time through Leerink Partners, its ordinary shares through an &#8220;at the market offering&#8221; (ATM). The offer and sale of our ordinary shares, if any, will be made pursuant to the Company&#8217;s shelf registration statement on Form F-3, as supplemented by a prospectus supplement. Pursuant to the applicable prospectus supplement, the Company may offer and sell up to $50,000 of its ordinary shares. As of June 30, 2023, 1,609,123 shares were issued and sold through the ATM, with proceeds of approximately $1,154 (net of $458 issuance expenses).</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>b.</span></span></span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share option plan:</span></span></span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>During the six-month period ended June 30, 2023, the Company&#8217;s Board of Directors granted 19,500 options to purchase ordinary shares of the Company to employees. The exercise prices for such options range from $0.67 to $1.06 per share, with vesting to occur in up to four years.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The following table presents the assumptions used to estimate the fair value of the options granted in the periods presented:</span></span></span></span></div>
          </div>
        </div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="margin-left:84.45pt">

            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>Six months ended</span></span></span></span></span></span></span></span></span></span></div>
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>June 30,</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>2023</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>2022</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>Unaudited</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>Volatility</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>75.9%-76.4</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>%</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>69.4%-72.0</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>%</span></span></span></span></span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>Risk-free interest rate</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>3.3%-4.2</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>%</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>1.5%-3.0</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>%</span></span></span></span></span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>Dividend yield</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>0</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>%</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>0</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>%</span></span></span></span></span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>Expected life (years)</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>5.0-5.1</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>5.0-5.4</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                </tr>

            </table>

        </div>
      </div>
    </div>
    <div>
      <div>
        <div>
          <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div>
            <div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="color:rgb(0, 0, 0)">Weighted average fair value of options granted during the six-month periods ended June 30, 2023 and 2022 were $</span>0.53<span style="color:rgb(0, 0, 0)"> and $1.94, respectively.</span></span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="color:rgb(0, 0, 0)">During the six-month periods ended June 30, 2023 and 2022, the Company recorded share based compensation related to stock options in a total amount of $</span>1,782<span style="color:rgb(0, 0, 0)"> and $2,092, respectively.</span></span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="color:rgb(0, 0, 0)">As of June 30, 2023, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date was $</span>6,267<span style="color:rgb(0, 0, 0)"> which is expected to be recognized over a weighted average period of approximately</span><span style="font-weight:bold;color:rgb(0, 0, 0)">&#160;</span>2.08<span style="color:rgb(0, 0, 0)"> years.</span></span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>For the six months ended June 30, 2023 and 2022, the total weighted average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were 7,460,568<span style="color:rgb(0, 0, 0)">&#160;</span>and 8,504,958, respectively.</span></span></span></span></div>
              <div></div>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                  <tr>
                    <td style="width:56.7pt">&#160;</td>
                    <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>c.</span></span></span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Employee Stock Purchase Plan:</span></span></span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company selected the Black-Scholes-Merton option-pricing model as the most appropriate fair value method for its share-option awards and Employee Share Purchase Plan (&#8220;ESPP&#8221;).</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>As of<span style="color:rgb(0, 0, 0)"> June 30, 2023 and </span>since its adoption<span style="color:rgb(0, 0, 0)">, </span>275,854<span style="color:rgb(0, 0, 0)"> Ordinary Shares had been purchased under the ESPP and </span>324,146<span style="color:rgb(0, 0, 0)"> Ordinary Shares were available for future issuance under the ESPP.</span></span></span></span></span></span></div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">&#160;</div>
            </div>
          </div>
          <div>
            <div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The following table presents the assumptions used to estimate the fair value of ESPP granted in the periods presented:</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="margin-left:81pt">

                  <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                          <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Six months ended</span></span></span></span></div>
                          <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>June 30,</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                          <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                          <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                          <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Unaudited</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:middle" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:middle" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                          <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Volatility</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>65%-70</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%" valign="bottom">
                          <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Risk-free interest rate</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.1%-1.7</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                          <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Dividend yield</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%" valign="bottom">
                          <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected life (years)</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="-sec-ix-hidden:FFact_286">-</span></span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.5</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                      </tr>

                  </table>

              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="color:rgb(0, 0, 0)">During the six-month periods ended June 30, 2023 and 2022, the Company recorded ESPP compensation in a total amount of $</span>0<span style="color:rgb(0, 0, 0)"> and $97.</span></span></span></span></span></div>
            </div>
          </div>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165164443040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL AND OTHER INCOME, NET<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>FINANCIAL AND OTHER INCOME, NET [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">FINANCIAL AND OTHER INCOME, NET</a></td>
<td class="text">
        <div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 7:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">FINANCIAL AND OTHER INCOME, NET</span></p>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;</span></span></span></div>
          <div>
            <div style="margin-left:56pt">

                <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                        <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest income</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,671</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>463</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:2px;width:76%" valign="bottom">
                        <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exchange rate differences and other</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">26</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">316</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:4px;width:76%" valign="bottom">
                        <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,697</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>779</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>

                </table>

            </div>
          </div>
        </div>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 610<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//610/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 720<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//720/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165166467792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY BALANCES AND TRANSACTIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY BALANCES AND TRANSACTIONS</a></td>
<td class="text">
            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 8:-</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>RELATED PARTY BALANCES AND TRANSACTIONS</strong></span></p>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>

                <div>
                  <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-left:56.7pt"><span style="font-family:Times New Roman,Times,serif"><span>Balances with related parties:</span></span></span></div>
                  <div>
                    <div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                      <div style="margin-left:56.7pt">
                        <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                            <tr>
                              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                                <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span>June 30,</span></strong></span></span></span></span></div>
                                <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span>2023</span></strong></span></span></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                                <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span>December&#160;31,</span></strong></span></span></span></span></div>
                                <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span>2022</span></strong></span></span></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                            </tr>
                            <tr>
                              <td rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" rowspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;border-bottom:2px solid black" valign="bottom">
                                <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>Unaudited</span></strong></span></span></div>
                              </td>
                              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                            </tr>
                            <tr>
                              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                            </tr>
                            <tr>
                              <td style="vertical-align:top;font-family:Times New Roman, Times, serif;padding-bottom:4px;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Trade and other payables (a)</span></span></span></div>
                              </td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                              </td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>36</span></span></span></div>
                              </td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                <div style="line-height:1.25;font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                <div style="line-height:1.25;font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>83</span></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                            </tr>

                        </table>
                      </div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
                      <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-left:56.7pt"><span style="font-family:Times New Roman,Times,serif"><span>Related parties' expenses:</span></span></span></div>
                      <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                      <div style="margin-left:56.7pt">
                        <div>
                          <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                              <tr>
                                <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>Six months ended</span></strong></span></span></div>
                                  <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>June 30,</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>2023</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>2022</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>Unaudited</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
                                  <div style="line-height:1.25;text-indent:-8.5pt;margin-left:11.35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Amounts charged to:</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:top;font-family:Times New Roman, Times, serif;padding-bottom:4px;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                                  <div style="line-height:1.25;text-indent:-8.5pt;margin-left:11.35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Research and development expenses (a)</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>70</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>114</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                              </tr>

                          </table>
                        </div>
                      </div>
                    </div>
                  </div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;width:56.7pt">&#160;</td>
                        <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:27.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(a)</span></span></span></td>
                        <td style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, serif;width:auto">
                          <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company incurred expenses for research and development services provided by related party for cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies.</span></span></span></div>
                        </td>
                      </tr>

                  </table>
                </div>

            </div>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165165550784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">
      <div>
        <div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">

                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 9:-</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SUBSEQUENT EVENTS</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 3, 2023, following recommendation of the compensation committee, the Company&#8217;s board of directors reduced the total number of shares reserved for issuance under the Company&#8217;s 2010 Plan by 500,000 and the total number of shares reserved for issuance under the ESPP by 210,000.</span></span></div>
          </div>
        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165166401856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments in marketable securities:</a></td>
<td class="text">
                  <div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span>Investments in marketable securities:</span></span></span></span></span></span></span></span></span></div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt">&#160;</div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span>The Company accounts for investments in marketable securities in accordance with ASC No. 320, &#8220;Investments - Debt Securities&#8221;.</span></span></span></span></span></span></span></span></span></div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt">&#160;</div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span>Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determinations at each balance sheet date. The Company classifies all of its debt securities as available-for-sale (&#8220;AFS&#8221;). Available-for-sale debt securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income (loss) in shareholders&#8217; equity. Realized gains and losses on sale of investments are included in financial income, net, and are derived using the specific identification method for determining the cost of securities sold.</span></span></span></span></span></span></span></span></span></div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization together with interest on securities is included in financial income, net.</span></span></span></span></span></span></span></div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt">&#160;</div>
                    <div style="text-align:justify;line-height:1.25;margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>At each reporting period, th</span></span></span></span></span></span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">e Company evaluates whethe</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>r declines in fair value below amortized cost are due to expected credit losses, as well as the Company&#8217;s ability and intent to hold the investment until a forecasted recovery occurs in accordance with ASC 326, Financial Instrument- Credit losses. Allowance for credit losses on AFS debt securities are recognized in the Company&#8217;s consolidated statements of income, and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive income (loss) in stockholders&#8217; equity.</span></span></span></span></span></span></span></div>
                  </div>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165166442160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of available-for-sale marketable securities</a></td>
<td class="text">
          <div>
            <div>
              <div style="margin-left:56pt">
                <table border="0" cellpadding="0" cellspacing="0" style="width:90%">

                    <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
                      <td style="padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:left" valign="top">
                        <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left">&#160;</p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                      <td colspan="2" style="border-width:2px;border-bottom-style:solid;border-bottom-color:black;padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center" valign="bottom">
                        <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Amortized</strong></span></span></span><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">cost</strong></span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                      <td colspan="2" style="border-width:2px;border-bottom-style:solid;border-bottom-color:black;padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center" valign="bottom">
                        <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Gross</strong></span></span></span><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">unrealized </strong></span></span></span></p>
                        <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">gains</strong></span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                      <td colspan="2" style="border-width:2px;border-bottom-style:solid;border-bottom-color:black;padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center" valign="bottom">
                        <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Gross</strong></span></span></span><br/><strong style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">unrealized</strong></p>
                        <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">losses</strong></span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                      <td colspan="2" style="border-width:2px;border-bottom-style:solid;border-bottom-color:black;padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;vertical-align:bottom" valign="top">
                        <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt"><strong>Fair value</strong></span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px">&#160;</td>
                    </tr>
                    <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255);height:15px">
                      <td style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px" valign="top">
                        <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">Available-for-sale &#8211; matures within one year:</span></span></span></p>
                      </td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px">&#160;</td>
                      <td colspan="2" style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td colspan="2" style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td colspan="2" style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td colspan="2" style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                      <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
                    </tr>
                    <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);height:15px">
                      <td style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;width:52%" valign="top">
                        <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">Governmental bonds</span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:1%">
                        <p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"><span style="font-size:10pt;text-align:left;margin:0px"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">$</span></span></span></p>
                      </td>
                      <td colspan="1" style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:9%" valign="bottom">
                        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">4,551</span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:1%">
                        <p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"><span style="font-size:10pt;text-align:left;margin:0px"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">$</span></span></span></p>
                      </td>
                      <td colspan="1" style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:9%" valign="bottom">
                        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><span style="-sec-ix-hidden:Fxbrl_20230728101901825">*</span>&#160;</span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:1%">
                        <p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"><span style="font-size:10pt;text-align:left;margin:0px"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">$</span></span></span></p>
                      </td>
                      <td colspan="1" style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:9%" valign="bottom">
                        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"><span style="-sec-ix-hidden:Fxbrl_20230728101905592">*</span></span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:1%">
                        <p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"><span style="font-size:10pt;text-align:left;margin:0px"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">$</span></span></span></p>
                      </td>
                      <td colspan="1" style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:9%" valign="bottom">
                        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt">4,551</span></span></span></p>
                      </td>
                      <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%">&#160;</td>
                    </tr>

                </table>
              </div>
              <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:56pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">*&#160; &#160; &#160; &#160; &#160; Represents an amount lower than $1</span></span></span></p>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165163005936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions used to estimate fair value of options granted</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>Six months ended</span></span></span></span></span></span></span></span></span></span></div>
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>June 30,</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>2023</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>2022</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>Unaudited</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>Volatility</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>75.9%-76.4</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>%</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>69.4%-72.0</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>%</span></span></span></span></span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>Risk-free interest rate</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>3.3%-4.2</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>%</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>1.5%-3.0</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>%</span></span></span></span></span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>Dividend yield</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>0</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>%</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>0</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>%</span></span></span></span></span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>Expected life (years)</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>5.0-5.1</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span>5.0-5.4</span></span></span></span></span></span></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions used to estimate fair value of options granted</a></td>
<td class="text">
                  <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                          <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Six months ended</span></span></span></span></div>
                          <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>June 30,</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                          <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                          <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                          <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Unaudited</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:middle" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:middle" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                          <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Volatility</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>65%-70</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%" valign="bottom">
                          <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Risk-free interest rate</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.1%-1.7</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                          <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Dividend yield</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%" valign="bottom">
                          <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected life (years)</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="-sec-ix-hidden:FFact_286">-</span></span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.5</span></span></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                      </tr>

                  </table>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165166427712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL AND OTHER INCOME, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>FINANCIAL AND OTHER INCOME, NET [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of financial and other income, net</a></td>
<td class="text">
                <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                        <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest income</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,671</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>463</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:2px;width:76%" valign="bottom">
                        <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exchange rate differences and other</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">26</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">316</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:4px;width:76%" valign="bottom">
                        <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,697</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>779</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>

                </table>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165158375296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RelatedPartyBalancesAndTransactionsAbstract', window );"><strong>Related Party Balances And Transactions Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of related party balances and transactions</a></td>
<td class="text">
                <div>
                  <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-left:56.7pt"><span style="font-family:Times New Roman,Times,serif"><span>Balances with related parties:</span></span></span></div>
                  <div>
                    <div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                      <div style="margin-left:56.7pt">
                        <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                            <tr>
                              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                                <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span>June 30,</span></strong></span></span></span></span></div>
                                <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span>2023</span></strong></span></span></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                                <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span>December&#160;31,</span></strong></span></span></span></span></div>
                                <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span>2022</span></strong></span></span></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                            </tr>
                            <tr>
                              <td rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" rowspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;border-bottom:2px solid black" valign="bottom">
                                <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>Unaudited</span></strong></span></span></div>
                              </td>
                              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                            </tr>
                            <tr>
                              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                            </tr>
                            <tr>
                              <td style="vertical-align:top;font-family:Times New Roman, Times, serif;padding-bottom:4px;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Trade and other payables (a)</span></span></span></div>
                              </td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                              </td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>36</span></span></span></div>
                              </td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                <div style="line-height:1.25;font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                <div style="line-height:1.25;font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>83</span></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                            </tr>

                        </table>
                      </div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
                      <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-left:56.7pt"><span style="font-family:Times New Roman,Times,serif"><span>Related parties' expenses:</span></span></span></div>
                      <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                      <div style="margin-left:56.7pt">
                        <div>
                          <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                              <tr>
                                <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>Six months ended</span></strong></span></span></div>
                                  <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>June 30,</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>2023</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>2022</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>Unaudited</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
                                  <div style="line-height:1.25;text-indent:-8.5pt;margin-left:11.35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Amounts charged to:</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:top;font-family:Times New Roman, Times, serif;padding-bottom:4px;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                                  <div style="line-height:1.25;text-indent:-8.5pt;margin-left:11.35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Research and development expenses (a)</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>70</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>114</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                              </tr>

                          </table>
                        </div>
                      </div>
                    </div>
                  </div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;width:56.7pt">&#160;</td>
                        <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:27.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(a)</span></span></span></td>
                        <td style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, serif;width:auto">
                          <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company incurred expenses for research and development services provided by related party for cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies.</span></span></span></div>
                        </td>
                      </tr>

                  </table>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RelatedPartyBalancesAndTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RelatedPartyBalancesAndTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165158734688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 05, 2013</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>GENERAL [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Upfront payment received</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AccruedMilestonePayment', window );">Accrued milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable', window );">Potential milestone compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable', window );">Preclinical milestone compensation</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue', window );">Amount of investment in Compugen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 455,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,615<span></span>
</td>
<td class="nump">$ 18,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,617<span></span>
</td>
<td class="nump">$ 20,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AccruedMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accrued milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AccruedMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentArrangementPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone revenue for preclinical stages of research from arrangements for research and development, including collaboration and licenses agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount on the investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 10<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480679/815-10-10-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 10<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480769/815-20-10-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165158393888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Details) - Governmental bonds [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 4,551<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 4,551<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">*   Represents an amount lower than $1</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165158747408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 05, 2018</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsLineItems', window );"><strong>Government and Other Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember', window );">May 2012 Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsLineItems', window );"><strong>Government and Other Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ParticipationRights', window );">Participation Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AgreementStartDate', window );">Agreement, start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  09,  2012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AgreementTerminationDescription', window );">Agreement termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In 2014, the May 2012 Agreement was terminated, except with respect to certain payments arising from the Bayer Agreement which survive termination of the May 2012 Agreement until August 5, 2025.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_CommercialLicenseAgreementMember', window );">Commercial License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsLineItems', window );"><strong>Government and Other Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PercentageOfRoyaltiesOnNetSales', window );">Percentage of royalties on net sales</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=cgen_GovernmentAndOtherGrantsMember', window );">Government and Other Grants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsLineItems', window );"><strong>Government and Other Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived', window );">Maximum royalty repaid as percentage of grant received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RoyaltyContingentObligations', window );">Royalty Contingent Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=cgen_GovernmentAndOtherGrantsMember', window );">Government and Other Grants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsLineItems', window );"><strong>Government and Other Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RoyaltyPercentageBasedOnFutureRevenues', window );">Royalty percentage based on future revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=cgen_GovernmentAndOtherGrantsMember', window );">Government and Other Grants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsLineItems', window );"><strong>Government and Other Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RoyaltyPercentageBasedOnFutureRevenues', window );">Royalty percentage based on future revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AgreementStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Start date of the agreement, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AgreementStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AgreementTerminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement termination description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AgreementTerminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAndOtherGrantsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government And Other Grants [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAndOtherGrantsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Royalty Repaid As Percentage Of Grant Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ParticipationRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to advisor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ParticipationRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PercentageOfRoyaltiesOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PercentageOfRoyaltiesOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RoyaltyContingentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RoyaltyContingentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RoyaltyPercentageBasedOnFutureRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Percentage Based On Future Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RoyaltyPercentageBasedOnFutureRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAndOtherGrantsAxis=cgen_CommercialLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAndOtherGrantsAxis=cgen_CommercialLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesByNatureAxis=cgen_GovernmentAndOtherGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesByNatureAxis=cgen_GovernmentAndOtherGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165156696224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Detail Textuals)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">30 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 14, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 10, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 14, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 16, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Stock options granted, exercise price, minimum | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Stock options granted, exercise price, maximum | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted during period | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Share based compensation stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,782<span></span>
</td>
<td class="nump">$ 2,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized estimated compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which compensation expense will be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total weighted average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,460,568<span></span>
</td>
<td class="nump">8,504,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of shares purchased for ESPP | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ordinary shares available for issuance | shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Share based compensation ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants purchase to ordinary shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,955,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants purchase to ordinary shares remain outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cgen_AgreementMember', window );">Agreement [Member] | Registered direct offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,316,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants purchase to ordinary shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,253,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable', window );">Expiration period of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cgen_MasterClinicalAgreementMember', window );">Master Clinical Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,424,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,332,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.57333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PercentageOfClosingPrice', window );">Percentage of closing price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cgen_CollaborativeArrangementsMember', window );">Collaborative Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RelativeFairValueOfDeferredParticipation', window );">Relative fair value of deferred participation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cgen_CollaborativeArrangementsTwoMember', window );">Collaborative Arrangements Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RelativeFairValueOfDeferredParticipation', window );">Relative fair value of deferred participation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember', window );">SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,816,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from ordinary shares in offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember', window );">SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member] | Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cgen_SalesAgreementWithLeerinkPartnerLlcMember', window );">Sales Agreement With Leerink Partner LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,609,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from ordinary shares in offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration period of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum authorized proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PercentageOfClosingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of closing price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PercentageOfClosingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RelativeFairValueOfDeferredParticipation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Relative fair value of deferred participation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RelativeFairValueOfDeferredParticipation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of plan compensation cost recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cgen_AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cgen_AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cgen_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cgen_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cgen_MasterClinicalAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cgen_MasterClinicalAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cgen_CollaborativeArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cgen_CollaborativeArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cgen_CollaborativeArrangementsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cgen_CollaborativeArrangementsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cgen_UnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cgen_UnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cgen_SalesAgreementWithLeerinkPartnerLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cgen_SalesAgreementWithLeerinkPartnerLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165164470848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Schedule of fair value assumptions) (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">75.90%<span></span>
</td>
<td class="nump">69.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">76.40%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Expected risk free interest rates range, minimum</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Expected risk free interest rate range, maximum</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Expected risk free interest rates range, minimum</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Expected risk free interest rate range, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165164572336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL AND OTHER INCOME, NET (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>FINANCIAL AND OTHER INCOME, NET [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 1,671<span></span>
</td>
<td class="nump">$ 463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Exchange rate differences and other</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_FinancialIncomeExpenseNet', window );">Financial and other income, net</a></td>
<td class="nump">$ 1,697<span></span>
</td>
<td class="nump">$ 779<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_FinancialIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of financial and other income net of expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_FinancialIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165162455296">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY BALANCES AND TRANSACTIONS [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_TradeAndOtherPayablesRelatedParties', window );">Trade and other payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Related parties' expenses amounts charged to research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company incurred expenses for research and development services provided by related party for cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_TradeAndOtherPayablesRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade and other payables related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_TradeAndOtherPayablesRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140165162481120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Narrative) (Details) - Subsequent Event [Member]<br></strong></div></th>
<th class="th">
<div>Aug. 03, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Plan 2010 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Employee Share Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="nump">210,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cgen_Plan2010Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cgen_Plan2010Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cgen_EmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cgen_EmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>zk2330082_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cgen="http://cgen.com/20230630"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cgen-20230630.xsd" xlink:type="simple"/>
    <context id="C_20230101to20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:RegisteredDirectOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-14</instant>
        </period>
    </context>
    <context id="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:RegisteredDirectOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-14</endDate>
        </period>
    </context>
    <context id="C_20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-10</instant>
        </period>
    </context>
    <context id="C_20181001to20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-10</endDate>
        </period>
    </context>
    <context id="C_20230630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20200301to20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-16</endDate>
        </period>
    </context>
    <context id="C_20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-16</instant>
        </period>
    </context>
    <context id="C_20200316_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-16</instant>
        </period>
    </context>
    <context id="C_20200401to20200414_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-14</endDate>
        </period>
    </context>
    <context id="C_20200401to20200414_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-14</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_20211101to20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_20230630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230630_usgaapAwardTypeAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20210101to20230630_usgaapAwardTypeAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20230130to20230131_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SalesAgreementWithLeerinkPartnerLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-30</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SalesAgreementWithLeerinkPartnerLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20130801to20130805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2013-08-01</startDate>
            <endDate>2013-08-05</endDate>
        </period>
    </context>
    <context id="C_20211110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2021-11-10</instant>
        </period>
    </context>
    <context id="C_20130805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2013-08-05</instant>
        </period>
    </context>
    <context id="C_20180301to20180330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-30</endDate>
        </period>
    </context>
    <context id="C_20180330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2018-03-30</instant>
        </period>
    </context>
    <context id="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20230630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20230101to20230630_srtRangeAxis_srtMinimumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_srtRangeAxis_srtMaximumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20230101to20230630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20180101to20180105_cgenGovernmentAndOtherGrantsAxis_cgenCommercialLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:CommercialLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-05</endDate>
        </period>
    </context>
    <context id="C_20230803_usgaapPlanNameAxis_cgenPlan2010Member_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:Plan2010Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-03</instant>
        </period>
    </context>
    <context id="C_20230803_usgaapPlanNameAxis_cgenEmployeeSharePurchasePlanMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-03</instant>
        </period>
    </context>
    <unit id="ILSPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="C_20230101to20230630" id="FFact_306">0001119774</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_20230101to20230630" id="FFact_307">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="C_20230101to20230630" id="FFact_309">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_20230101to20230630"
      id="Fdei_DocumentFiscalPeriodFocus20220803133013452">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentPeriodEndDate
      contextRef="C_20230101to20230630"
      id="Fdei_DocumentPeriodEndDate20220803135349061">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentType
      contextRef="C_20230101to20230630"
      id="Fxbrl_20220803132217335">6-K</dei:DocumentType>
    <dei:DocumentFiscalYearFocus
      contextRef="C_20230101to20230630"
      id="Fxbrl_20220803135229207">2023</dei:DocumentFiscalYearFocus>
    <dei:EntityFileNumber
      contextRef="C_20230101to20230630"
      id="Fxbrl_20220803132624667">000-30902</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_20230101to20230630"
      id="Fxbrl_20220803132653437">COMPUGEN LTD.</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1
      contextRef="C_20230101to20230630"
      id="Fxbrl_20220803132710165">26 Harokmim Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_20230101to20230630"
      id="Fxbrl_20220803132729395">Holon</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="C_20230101to20230630"
      id="Fxbrl_20220803132743972">5885849</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="C_20230101to20230630"
      id="Fxbrl_20220803132757086">IL</dei:EntityAddressCountry>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20230630"
      id="Fxbrl_20230803123831627"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20221231"
      id="Fxbrl_20230803123835179"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_20230101to20230630"
      id="Fxbrl_20230728034213148"
      unitRef="usd"
      xsi:nil="true"/>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20220727223450181_xbrl_20220720105058426"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20220727223630806"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      id="Fxbrl_20230728042446448_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105006668"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_20230630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember"
      id="Fxbrl_20230728101901825"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_20230630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember"
      id="Fxbrl_20230728101905592"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20230101to20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      id="FFact_286"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20230630"
      decimals="-3"
      id="FFact_1"
      unitRef="usd">17071000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_2"
      unitRef="usd">11059000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_20230630"
      decimals="-3"
      id="FFact_3"
      unitRef="usd">615000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_4"
      unitRef="usd">362000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherShortTermInvestments
      contextRef="C_20230630"
      decimals="-3"
      id="FFact_5"
      unitRef="usd">44297000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_6"
      unitRef="usd">72287000</us-gaap:OtherShortTermInvestments>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20230728025352671_Fact_5"
      unitRef="usd">4551000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230728025352671_Fact_6"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20230630"
      decimals="-3"
      id="FFact_9"
      unitRef="usd">2865000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_10"
      unitRef="usd">2417000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20230630"
      decimals="-3"
      id="FFact_11"
      unitRef="usd">69399000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_12"
      unitRef="usd">86125000</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20230630"
      decimals="-3"
      id="FFact_13"
      unitRef="usd">1912000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_14"
      unitRef="usd">1899000</us-gaap:PrepaidExpenseNoncurrent>
    <cgen:SeverancePayFundNonCurrent
      contextRef="C_20230630"
      decimals="-3"
      id="FFact_15"
      unitRef="usd">2788000</cgen:SeverancePayFundNonCurrent>
    <cgen:SeverancePayFundNonCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_16"
      unitRef="usd">2794000</cgen:SeverancePayFundNonCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20230630"
      decimals="-3"
      id="FFact_17"
      unitRef="usd">1606000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_18"
      unitRef="usd">1826000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20230630"
      decimals="-3"
      id="FFact_19"
      unitRef="usd">1350000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_20"
      unitRef="usd">1532000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20230630"
      decimals="-3"
      id="FFact_21"
      unitRef="usd">7656000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_22"
      unitRef="usd">8051000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_20230630"
      decimals="-3"
      id="FFact_23"
      unitRef="usd">77055000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_24"
      unitRef="usd">94176000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20230630"
      decimals="-3"
      id="F20220719213713620_0"
      unitRef="usd">1680000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20220719213713621_1"
      unitRef="usd">1773000</us-gaap:AccountsPayableCurrent>
    <cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20230630"
      decimals="-3"
      id="F20220719213713621_2"
      unitRef="usd">0</cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses>
    <cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20221231"
      decimals="-3"
      id="F20220719213713622_3"
      unitRef="usd">325000</cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20230630"
      decimals="-3"
      id="F20220719213713622_4"
      unitRef="usd">610000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20220719213713622_5"
      unitRef="usd">613000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="C_20230630"
      decimals="-3"
      id="F20220719213713623_6"
      unitRef="usd">8511000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="C_20221231"
      decimals="-3"
      id="F20220719213713623_7"
      unitRef="usd">9208000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20230630"
      decimals="-3"
      id="F20220719213713623_8"
      unitRef="usd">10801000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20220719213713623_9"
      unitRef="usd">11919000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20230630"
      decimals="-3"
      id="F20220719213713624_12"
      unitRef="usd">991000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20220719213713625_13"
      unitRef="usd">1312000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityNoncurrent
      contextRef="C_20230630"
      decimals="-3"
      id="F20220719213713625_14"
      unitRef="usd">3262000</us-gaap:PostemploymentBenefitsLiabilityNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20220719213713625_15"
      unitRef="usd">3265000</us-gaap:PostemploymentBenefitsLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20230630"
      decimals="-3"
      id="F20220719213713627_16"
      unitRef="usd">4253000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20220719213713627_17"
      unitRef="usd">4577000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20220719214834949"
      unitRef="ILSPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20230630"
      decimals="INF"
      id="F20220719213713628_18"
      unitRef="ILSPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20220719214917721"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20230630"
      decimals="INF"
      id="F20220719213713628_20"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20230630"
      decimals="INF"
      id="Fxbrl_20220719215055193"
      unitRef="Shares">88233766</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20230630"
      decimals="INF"
      id="F20220719213713629_22"
      unitRef="Shares">88233766</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20220719215111705"
      unitRef="Shares">86624643</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20221231"
      decimals="INF"
      id="F20220719213713629_24"
      unitRef="Shares">86624643</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_20230630"
      decimals="-3"
      id="F20220719213713630_26"
      unitRef="usd">244000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_20221231"
      decimals="-3"
      id="F20220719213713630_27"
      unitRef="usd">240000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_20230630"
      decimals="-3"
      id="F20220719213713630_28"
      unitRef="usd">536145000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_20221231"
      decimals="-3"
      id="F20220719213713631_29"
      unitRef="usd">533213000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20230630"
      decimals="-3"
      id="F20220719213713631_30"
      unitRef="usd">-474388000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20221231"
      decimals="-3"
      id="F20220719213713632_31"
      unitRef="usd">-455773000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630"
      decimals="-3"
      id="F20220719213713632_32"
      unitRef="usd">62001000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="F20220719213713632_33"
      unitRef="usd">77680000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20230630"
      decimals="-3"
      id="F20220719213713633_34"
      unitRef="usd">77055000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="F20220719213713633_35"
      unitRef="usd">94176000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_61"
      unitRef="usd">15206000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_62"
      unitRef="usd">13982000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:BusinessDevelopment
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_63"
      unitRef="usd">165000</us-gaap:BusinessDevelopment>
    <us-gaap:BusinessDevelopment
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_64"
      unitRef="usd">478000</us-gaap:BusinessDevelopment>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_65"
      unitRef="usd">4977000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_66"
      unitRef="usd">5173000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_67"
      unitRef="usd">20348000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_68"
      unitRef="usd">19633000</us-gaap:OperatingExpenses>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_69"
      unitRef="usd">1697000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_70"
      unitRef="usd">779000</cgen:FinancialIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_71"
      unitRef="usd">-18651000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_72"
      unitRef="usd">-18854000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220719215810562_Fact_71"
      unitRef="usd">-36000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220719215810562_Fact_72"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_75"
      unitRef="usd">-18615000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_76"
      unitRef="usd">-18854000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230728033938209_xbrl_20220719215810562_Fact_72"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728030537018_Fact_75"
      unitRef="usd">-18615000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230728030537018_Fact_76"
      unitRef="usd">-18854000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="Fxbrl_20220719220126329"
      unitRef="USDPerShare">0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="FFact_77"
      unitRef="USDPerShare">0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20220101to20220630"
      decimals="INF"
      id="Fxbrl_20220719220147427"
      unitRef="USDPerShare">0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20220101to20220630"
      decimals="INF"
      id="FFact_78"
      unitRef="USDPerShare">0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="Fxbrl_20220720012025614"
      unitRef="Shares">86903741</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="FFact_81"
      unitRef="Shares">86903741</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20220101to20220630"
      decimals="INF"
      id="Fxbrl_20220720012118943"
      unitRef="Shares">86486612</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20220101to20220630"
      decimals="INF"
      id="FFact_82"
      unitRef="Shares">86486612</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220727223132738_Fact_109"
      unitRef="Shares">86433432</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220727223132738_Fact_110"
      unitRef="usd">239000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727223132738_Fact_111"
      unitRef="usd">528533000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727223132738_Fact_112"
      unitRef="usd">-422079000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220727223132738_Fact_113"
      unitRef="usd">106693000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220727222823749_Fact_114"
      unitRef="Shares">33186</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727222823749_Fact_116"
      unitRef="usd">104000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727222823749_xbrl_20220720104943489"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220727222823749_Fact_117"
      unitRef="usd">104000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220727223329630_Fact_122"
      unitRef="Shares">158025</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220727223329630_xbrl_20220719224804137"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727223329630_Fact_124"
      unitRef="usd">248000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727223329630_xbrl_20220720104955752"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220727223329630_Fact_125"
      unitRef="usd">249000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727223450181_Fact_126"
      unitRef="usd">2189000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727223450181_xbrl_20220720105006668"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220727223450181_Fact_127"
      unitRef="usd">2189000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220727222823775_xbrl_20220720105044504"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727222823775_xbrl_20220720105025339"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727222823775_Fact_128"
      unitRef="usd">-18854000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220727222823775_Fact_129"
      unitRef="usd">-18854000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220727222823781_Fact_130"
      unitRef="Shares">86624643</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220727222823781_Fact_131"
      unitRef="usd">240000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727222823781_Fact_132"
      unitRef="usd">531074000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727222823781_Fact_133"
      unitRef="usd">-440933000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630"
      decimals="-3"
      id="Fxbrl_20220727222823781_Fact_134"
      unitRef="usd">90381000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_109"
      unitRef="Shares">86624643</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_110"
      unitRef="usd">240000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_111"
      unitRef="usd">533213000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_112"
      unitRef="usd">-455773000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230728041413873_xbrl_20220727223132738_Fact_113"
      unitRef="usd">77680000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230728041429297_xbrl_20220727223504334_Fact_96"
      unitRef="Shares">1609123</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230728041429297_xbrl_20220727223710614"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230728041429297_xbrl_20220727223504334_Fact_98"
      unitRef="usd">1150000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230728041429297_xbrl_20220727223504334_xbrl_20220720104851290"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728041429297_xbrl_20220727223504334_Fact_99"
      unitRef="usd">1154000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105058426"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230728041439032_xbrl_20220727223450181_Fact_126"
      unitRef="usd">1782000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105006668"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728041439032_xbrl_20220727223450181_Fact_127"
      unitRef="usd">1782000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728042446448_xbrl_20230728041439032_xbrl_20220727223450181_Fact_127"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230728041511128_xbrl_20220727222823775_xbrl_20220720105044504"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230728041511128_xbrl_20220727222823775_xbrl_20220720105025339"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230728041511128_xbrl_20220727222823775_Fact_128"
      unitRef="usd">-18615000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728041511128_xbrl_20220727222823775_Fact_129"
      unitRef="usd">-18615000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_130"
      unitRef="Shares">88233766</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_131"
      unitRef="usd">244000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_132"
      unitRef="usd">536145000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_133"
      unitRef="usd">-474388000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20230728041521608_xbrl_20220727222823781_Fact_134"
      unitRef="usd">62001000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728044607285"
      unitRef="usd">-18615000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230728044615653"
      unitRef="usd">-18854000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_137"
      unitRef="usd">1782000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_138"
      unitRef="usd">2189000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_139"
      unitRef="usd">237000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_140"
      unitRef="usd">232000</us-gaap:Depreciation>
    <cgen:AccretionOfDiscountOnMarketableSecurities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728052415879_Fact_139"
      unitRef="usd">13000</cgen:AccretionOfDiscountOnMarketableSecurities>
    <cgen:AccretionOfDiscountOnMarketableSecurities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230728052415879_Fact_140"
      unitRef="usd">0</cgen:AccretionOfDiscountOnMarketableSecurities>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728052418474_Fact_139"
      unitRef="usd">2000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230728052418474_Fact_140"
      unitRef="usd">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <cgen:SeverancePayNet
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_141"
      unitRef="usd">3000</cgen:SeverancePayNet>
    <cgen:SeverancePayNet
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220719231801817"
      unitRef="usd">-24000</cgen:SeverancePayNet>
    <cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_145"
      unitRef="usd">-290000</cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_146"
      unitRef="usd">-295000</cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220719231852648"
      unitRef="usd">140000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230728053007019"
      unitRef="usd">114000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728053015979"
      unitRef="usd">448000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220719231907400"
      unitRef="usd">-764000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728053037345"
      unitRef="usd">13000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_154"
      unitRef="usd">-5000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220719232044563"
      unitRef="usd">-85000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230728053025234"
      unitRef="usd">-2387000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728053044499"
      unitRef="usd">-894000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_158"
      unitRef="usd">242000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_159"
      unitRef="usd">-394000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_160"
      unitRef="usd">-644000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_161"
      unitRef="usd">-325000</cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses>
    <cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_162"
      unitRef="usd">-2387000</cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_163"
      unitRef="usd">-18617000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_164"
      unitRef="usd">-20683000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_165"
      unitRef="usd">51350000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_166"
      unitRef="usd">58945000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_167"
      unitRef="usd">23220000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_168"
      unitRef="usd">38500000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728052423298_Fact_139"
      unitRef="usd">1000000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230728052423298_Fact_140"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728052426602_Fact_139"
      unitRef="usd">5536000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230728052426602_Fact_140"
      unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_169"
      unitRef="usd">63000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_170"
      unitRef="usd">258000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_173"
      unitRef="usd">23531000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_174"
      unitRef="usd">20187000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_175"
      unitRef="usd">1351000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_176"
      unitRef="usd">249000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_179"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_180"
      unitRef="usd">104000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_181"
      unitRef="usd">1351000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_182"
      unitRef="usd">353000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220719232250681"
      unitRef="usd">6265000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230728053102843"
      unitRef="usd">-143000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_185"
      unitRef="usd">11421000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_186"
      unitRef="usd">8514000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20230630"
      decimals="-3"
      id="FFact_187"
      unitRef="usd">17686000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_188"
      unitRef="usd">8371000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728044639062"
      unitRef="usd">8000</cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction>
    <cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230728044646863"
      unitRef="usd">80000</cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction>
    <cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728052431875_Fact_139"
      unitRef="usd">70000</cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability>
    <cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230728052431875_Fact_140"
      unitRef="usd">0</cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability>
    <cgen:IssuanceExpenses
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230728052434971_Fact_139"
      unitRef="usd">197000</cgen:IssuanceExpenses>
    <cgen:IssuanceExpenses
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230728052434971_Fact_140"
      unitRef="usd">0</cgen:IssuanceExpenses>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="C_20230101to20230630" id="FFact_200">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;NOTE 1:-&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;GENERAL&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="text-align:justify;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;line-height:1.25"&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:27.75pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Compugen Ltd. (the &#x201c;Company&#x201d;) is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Compugen&#x2019;s innovative immuno-oncology pipeline consists of three clinical stage programs, targeting immune checkpoints Compugen discovered computationally by COM701, COM902 and rilvegostomig. The Company&#x2019;s lead product candidates, COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody are in Phase 1 clinical trials in patients with MSS CRC and platinum resistant ovarian cancer. Rilvegostomig, a novel anti PD-1/TIGIT bispecific antibody with a TIGIT specific component that is derived from Compugen&#x2019;s COM902 antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is in a Phase 2 clinical trial in patients with advanced or metastatic non-small cell lung and locally advanced or metastatic gastric cancer. In addition, the Company&#x2019;s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. The most advanced preclinical program, COM503, is in IND enabling studies. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 to inhibit cancer growth in the tumor microenvironment.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:27.75pt;vertical-align:top"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:27.75pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company is headquartered in Holon, Israel. Its clinical development activities operate from its U.S. subsidiary in San Francisco, California.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:27.75pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has incurred losses in the amount of $18,615 during the six months ended June 30, 2023, has an accumulated deficit of $ 474,388 as of June 30, 2023, and has an accumulated negative cash flow from operating activities in the amount of $ 18,617 for the six months ended June 30, 2023. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements at the current level of yearly expenditures at least twelve months from the reporting date.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:27.75pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On August 5, 2013, the Company entered into a Research and Development Collaboration and License Agreement (&#x201c;Bayer Agreement&#x201d;) with Bayer Pharma AG (&#x201c;Bayer&#x201d;) for the research, development, and commercialization of antibody-based therapeutics against two novel Compugen-discovered immune checkpoint regulators.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under the terms of the Bayer Agreement, the Company received an upfront payment of $10,000, and additional aggregate milestone payments of approximately $23,000.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On November 29, 2022, Bayer notified the Company that it had resolved to terminate, effective as of February 27, 2023, the Bayer Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:27.75pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Effective March 30, 2018, the Company entered into an exclusive license agreement with MedImmune Limited, the global biologics research and development arm of AstraZeneca (&#x201c;AstraZeneca&#x201d;) to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bi-specific and multi-specific antibody products derived from COM902. AstraZeneca has the right to create multiple products under this license and is solely responsible for all research, development and commercial activities under the agreement. Compugen received a $10,000 upfront payment and $15,500 milestone payment out of up to $200,000 that the Company is eligible to receive in development, regulatory and commercial milestones for the first product as well as tiered royalties on future product sales. If additional products are developed, additional milestones and royalties would be due to Compugen for each product.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

                &lt;tr&gt;
                  &lt;td style="width:54pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:31.5pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;f.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#x201c;Master Clinical Agreement&#x201d;) with Bristol Myers Squibb Company (&#x201c;Bristol Myers Squibb&#x201d;) to evaluate the safety and tolerability of Compugen&#x2019;s COM701 in combination with Bristol Myers Squibb&#x2019;s PD-1 immune checkpoint inhibitor Opdivo&#xae; (nivolumab), in patients with advanced solid tumors.&lt;br/&gt;&#160;&lt;br/&gt;Pursuant to the Master Clinical Agreement, as amended from time to time, Compugen sponsored the trials, which included the evaluation of the combination of COM701 and Opdivo&#xae; &#xb1; Bristol Myers Squibb investigational anti-TIGIT, BMS-986207. Bristol Myers Squibb and Compugen each supplies its own compound(s) for the studies.&lt;br/&gt;&#160;&lt;br/&gt;In conjunction with the signing of the Master Clinical Agreement, Bristol Myers Squibb made a $12,000 investment in Compugen, see Note 6a.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Among several amendments to the Master Clinical Agreement, on November 10, 2021, the agreement was further amended and in conjunction with the signing of the amendment to the Agreement, Bristol Myers Squibb made a $20,000 investment in Compugen, see Note 6a.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On August 3, 2022, the Company and Bristol Myers Squibb entered into a letter agreement pursuant to which the Master Clinical Agreement, as amended from time to time, was terminated as of such date.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230802202124242"
      unitRef="usd">-18615000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20230802202128417"
      unitRef="usd">-474388000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230802202134755"
      unitRef="usd">-18617000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="C_20130801to20130805"
      decimals="-3"
      id="FFact_193"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <cgen:ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable
      contextRef="C_20130805"
      decimals="-3"
      id="Fxbrl_20230728104443796"
      unitRef="usd">23000000</cgen:ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="C_20180301to20180330"
      decimals="-3"
      id="Fxbrl_20230802201751108"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <cgen:AccruedMilestonePayment
      contextRef="C_20180301to20180330"
      decimals="-3"
      id="Fxbrl_20230802201758034"
      unitRef="usd">15500000</cgen:AccruedMilestonePayment>
    <cgen:ResearchAndDevelopmentArrangementPaymentsReceivable
      contextRef="C_20180330"
      decimals="-3"
      id="Fxbrl_20230802201804474"
      unitRef="usd">200000000</cgen:ResearchAndDevelopmentArrangementPaymentsReceivable>
    <us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue
      contextRef="C_20230630"
      decimals="-3"
      id="FFact_199"
      unitRef="usd">12000000</us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue>
    <us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue
      contextRef="C_20211110"
      decimals="-3"
      id="Fxbrl_20220728112859416"
      unitRef="usd">20000000</us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20230802203528979">
    &lt;div&gt;
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 2:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;line-height:1.25;margin-left:56.7pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2022. The significant accounting policies applied in the annual financial statements of the Company as of December 31, 2022, are applied consistently in these interim consolidated financial statements, except as described below.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;line-height:1.25;margin-left:56.7pt"&gt;&#160;&lt;/div&gt;
      &lt;/div&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
        &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
          &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
            &lt;div&gt;
              &lt;div&gt;

                  &lt;div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;margin-left:56.7pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Investments in marketable securities:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;margin-left:56.7pt"&gt;&#160;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;margin-left:56.7pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company accounts for investments in marketable securities in accordance with ASC No. 320, &#x201c;Investments - Debt Securities&#x201d;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;margin-left:56.7pt"&gt;&#160;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;margin-left:56.7pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determinations at each balance sheet date. The Company classifies all of its debt securities as available-for-sale (&#x201c;AFS&#x201d;). Available-for-sale debt securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income (loss) in shareholders&#x2019; equity. Realized gains and losses on sale of investments are included in financial income, net, and are derived using the specific identification method for determining the cost of securities sold.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;margin-left:56.7pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;margin-left:56.7pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization together with interest on securities is included in financial income, net.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;margin-left:56.7pt"&gt;&#160;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;margin-left:56.7pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;At each reporting period, th&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;e Company evaluates whethe&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;r declines in fair value below amortized cost are due to expected credit losses, as well as the Company&#x2019;s ability and intent to hold the investment until a forecasted recovery occurs in accordance with ASC 326, Financial Instrument- Credit losses. Allowance for credit losses on AFS debt securities are recognized in the Company&#x2019;s consolidated statements of income, and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive income (loss) in stockholders&#x2019; equity.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;

              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_20230101to20230630"
      id="Fxbrl_20230803004059990">
                  &lt;div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;margin-left:56.7pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Investments in marketable securities:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;margin-left:56.7pt"&gt;&#160;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;margin-left:56.7pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company accounts for investments in marketable securities in accordance with ASC No. 320, &#x201c;Investments - Debt Securities&#x201d;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;margin-left:56.7pt"&gt;&#160;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;margin-left:56.7pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determinations at each balance sheet date. The Company classifies all of its debt securities as available-for-sale (&#x201c;AFS&#x201d;). Available-for-sale debt securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income (loss) in shareholders&#x2019; equity. Realized gains and losses on sale of investments are included in financial income, net, and are derived using the specific identification method for determining the cost of securities sold.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;margin-left:56.7pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;margin-left:56.7pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization together with interest on securities is included in financial income, net.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;margin-left:56.7pt"&gt;&#160;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;margin-left:56.7pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;At each reporting period, th&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;e Company evaluates whethe&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;r declines in fair value below amortized cost are due to expected credit losses, as well as the Company&#x2019;s ability and intent to hold the investment until a forecasted recovery occurs in accordance with ASC 326, Financial Instrument- Credit losses. Allowance for credit losses on AFS debt securities are recognized in the Company&#x2019;s consolidated statements of income, and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive income (loss) in stockholders&#x2019; equity.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                </us-gaap:MarketableSecuritiesPolicy>
    <cgen:UnauditedInterimConsolidatedFinancialStatementsTextBlock contextRef="C_20230101to20230630" id="FFact_202">
    &lt;div&gt;
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 3:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:56.7pt;line-height:1.25;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:110%"&gt;Operating results for the six-month period ended June&#160;30, 2023, are not necessarily indicative of the results that may be expected for the year ended December 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="margin-left:56.7pt;line-height:1.25;text-align:justify"&gt;&#160;&lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </cgen:UnauditedInterimConsolidatedFinancialStatementsTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20230728102752242">
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;NOTE 4:-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:110%"&gt;MARKETABLE SECURITIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:56pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The following is a summary of available-for-sale marketable securities as of June 30, 2023:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:56pt"&gt;&#160;&lt;/p&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div style="margin-left:56pt"&gt;
                &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%"&gt;

                    &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;
                      &lt;td style="padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:left" valign="top"&gt;
                        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left"&gt;&#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="border-width:2px;border-bottom-style:solid;border-bottom-color:black;padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center" valign="bottom"&gt;
                        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Amortized&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;cost&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="border-width:2px;border-bottom-style:solid;border-bottom-color:black;padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center" valign="bottom"&gt;
                        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Gross&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;unrealized &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;gains&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="border-width:2px;border-bottom-style:solid;border-bottom-color:black;padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center" valign="bottom"&gt;
                        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Gross&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&lt;strong style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;unrealized&lt;/strong&gt;&lt;/p&gt;
                        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;losses&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="border-width:2px;border-bottom-style:solid;border-bottom-color:black;padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;vertical-align:bottom" valign="top"&gt;
                        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt"&gt;&lt;strong&gt;Fair value&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255);height:15px"&gt;
                      &lt;td style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px" valign="top"&gt;
                        &lt;p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;Available-for-sale &#x2013; matures within one year:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);height:15px"&gt;
                      &lt;td style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;width:52%" valign="top"&gt;
                        &lt;p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;Governmental bonds&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:1%"&gt;
                        &lt;p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"&gt;&lt;span style="font-size:10pt;text-align:left;margin:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:9%" valign="bottom"&gt;
                        &lt;p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"&gt;&lt;span style="font-size:10pt;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;4,551&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:1%"&gt;
                        &lt;p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"&gt;&lt;span style="font-size:10pt;text-align:left;margin:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:9%" valign="bottom"&gt;
                        &lt;p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"&gt;&lt;span style="font-size:10pt;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20230728101901825"&gt;*&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:1%"&gt;
                        &lt;p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"&gt;&lt;span style="font-size:10pt;text-align:left;margin:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:9%" valign="bottom"&gt;
                        &lt;p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"&gt;&lt;span style="font-size:10pt;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20230728101905592"&gt;*&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:1%"&gt;
                        &lt;p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"&gt;&lt;span style="font-size:10pt;text-align:left;margin:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:9%" valign="bottom"&gt;
                        &lt;p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"&gt;&lt;span style="font-size:10pt;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;4,551&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;
              &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:56pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;*&#160; &#160; &#160; &#160; &#160; Represents an amount lower than $1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
            &lt;/div&gt;
          &lt;/div&gt;

        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:56pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company did not have investments in marketable securities as of June 30, 2022.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:56pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;As of June 30, 2023, the Company did not record an allowance for credit losses for its available for sale marketable securities.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    </us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20230728102812931">
          &lt;div&gt;
            &lt;div&gt;
              &lt;div style="margin-left:56pt"&gt;
                &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%"&gt;

                    &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;
                      &lt;td style="padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:left" valign="top"&gt;
                        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left"&gt;&#160;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="border-width:2px;border-bottom-style:solid;border-bottom-color:black;padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center" valign="bottom"&gt;
                        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Amortized&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;cost&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="border-width:2px;border-bottom-style:solid;border-bottom-color:black;padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center" valign="bottom"&gt;
                        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Gross&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;unrealized &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;gains&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="border-width:2px;border-bottom-style:solid;border-bottom-color:black;padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center" valign="bottom"&gt;
                        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Gross&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&lt;strong style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;unrealized&lt;/strong&gt;&lt;/p&gt;
                        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;losses&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="border-width:2px;border-bottom-style:solid;border-bottom-color:black;padding:0px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;vertical-align:bottom" valign="top"&gt;
                        &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt"&gt;&lt;strong&gt;Fair value&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding:0px"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255);height:15px"&gt;
                      &lt;td style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px" valign="top"&gt;
                        &lt;p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;Available-for-sale &#x2013; matures within one year:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);height:15px"&gt;
                      &lt;td style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;width:52%" valign="top"&gt;
                        &lt;p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;Governmental bonds&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:1%"&gt;
                        &lt;p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"&gt;&lt;span style="font-size:10pt;text-align:left;margin:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:9%" valign="bottom"&gt;
                        &lt;p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"&gt;&lt;span style="font-size:10pt;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;4,551&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:1%"&gt;
                        &lt;p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"&gt;&lt;span style="font-size:10pt;text-align:left;margin:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:9%" valign="bottom"&gt;
                        &lt;p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"&gt;&lt;span style="font-size:10pt;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20230728101901825"&gt;*&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:1%"&gt;
                        &lt;p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"&gt;&lt;span style="font-size:10pt;text-align:left;margin:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:9%" valign="bottom"&gt;
                        &lt;p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"&gt;&lt;span style="font-size:10pt;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="-sec-ix-hidden:Fxbrl_20230728101905592"&gt;*&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%"&gt;&#160;&lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:1%"&gt;
                        &lt;p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:left"&gt;&lt;span style="font-size:10pt;text-align:left;margin:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;width:9%" valign="bottom"&gt;
                        &lt;p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"&gt;&lt;span style="font-size:10pt;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:12pt;margin-top:0pt;margin-bottom:0pt"&gt;4,551&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;
              &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:56pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;*&#160; &#160; &#160; &#160; &#160; Represents an amount lower than $1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_20230630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fxbrl_20230728101843888"
      unitRef="usd">4551000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_20230630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fxbrl_20230728101909777"
      unitRef="usd">4551000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20230802221122558">
        &lt;div&gt;
          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

                    &lt;tr style="vertical-align:top"&gt;
                      &lt;td style="text-align:right;vertical-align:top;width:56.7pt"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;NOTE 5:-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
                          &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:27.75pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company provided bank guarantees in the amount of $284 in favor of its offices in Israel, car leases in Israel and credit card security for its U.S. subsidiary.&lt;/span&gt;&lt;/span&gt;
                        &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:27.75pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company received in the past grants from the office of the Israel Innovation Authority of the Israeli Ministry of Industry, Trade and Labor, formerly known as the Office of the Chief Scientist (&#x201c;IIA&#x201d;). The Company is not obligated to repay any amounts received from the IIA if it does not generate any income from products which incorporate technologies which were funded by such research program(s).&lt;/span&gt;&lt;/span&gt;
                        &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;If income is generated from products which incorporate technologies which were funded by a research program, the Company is committed to pay royalties at a rate of between 3% to 5% of future revenue generated from products that incorporate technologies that were funded by such research program(s), up to a maximum of 100% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum amount to be repaid is 100% plus interest at LIBOR).&lt;/span&gt;&lt;/span&gt;
                &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/div&gt;
              &lt;div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of June 30, 2023, the Company&#x2019;s aggregate contingent obligations for payments to IIA, based on royalty-bearing participation received or accrued, net of royalties paid or accrued, totaled $9,800.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:27.75pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On June 25, 2012, the Company entered into an Antibodies Discovery Collaboration Agreement (the &#x201c;Antibodies Discovery Agreement&#x201d;) with a U.S. antibody technology company (&#x201c;mAb Technology Company&#x201d;), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement, the mAb Technology Company is entitled to certain royalties that could be eliminated upon payment of certain one-time fees (all milestone and royalties payments referred together as &#x201c;Contingent Fees&#x201d;). For the six-month periods ended June 30, 2023 and 2022, the Company did not incur Contingent Fees.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:84pt;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/div&gt;
          &lt;div&gt;&lt;/div&gt;
          &lt;div&gt;
            &lt;div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:56.7pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:27.75pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="vertical-align:top;text-align:justify;width:auto"&gt;
                      &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On May 9, 2012, the Company entered into agreement (the &#x201c;May 2012 Agreement&#x201d;) with a U.S. Business Development Strategic Advisor (&#x201c;Advisor&#x201d;) for the purpose of entering into transactions with pharma companies related to selected pipeline program candidates. Under the agreement, the Advisor was to be entitled to 4% of the cash considerations that may be received under such transactions. In 2014, the May 2012 Agreement was terminated, except with respect to certain payments arising from the Bayer Agreement which survive termination of the May 2012 Agreement until August 5, 2025.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
                &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Bayer Agreement was terminated effective February 27, 2023 and no further payments to the Advisor are expected under the May 2012 Agreement.&lt;br/&gt;&#160;&lt;br/&gt;For the six months ended June 30, 2023 and 2022, the Company had not paid nor accrued any expenses related to the May 2012 Agreement.&lt;/span&gt;&lt;/span&gt;
                &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/div&gt;
              &lt;div style="text-align:justify;line-height:1.25"&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

                    &lt;tr&gt;
                      &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Effective as of January 5, 2018, the Company entered into a Commercial License Agreement (&#x201c;CLA&#x201d;) with a European cell line development company. Under the agreement the Company is required to pay an annual maintenance fee, certain amounts upon the occurrence of specified milestones events, and 1% royalties on annual net sales with respect to each commercialized product manufactured using the company&#x2019;s cell line. Royalties due under the CLA are creditable against the annual maintenance fee. In addition, the Company may at any time prior to the occurrence of a specific milestone event buy-out the royalty payment obligations in a single fixed amount. For the six-month periods ended June 30, 2023 and 2022, the Company did not incur milestone payments.&lt;/span&gt;&lt;/span&gt;
                          &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;f.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Effective as of October 28, 2020, the Company entered into a collaboration agreement with a U.S. antibody discovery and optimization company for generation and optimization of therapeutic antibodies for the Company. Under the agreement, the Company is required to pay service fees per services performed and certain amounts upon the occurrence of specified milestones events, and single-digit percent royalties on annual net sales with respect to each product sold that comprises or contains one or more antibodies so generated or optimized. The royalty rate is dependent upon the product type and any third-party contribution. For the six-month periods ended June 30, 2023 and 2022 the Company did not incur milestone payments.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20230802221055283"
      unitRef="usd">284000</us-gaap:GuaranteeObligationsMaximumExposure>
    <cgen:RoyaltyPercentageBasedOnFutureRevenues
      contextRef="C_20230101to20230630_srtRangeAxis_srtMinimumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"
      decimals="2"
      id="Fxbrl_20220720062450451"
      unitRef="Pure">0.03</cgen:RoyaltyPercentageBasedOnFutureRevenues>
    <cgen:RoyaltyPercentageBasedOnFutureRevenues
      contextRef="C_20230101to20230630_srtRangeAxis_srtMaximumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"
      decimals="2"
      id="Fxbrl_20220720062556413"
      unitRef="Pure">0.05</cgen:RoyaltyPercentageBasedOnFutureRevenues>
    <cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived
      contextRef="C_20230101to20230630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"
      decimals="2"
      id="Fxbrl_20220720062648820"
      unitRef="Pure">1</cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived>
    <cgen:RoyaltyContingentObligations
      contextRef="C_20230630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"
      decimals="-3"
      id="Fxbrl_20220720062746091"
      unitRef="usd">9800000</cgen:RoyaltyContingentObligations>
    <cgen:AgreementStartDate
      contextRef="C_20230101to20230630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember"
      id="Fxbrl_20230802220955963">2012-05-09</cgen:AgreementStartDate>
    <cgen:ParticipationRights
      contextRef="C_20230101to20230630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember"
      decimals="2"
      id="Fxbrl_20230802221007541"
      unitRef="Pure">0.04</cgen:ParticipationRights>
    <cgen:AgreementTerminationDescription
      contextRef="C_20230101to20230630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember"
      id="Fxbrl_20230802221014450">In 2014, the May 2012 Agreement was terminated, except with respect to certain payments arising from the Bayer Agreement which survive termination of the May 2012 Agreement until August 5, 2025.</cgen:AgreementTerminationDescription>
    <cgen:PercentageOfRoyaltiesOnNetSales
      contextRef="C_20180101to20180105_cgenGovernmentAndOtherGrantsAxis_cgenCommercialLicenseAgreementMember"
      decimals="2"
      id="Fxbrl_20230802221025410"
      unitRef="Pure">0.01</cgen:PercentageOfRoyaltiesOnNetSales>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="C_20230101to20230630" id="FFact_289">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;NOTE 6:-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;SHAREHOLDERS' EQUITY&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Issuance of Shares:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On June 14, 2018, the Company entered into an agreement in connection with a registered direct offering (the &#x201c;Offering&#x201d;) of an aggregate of 5,316,457 Ordinary Shares (the &#x201c;RD Shares&#x201d;) of the Company at a purchase price of $3.95 per RD Share. In connection with the issuance of the RD Shares, the Company also issued warrants to purchase an aggregate of up to 4,253,165 additional Ordinary Shares (the &#x201c;Warrants&#x201d;). The Warrants were exercisable at a price of $4.74 per Ordinary Share and had a term of five years from the date of issuance. The Offering was made pursuant to the Company&#x2019;s Registration Statement. Proceeds from the Offering were $19,767 (net of $1,233 issuance expenses).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div&gt;&lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;During the period from January 1, 2021 through June 30, 2023, warrants to purchase an aggregate of 3,955,696 Ordinary Shares were exercised with proceeds of approximately $18,750, and the remaining warrants to purchase up to 297,469 Ordinary Shares expired in June 2023.&lt;br/&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement with Bristol Myers Squibb to evaluate the safety and tolerability of the Company&#x2019;s COM701 in combination with Bristol Myers Squibb&#x2019;s PD-1 immune checkpoint inhibitor Opdivo&#xae; (nivolumab), in patients with advanced solid tumors. In conjunction with the Master Clinical Agreement, Bristol Myers Squibb made a $12,000 equity investment in the Company.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Under the terms of the securities purchase agreement, Bristol Myers Squibb purchased 2,424,243 ordinary shares of the Company at a purchase price of $4.95 per share. The share price represented a 33% premium over the average closing price of the Company&#x2019;s ordinary shares for twenty (20) Nasdaq trading days prior to the execution of the securities purchase agreement. The investment closed on October 12, 2018.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The premium over the fair market value in the amount of $4,121 represents the relative fair value of deferred participation of Bristol Myers Squibb in R&amp;amp;D expenses which are amortized over the period of the clinical trial based on the progress in the R&amp;amp;D, in accordance with ASC 808 &#x201c;Collaborative Arrangements&#x201d; and $7,788 (net of $91 issuance expenses) were considered equity investment.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In conjunction with the signing of the amendment to the Master Clinical Agreement in November 2021, Bristol Myers Squibb made a $20,000 investment in the Company, purchasing 2,332,815 ordinary shares of the Company at a purchase price of $8.57333 per share. The share price represented a 33% premium over the closing price of Company&#x2019;s ordinary shares on the last Nasdaq trading day immediately prior to the execution of the securities purchase agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The premium over the fair market value in the amount of $5,000 represents the relative fair value of deferred participation of Bristol Myers Squibb in R&amp;amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;amp;D, in accordance with ASC 808 &#x201c;Collaborative Arrangements&#x201d;) and $14,958 (net of $42 issuance expenses) were considered equity investment.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In March 2020, the Company entered into an underwriting agreement with SVB Leerink LLC and Stifel, Nicolaus &amp;amp; Company, Incorporated, as representatives of the several underwriters relating to the issuance and sale in a public offering of 8,333,334 of the Company&#x2019;s ordinary shares at a price to the public of $9.00 per share (and a price of $8.46 per share to the underwriters). Such shares were issued on March 16, 2020. In addition, the Company granted the underwriters a 30-day option to purchase additional ordinary shares at the price set forth above. On April 14, 2020, the Company issued and sold, pursuant to that underwriting agreement an additional 483,005 ordinary shares pursuant to the underwriters&#x2019; option specified above. The Company sold a total of 8,816,339 ordinary shares in the offering with proceeds of $74,147 (net of $5,200 issuance expenses).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div&gt;&lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;On January 31, 2023, the Company entered into a Sales Agreement with Leerink Partners LLC (previously known as SVB Securities LLC) (&#x201c;Leerink Partners&#x201d;), as sales agent, pursuant to which the Company may offer and sell, from time to time through Leerink Partners, its ordinary shares through an &#x201c;at the market offering&#x201d; (ATM). The offer and sale of our ordinary shares, if any, will be made pursuant to the Company&#x2019;s shelf registration statement on Form F-3, as supplemented by a prospectus supplement. Pursuant to the applicable prospectus supplement, the Company may offer and sell up to $50,000 of its ordinary shares. As of June 30, 2023, 1,609,123 shares were issued and sold through the ATM, with proceeds of approximately $1,154 (net of $458 issuance expenses).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Share option plan:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;During the six-month period ended June 30, 2023, the Company&#x2019;s Board of Directors granted 19,500 options to purchase ordinary shares of the Company to employees. The exercise prices for such options range from $0.67 to $1.06 per share, with vesting to occur in up to four years.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The following table presents the assumptions used to estimate the fair value of the options granted in the periods presented:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:84.45pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%" width="90%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;75.9%-76.4&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;69.4%-72.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3.3%-4.2&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1.5%-3.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;5.0-5.1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;5.0-5.4&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
          &lt;div&gt;
            &lt;div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="color:rgb(0, 0, 0)"&gt;Weighted average fair value of options granted during the six-month periods ended June 30, 2023 and 2022 were $&lt;/span&gt;0.53&lt;span style="color:rgb(0, 0, 0)"&gt; and $1.94, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="color:rgb(0, 0, 0)"&gt;During the six-month periods ended June 30, 2023 and 2022, the Company recorded share based compensation related to stock options in a total amount of $&lt;/span&gt;1,782&lt;span style="color:rgb(0, 0, 0)"&gt; and $2,092, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="color:rgb(0, 0, 0)"&gt;As of June 30, 2023, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date was $&lt;/span&gt;6,267&lt;span style="color:rgb(0, 0, 0)"&gt; which is expected to be recognized over a weighted average period of approximately&lt;/span&gt;&lt;span style="font-weight:bold;color:rgb(0, 0, 0)"&gt;&#160;&lt;/span&gt;2.08&lt;span style="color:rgb(0, 0, 0)"&gt; years.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;For the six months ended June 30, 2023 and 2022, the total weighted average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were 7,460,568&lt;span style="color:rgb(0, 0, 0)"&gt;&#160;&lt;/span&gt;and 8,504,958, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Employee Stock Purchase Plan:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The Company selected the Black-Scholes-Merton option-pricing model as the most appropriate fair value method for its share-option awards and Employee Share Purchase Plan (&#x201c;ESPP&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;text-indent:0.45pt;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;As of&lt;span style="color:rgb(0, 0, 0)"&gt; June 30, 2023 and &lt;/span&gt;since its adoption&lt;span style="color:rgb(0, 0, 0)"&gt;, &lt;/span&gt;275,854&lt;span style="color:rgb(0, 0, 0)"&gt; Ordinary Shares had been purchased under the ESPP and &lt;/span&gt;324,146&lt;span style="color:rgb(0, 0, 0)"&gt; Ordinary Shares were available for future issuance under the ESPP.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
          &lt;div&gt;
            &lt;div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The following table presents the assumptions used to estimate the fair value of ESPP granted in the periods presented:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="margin-left:81pt"&gt;

                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:middle" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:middle" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                          &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;65%-70&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:76%" valign="bottom"&gt;
                          &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.1%-1.7&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                          &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:76%" valign="bottom"&gt;
                          &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:FFact_286"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;

              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="color:rgb(0, 0, 0)"&gt;During the six-month periods ended June 30, 2023 and 2022, the Company recorded ESPP compensation in a total amount of $&lt;/span&gt;0&lt;span style="color:rgb(0, 0, 0)"&gt; and $97.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"
      decimals="INF"
      id="FFact_223"
      unitRef="Shares">5316457</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"
      decimals="INF"
      id="FFact_224"
      unitRef="USDPerShare">3.95</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"
      decimals="INF"
      id="FFact_225"
      unitRef="Shares">4253165</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"
      decimals="INF"
      id="FFact_226"
      unitRef="USDPerShare">4.74</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cgen:ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable
      contextRef="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"
      id="FFact_227">P5Y</cgen:ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"
      decimals="-3"
      id="FFact_228"
      unitRef="usd">19767000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"
      decimals="-3"
      id="FFact_229"
      unitRef="usd">1233000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_20230630_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="INF"
      id="Fxbrl_20230728024501070"
      unitRef="Shares">3955696</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_20210101to20230630_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="-3"
      id="Fxbrl_20230728024514846"
      unitRef="usd">18750000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20230630_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="INF"
      id="Fxbrl_20230728024526061"
      unitRef="Shares">297469</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="-3"
      id="FFact_235"
      unitRef="usd">12000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20181001to20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="INF"
      id="FFact_236"
      unitRef="Shares">2424243</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="INF"
      id="FFact_237"
      unitRef="USDPerShare">4.95</us-gaap:SharesIssuedPricePerShare>
    <cgen:PercentageOfClosingPrice
      contextRef="C_20181001to20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="2"
      id="FFact_238"
      unitRef="Pure">0.33</cgen:PercentageOfClosingPrice>
    <cgen:RelativeFairValueOfDeferredParticipation
      contextRef="C_20230630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember"
      decimals="-3"
      id="FFact_239"
      unitRef="usd">4121000</cgen:RelativeFairValueOfDeferredParticipation>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="C_20230101to20230630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember"
      decimals="-3"
      id="FFact_240"
      unitRef="usd">7788000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20230101to20230630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember"
      decimals="-3"
      id="FFact_241"
      unitRef="usd">91000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="-3"
      id="Fxbrl_20220720034631668"
      unitRef="usd">20000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20211101to20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="INF"
      id="Fxbrl_20220720034743180"
      unitRef="Shares">2332815</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="5"
      id="Fxbrl_20220720034904580"
      unitRef="USDPerShare">8.57333</us-gaap:SharesIssuedPricePerShare>
    <cgen:PercentageOfClosingPrice
      contextRef="C_20211101to20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="2"
      id="Fxbrl_20220720034949299"
      unitRef="Pure">0.33</cgen:PercentageOfClosingPrice>
    <cgen:RelativeFairValueOfDeferredParticipation
      contextRef="C_20230630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember"
      decimals="-3"
      id="Fxbrl_20220720035100582"
      unitRef="usd">5000000</cgen:RelativeFairValueOfDeferredParticipation>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="C_20230101to20230630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember"
      decimals="-3"
      id="Fxbrl_20220720035407188"
      unitRef="usd">14958000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20230101to20230630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember"
      decimals="-3"
      id="Fxbrl_20220720035509163"
      unitRef="usd">42000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20200301to20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="INF"
      id="FFact_242"
      unitRef="Shares">8333334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="2"
      id="FFact_243"
      unitRef="USDPerShare">9</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20200316_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="2"
      id="FFact_244"
      unitRef="USDPerShare">8.46</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20200401to20200414_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="INF"
      id="FFact_245"
      unitRef="Shares">483005</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20200401to20200414_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="INF"
      id="FFact_246"
      unitRef="Shares">8816339</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_20200401to20200414_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="-3"
      id="FFact_247"
      unitRef="usd">74147000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20200401to20200414_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="-3"
      id="FFact_248"
      unitRef="usd">5200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="C_20230130to20230131_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember"
      decimals="-3"
      id="Fxbrl_20230728031246595"
      unitRef="usd">50000000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20230101to20230630_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember"
      decimals="INF"
      id="Fxbrl_20230728031257218"
      unitRef="Shares">1609123</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_20230101to20230630_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember"
      decimals="-3"
      id="Fxbrl_20230728031311578"
      unitRef="usd">1154000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20230101to20230630_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithLeerinkPartnerLlcMember"
      decimals="-3"
      id="Fxbrl_20230728031320267"
      unitRef="usd">458000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="Fxbrl_20220720040533152"
      unitRef="Shares">19500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="Fxbrl_20220720040558485"
      unitRef="USDPerShare">0.67</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="FFact_251"
      unitRef="USDPerShare">1.06</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="C_20230101to20230630" id="FFact_252">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20220728002533924">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%" width="90%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;75.9%-76.4&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;69.4%-72.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3.3%-4.2&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1.5%-3.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;5.0-5.1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;5.0-5.4&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_20230101to20230630"
      decimals="3"
      id="Fxbrl_20220727222002683"
      unitRef="Pure">0.759</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_20230101to20230630"
      decimals="3"
      id="Fxbrl_20220727222015231"
      unitRef="Pure">0.764</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_20220101to20220630"
      decimals="3"
      id="Fxbrl_20220727222026940"
      unitRef="Pure">0.694</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_20220101to20220630"
      decimals="3"
      id="Fxbrl_20220727222103489"
      unitRef="Pure">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_20230101to20230630"
      decimals="3"
      id="Fxbrl_20220727222244528"
      unitRef="Pure">0.033</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_20230101to20230630"
      decimals="3"
      id="Fxbrl_20220727233307366"
      unitRef="Pure">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_20220101to20220630"
      decimals="3"
      id="Fxbrl_20220727233317706"
      unitRef="Pure">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_20220101to20220630"
      decimals="3"
      id="Fxbrl_20220727235651276"
      unitRef="Pure">0.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20230101to20230630"
      decimals="2"
      id="Fxbrl_20220727235701651"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20220101to20220630"
      decimals="2"
      id="Fxbrl_20220727235716123"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20230101to20230630_srtRangeAxis_srtMinimumMember"
      id="Fxbrl_20220727235725275">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20230101to20230630_srtRangeAxis_srtMaximumMember"
      id="Fxbrl_20220727235734670">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20220101to20220630_srtRangeAxis_srtMinimumMember"
      id="Fxbrl_20230728030223347">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20220101to20220630_srtRangeAxis_srtMaximumMember"
      id="Fxbrl_20230728030231097">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="FFact_267"
      unitRef="USDPerShare">0.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20220101to20220630"
      decimals="INF"
      id="FFact_268"
      unitRef="USDPerShare">1.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockOptionPlanExpense
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_269"
      unitRef="usd">1782000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_270"
      unitRef="usd">2092000</us-gaap:StockOptionPlanExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_20230630"
      decimals="-3"
      id="FFact_271"
      unitRef="usd">6267000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_20230101to20230630" id="FFact_272">P2Y29D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="Fxbrl_20220720041818515"
      unitRef="Shares">7460568</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20220101to20220630"
      decimals="INF"
      id="FFact_274"
      unitRef="Shares">8504958</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="C_20230101to20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="INF"
      id="FFact_275"
      unitRef="Shares">275854</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="INF"
      id="FFact_276"
      unitRef="Shares">324146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_20230101to20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      id="Fxbrl_20220728002557752">
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:middle" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:middle" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                          &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;65%-70&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:76%" valign="bottom"&gt;
                          &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.1%-1.7&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                          &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:76%" valign="bottom"&gt;
                          &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:FFact_286"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_20230101to20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="2"
      id="FFact_277"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="2"
      id="Fxbrl_20220720042810087"
      unitRef="Pure">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="2"
      id="Fxbrl_20220720042816078"
      unitRef="Pure">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_20230101to20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="2"
      id="FFact_280"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="3"
      id="Fxbrl_20220720042753766"
      unitRef="Pure">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="3"
      id="Fxbrl_20220720042801271"
      unitRef="Pure">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20230101to20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="2"
      id="FFact_283"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="2"
      id="Fxbrl_20220720042946790"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      id="Fxbrl_20220720042714542">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="C_20230101to20230630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="Fxbrl_20220720043008949"
      unitRef="usd">0</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_288"
      unitRef="usd">97000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20220727231501241">
        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 7:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                  &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold"&gt;FINANCIAL AND OTHER INCOME, NET&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div&gt;
            &lt;div style="margin-left:56pt"&gt;

                &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%"&gt;

                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                        &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest income&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,671&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;463&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:2px;width:76%" valign="bottom"&gt;
                        &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exchange rate differences and other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:4px;width:76%" valign="bottom"&gt;
                        &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Financial and other income, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,697&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;779&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20220727231515518">
                &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%"&gt;

                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                        &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest income&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,671&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;463&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:2px;width:76%" valign="bottom"&gt;
                        &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exchange rate differences and other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:4px;width:76%" valign="bottom"&gt;
                        &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Financial and other income, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,697&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;779&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              </us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_290"
      unitRef="usd">1671000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_291"
      unitRef="usd">463000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220720002002984"
      unitRef="usd">26000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_293"
      unitRef="usd">316000</us-gaap:OtherNonoperatingIncomeExpense>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_294"
      unitRef="usd">1697000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_295"
      unitRef="usd">779000</cgen:FinancialIncomeExpenseNet>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20220727224715083">
            &lt;div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 8:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;RELATED PARTY BALANCES AND TRANSACTIONS&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt;margin-left:56.7pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Balances with related parties:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div&gt;
                    &lt;div&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                      &lt;div style="margin-left:56.7pt"&gt;
                        &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%"&gt;

                            &lt;tr&gt;
                              &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                                &lt;div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span&gt;June 30,&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                                &lt;div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" rowspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;border-bottom:2px solid black" valign="bottom"&gt;
                                &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;Unaudited&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;padding-bottom:4px;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Trade and other payables (a)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                                &lt;div style="line-height:1.25;font-family:Arial"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                                &lt;div style="line-height:1.25;font-family:Arial"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;83&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;/tr&gt;

                        &lt;/table&gt;
                      &lt;/div&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt;margin-left:56.7pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Related parties' expenses:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                      &lt;div style="margin-left:56.7pt"&gt;
                        &lt;div&gt;
                          &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%"&gt;

                              &lt;tr&gt;
                                &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;Six months ended&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                  &lt;div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;June 30,&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;Unaudited&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25;text-indent:-8.5pt;margin-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Amounts charged to:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;padding-bottom:4px;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25;text-indent:-8.5pt;margin-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Research and development expenses (a)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;70&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;

                          &lt;/table&gt;
                        &lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
                  &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                      &lt;tr&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;width:56.7pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:27.7pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(a)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                        &lt;td style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, serif;width:auto"&gt;
                          &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company incurred expenses for research and development services provided by related party for cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20220728112628625">
                &lt;div&gt;
                  &lt;div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt;margin-left:56.7pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Balances with related parties:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div&gt;
                    &lt;div&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                      &lt;div style="margin-left:56.7pt"&gt;
                        &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%"&gt;

                            &lt;tr&gt;
                              &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                                &lt;div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span&gt;June 30,&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                                &lt;div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" rowspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;border-bottom:2px solid black" valign="bottom"&gt;
                                &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;Unaudited&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;padding-bottom:4px;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Trade and other payables (a)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                                &lt;div style="line-height:1.25;font-family:Arial"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                                &lt;div style="line-height:1.25;font-family:Arial"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;83&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;/tr&gt;

                        &lt;/table&gt;
                      &lt;/div&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt;margin-left:56.7pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Related parties' expenses:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                      &lt;div style="margin-left:56.7pt"&gt;
                        &lt;div&gt;
                          &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%"&gt;

                              &lt;tr&gt;
                                &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;Six months ended&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                  &lt;div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;June 30,&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;Unaudited&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25;text-indent:-8.5pt;margin-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Amounts charged to:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;padding-bottom:4px;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25;text-indent:-8.5pt;margin-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Research and development expenses (a)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;70&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;

                          &lt;/table&gt;
                        &lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
                  &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                      &lt;tr&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;width:56.7pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:27.7pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(a)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                        &lt;td style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, serif;width:auto"&gt;
                          &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company incurred expenses for research and development services provided by related party for cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
              </us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <cgen:TradeAndOtherPayablesRelatedParties
      contextRef="C_20230630"
      decimals="-3"
      id="FFact_298"
      unitRef="usd">36000</cgen:TradeAndOtherPayablesRelatedParties>
    <cgen:TradeAndOtherPayablesRelatedParties
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_299"
      unitRef="usd">83000</cgen:TradeAndOtherPayablesRelatedParties>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_300"
      unitRef="usd">70000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_301"
      unitRef="usd">114000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20220728193545297">
      &lt;div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 9:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On August 3, 2023, following recommendation of the compensation committee, the Company&#x2019;s board of directors reduced the total number of shares reserved for issuance under the Company&#x2019;s 2010 Plan by 500,000 and the total number of shares reserved for issuance under the ESPP by 210,000.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_20230803_usgaapPlanNameAxis_cgenPlan2010Member_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="INF"
      id="Fxbrl_20230728015337735"
      unitRef="Shares">500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_20230803_usgaapPlanNameAxis_cgenEmployeeSharePurchasePlanMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="INF"
      id="Fxbrl_20230728015343566"
      unitRef="Shares">210000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fxbrl_20230728034213148"
          xlink:label="Fxbrl_20230728034213148"
          xlink:type="locator"/>
        <link:footnote id="FN20230728034116852" xlink:label="FN20230728034116852" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents an amount lower than $1</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230728034213148"
          xlink:to="FN20230728034116852"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220727223630806"
          xlink:label="Fxbrl_20220727223630806"
          xlink:type="locator"/>
        <link:footnote id="FN20230728141130882" xlink:label="FN20230728141130882" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents an amount lower than $ 1.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220727223630806"
          xlink:to="FN20230728141130882"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230728042446448_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105006668"
          xlink:label="Fxbrl_20230728042446448_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105006668"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230728042446448_xbrl_20230728041439032_xbrl_20220727223450181_xbrl_20220720105006668"
          xlink:to="FN20230728141130882"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230728101901825"
          xlink:label="Fxbrl_20230728101901825"
          xlink:type="locator"/>
        <link:footnote id="FN20230728102035190" xlink:label="FN20230728102035190" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">*   Represents an amount lower than $1</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230728101901825"
          xlink:to="FN20230728102035190"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230728101905592"
          xlink:label="Fxbrl_20230728101905592"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230728101905592"
          xlink:to="FN20230728102035190"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_298"
          xlink:label="FFact_298"
          xlink:type="locator"/>
        <link:footnote id="FN20220720121444312" xlink:label="FN20220720121444312" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company incurred expenses for research and development services provided by related party for cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_298"
          xlink:to="FN20220720121444312"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_299"
          xlink:label="FFact_299"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_299"
          xlink:to="FN20220720121444312"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_300"
          xlink:label="FFact_300"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_300"
          xlink:to="FN20220720121444312"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_301"
          xlink:label="FFact_301"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_301"
          xlink:to="FN20220720121444312"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>41
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M6L3B+GV^8MN '.DO3..\_(^>M[96"X5%+M+5=C @6$7)YI=^WT[$W@#<;1A
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MD!A6K$SUC=B>0^VG;_@BD2K[3[95+J4.B4JE15:#44'&\^K)[NLZ[ "ZO6<
M?@WP7PL(:D!@C5;*K*TITRP<2K$ETF0CFQG8VE@TNN&Y>8L++7&5(TZ'D^NK
MZ>QJ,9L2'"VN+R^FXUL,3L>7XZO)C"S.9[-;\G[.).0Z <TCEGX@'\G!NT%
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MK'11? (H3A3?Y"_%"Z[@%3L_C F.B- &<'_%N7H]T0^H/L2,_P502P,$%
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M$8#W,R'T\XWY@<VI^^0_4$L#!!0    ( !(X!U>S"F$#J@D  ( 7   8
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M=@FVD8KQ(9<U 4YP9AFX8AFQ1+<6=J8E5]+67J!+R9Y-J0B95(,^]]ZAE$4
MNQU\#AW.]\<=U)=?WS.A4/AH5^O:#"5MVJT)U?:Q3!NS$E,#XWF.'=QZ0,92
MIB5+@/5/CQ"V<8*:&$TR/0LN/T\6Q^ R<AL;PS@G9*"$?^/A-@)LR\$?6J*X
M:PV,"()4=%4I$^GZXEB@@8$07>ET;4VAE:G10MU*HQ5Q<+J73/<&!8<<+%%K
M?K7<.%_"(/X[PH1P7UK#104.($ 1Q&%#\3-9: '(#(,"%=**VLJ/Z<T4LV)B
M928Q+I+:&Z3'1P-;J5XB"KR2&$N51/M+-XT"]2&0MH8,JK2U(G8$7NN6*D?.
MG@.C5XM#EK7&\P4OK;Q#_/U<(VBN87\00_JI9.SU<IHET[9N48X$-4C4"1D4
MLH.C@_'^\3'CGF /A"DR.Q0H482&DW);LAQC<@ A($*6#6#:=H)Y+XX8D/@;
M+FPT"S"ID@B'[8H;4!=WR 7:$_U9.H0+V:%;DPHJ%A55>Z2&0+ 1*A#(PD"+
MIAU$433)H4K^:A$T\-E@I32^=L%MY^WS08'M%?& /%C[3/?B8#(8*OQ:-##D
M(9B.BMX[Y'$A)48TVG@[J:M-][+IWC?%SML"$S,[)%<7^QOE!ECT[*2ZP*XQ
MS7&#'*.@O!]0$N-]Q1-M>#@TX.WGK@R?QS+\LINLWO$ULB8^CQ.6+ZOA)8HP
MS@[L_-.F4%S:1\UT]HR'^1$H@Q94"Y.B>LB_@E4 K:\4$SJ29)NC#R]P&//8
MZ:[_]?UB,I@TM@82V% 0);5!]?H!Z@3+ %O=C3J"/?!X$V)42N%;(PC>-H@5
M=#9\[2'SZ38?S^?SX%3?$\ P7D!=082J985A NVV%_/[8JXT^D[B!"9 D^?(
M)&B9,L3[*URI$QBT?.W9C<DD&(@)#]T[X!+-ZSB.%,P\JRLR%60@!R5*HQ@S
MD><BC*TA@3^*Q+14?)9'?1+O0&&Z!P9^B*)?/*]"PG55^!$6/MWLP_PCLLL0
MJ,_H:LBNH*^H=$*S5S<0V\B?K9D=]"-/AD-"S\3!L\A'F.5;F3\2;"B"DD1.
M!G-3QE#!W.#1PRX=NUDWACY.*WY/J#C:0.A69H%-VS#!SJ%+?1K]?P9O&?A@
MN/.SW'1C(ZK?/E_IM$]6I$9XZI+FQA]].E5MYRKZ8XQMF,Y /6(R0M;0^$)@
MD_TT:NTL P^JP+ =M!'/".']H6:0D'WR;>4EJ7Z^.!P?XMU6^C'=>AC;ACQ]
MOIP''3Z1W.8(@$92>$^PL-N6>M5&,8OU9?W0H[BSC9'T@U(\P #U%4VAA+[T
M&63TFE=A<E L;ZEMQ-665S2!7>;#,A,#0T>0.(R/ATL&9OA35MQBI5N<(M'[
MLM9[&!$F:P5'VG7:IWNY[T3?4J>I,"W^1A5 P;"X9Q?]A/3=S^F;C6C0? 9'
M^X>2C[4B@Z:N*_8%9<NR&_3D)(G&Q+ZT8]%&6;CE56C[-&3P7+@01LB@]_BC
M_)K(LNM(A ,GL0$13ZC2DD./&A;EZ+RVHTMU,RN _]9D\E:_>+8X.GC+7BI<
M5VW-D]_&3YQQD'LR"Z,M&'*.N0(C.\A 8S$'<EEH.]062K$5F4'CTX/V$Z*\
M7(PW,Y&M0->\-=2<@W)?S;( A?I/J])[*,+H5BB::?JJV-O3FS/8?F=(:XQF
ME.O+D*=28;1S7H&\/S..X:^ [8CD*^[;:#<V[?<]=$A5,G?G7@\X7 E'2-W[
M/CS5AM/,_P"4!N,.HS#FR=KG&OV//92Q46==>[8MU/H!<-?7N-G@JR@*3>&_
M_=*1$9-S^$ :G\;/R^?AJ^K]\O!M&BV]P$@%+W.(SJ='AZ/0 ?H;IQO_C371
MSNG:7]*A2!A:@/>Y!M[=#6T0/[J?_1=02P,$%     @ $C@'5\M/-"H[!0
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M5<N_3P4?L?>>QN8..G"5R/ XH19Q:)>8#-^\WMWO'[[ ?*]EOO<2^J_DZF7
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M3P-6SU@'[)"+0)'O207@:TF3@^]90[A'X1J2*:$5:W30OZR).G#JW:9'?;E
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M:MLPV0NX>^*PR;#T&:P8.<,^K(U!0(4EP^W5>'2''B9S@O'0B0;CK;7!!]Q
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M NQ-;\@SD_3ZUS9QFZL",9;;L*M'0TI8;6U*VEU#K)].D,.S^VO;9K=402:
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MA,ZP[X[?](8#-^J\Z0S&;@0W@>O!S1U7#[T9\!U2("0?%*A8)71"-WS3B]P
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MTSWD=:W1U!ITI=!4RC*5,A_/>F*DC*G"V)HSA3J& LHBGJ/UT>IV@GY7K[W
MMV;[*"5LBR"(0HAIDFAG%J$$PF+@*D5A>8'E=P/KEC+"(DJRUZN&LP,,54U\
MW==KOW\-IY[=.6J7',6V&@H2(EXR57=.>]K.G7'=;J_N]="Z)V)+F80,$PUU
M+_J7-HAZ$-2&XD75?!NN="M7VU3/3A3&0=\GG*N#80*TTSC\"U!+ P04
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M;"]W;W)K<VAE971S+W-H965T,34N>&ULI93?;]HP$,??]U><4JE/C)A ?S%
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MM7.@_:52=KMP![1-?/(+4$L#!!0    ( !(X!U?J1:WNI00  !$+   9
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M5N0#FB-XH0P*PMU2D'--PE-:.160L9-]I/\'6/$U)S&Q12G-/;HJM16;8S[
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M<*8LZ=DO<QJ@J%T [<^5LJ^&*U"/Y.0O4$L#!!0    ( !(X!U=18C2=]@(
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MN&\([%9@7RIP6H%SZ9#<5N!>*O!:@7>I8-P*QK59S=.MK0FPP+,)HWO$JM9
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MN(%_=<CC(T_Y]Q=S^PPG+Y.Q0?!PTTI5'0(^LD5XN_!CP[E_N" VDSK#JC'
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M@1@34F3JEF\NL?+3-7P1SZ3]A4V9&_0<B JI>%Z!M8*<LO)+GJHZ[  T3S/
MJP#>/J#S!L"O +XU6BJSMB9$D; O^ :$R=9L9F!K8]':#67F7[Q30J]2C5/A
MQ6P^G(]GPZ\PG$_@^OYR>@NS^?CZ:GH"\^D]'$]0$9K)#_ 1'NXF<'ST 8Z
M,KA/>2$)BV7?55J'87.C:L]1N:?WQIX!7'&F4@E3%F/\$N]J_;4);VMBY!TD
M_%*P4_!;)^"U/+]!S_COX=X!.7Y=4]_R^?]8TQ_#A51"'^"?3;4KN3O-W.92
MG\L5B7#@Z%LK4:S1"=^_:P>MSTW&_Q/9BS)TZC)T#K&',Z90LRI]6B*>8Y/7
MDJ!K"4R_68?MH-?NN^M=#Z^3.H%?Y[R0UJVE=0]*FSY%*6%+!$$40DR31"ME
M$4K0)QJX2E$TR2U)@QTE7K G]G6*WPZ:Q0:UV."@V O*"(LHR9[%524] 8:J
M26C04->SWI[4UTF]WMF>5'>GL^0HEK;A2HAXP51Y/^O9NJ</;2O;FQ_I7E^V
MYF>:\J&X(F))F80,$TW9.NUI1:)LOF6@^,KVKP57NAO:8:K?*Q0F0:\GG*MM
M8#:H7\#P#U!+ P04    "  2. =74H 6-&D#  #F"0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6RM5FV/XC80_BM6>FIWI>LF(;R<*$3*$JI>=;==
M =>J.O6#209B76+G; >6?]^QD\T!&^BUO2\03^9Y9N;QQ)[)7LA/*@/0Y*G(
MN9HZF=;EV'55DD%!U9TH@>.;C9 %U;B46U>5$FAJ047N]CQOZ!:4<2><6-NC
M#">BTCGC\"B)JHJ"RL,]Y&(_=7SGV;!@VTP;@QM.2KJ%)>@/Y:/$E=NRI*P
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M$;*>*NJ%%J6]-M="XR5L'S,<Q$ :!WR_$4(_+TR =K0+_P902P,$%     @
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ $C@'5QZ($?@P P  >Q,
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M+GAM;%!+ 0(4 Q0    ( !(X!U<SR<<&[@   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( !(X!U>97)PC$ 8
M )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ $C@'5^W!T<): P  J L  !@              ("!#0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( !(X!U=#-1VMCP8
M -4:   8              " @9T+  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    "  2. =7;>(<W:H"  !0!P  &               @(%B
M$@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ $C@'5TM7
M*MK?!   E!$  !@              ("!0A4  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( !(X!U?NFVVRW04  +,<   8
M  " @5<:  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  2
M. =7;NIB_"D'  "!'P  &               @(%J(   >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ $C@'5[,*80.J"0  @!<  !@
M         ("!R2<  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( !(X!U?+3S0J.P4  - ,   8              " @:DQ  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  2. =75Y1M4'P#   ""
M&               @($:-P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ $C@'5\?40FD0 P  Q08  !D              ("!S#H  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  2. =79V&$^$ (
M  !%%0  &0              @($3/@  >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( !(X!U=Y.$:(/PL  " @   9              "
M@8I&  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ $C@'
M5Y6^X7)[ @  F04  !D              ("! %(  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    "  2. =7NHA&RPD#  #+!@  &0
M        @(&R5   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( !(X!U<)![S>F@(  - %   9              " @?)7  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ $C@'5^I%K>ZE!   $0L
M !D              ("!PUH  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    "  2. =7^-=W.;("  ">!0  &0              @(&?7P
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( !(X!U=18C2=
M]@(  #4'   9              " @8AB  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ $C@'5W#$M:B" @  A04  !D
M ("!M64  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  2
M. =7^,CHYB(#  "M!@  &0              @(%N:   >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( !(X!U<O?EA>-@0  )(7   9
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M970R-2YX;6Q02P$"% ,4    "  2. =7_49J!;0"   -!P  &0
M    @(&:C0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M !(X!U=2@!8T:0,  .8)   9              " @860  !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ $C@'5Y27*MUG @  V 8  !D
M             ("!)90  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    "  2. =7<JS6YT<#  !2$P  #0              @ '#E@  >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( !(X!U>7BKL<P    !,"   +
M      "  36:  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( !(X!U<>B!'X, ,
M 'L3   /              "  1Z;  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    "  2. =7+P""5$P!  !K$0  &@              @ %[G@  >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  2. =7(N!HUWL!   Z
M$@  $P              @ '_GP  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    )  D +,)  "KH0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>64</ContextCount>
  <ElementCount>160</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>22</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-daei1</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-cbs</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-cbsp</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-csocl</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-socise1</Role>
      <ShortName>CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Disclosure - GENERAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-g</Role>
      <ShortName>GENERAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sap1</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/UnauditedInterimConsolidatedFinancialStatements</Role>
      <ShortName>UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - MARKETABLE SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/MARKETABLESECURITIES</Role>
      <ShortName>MARKETABLE SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-cac</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-se1</Role>
      <ShortName>SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - FINANCIAL AND OTHER INCOME, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-fin</Role>
      <ShortName>FINANCIAL AND OTHER INCOME, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0014 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-rpbat</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0015 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0017 - Disclosure - MARKETABLE SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/MARKETABLESECURITIESTables</Role>
      <ShortName>MARKETABLE SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/MARKETABLESECURITIES</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0018 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-set</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-se1</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0019 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-fint</Role>
      <ShortName>FINANCIAL AND OTHER INCOME, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-fin</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0020 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-rpbat</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0021 - Disclosure - GENERAL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-gd1</Role>
      <ShortName>GENERAL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-g</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0022 - Disclosure - MARKETABLE SECURITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/MARKETABLESECURITIESDetails</Role>
      <ShortName>MARKETABLE SECURITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/MARKETABLESECURITIESTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0023 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-cac</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0024 - Disclosure - SHAREHOLDERS' EQUITY (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-set</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0025 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of fair value assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Schedule of fair value assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-set</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0026 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-find</Role>
      <ShortName>FINANCIAL AND OTHER INCOME, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-fint</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0027 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-rpbatd</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="zk2330082.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0028 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>28</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cgen-20230630.xsd</File>
    <File>cgen-20230630_cal.xml</File>
    <File>cgen-20230630_def.xml</File>
    <File>cgen-20230630_lab.xml</File>
    <File>cgen-20230630_pre.xml</File>
    <File doctype="6-K" isDefinitelyFs="true" isUsgaap="true" original="zk2330082.htm">zk2330082.htm</File>
    <File doctype="6-K" isDefinitelyFs="true" isUsgaap="true" original="exhibit_99-2.htm">exhibit_99-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="276">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="13">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>46
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "zk2330082.htm exhibit_99-2.htm": {
   "nsprefix": "cgen",
   "nsuri": "http://cgen.com/20230630",
   "dts": {
    "schema": {
     "local": [
      "cgen-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cgen-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cgen-20230630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cgen-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cgen-20230630_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "exhibit_99-2.htm",
      "zk2330082.htm"
     ]
    }
   },
   "keyStandard": 133,
   "keyCustom": 27,
   "axisStandard": 9,
   "axisCustom": 1,
   "memberStandard": 9,
   "memberCustom": 13,
   "hidden": {
    "total": 14,
    "http://fasb.org/us-gaap/2023": 8,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://cgen.com/20230630": 1
   },
   "contextCount": 64,
   "entityCount": 1,
   "segmentCount": 22,
   "elementCount": 273,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 276,
    "http://xbrl.sec.gov/dei/2023": 13
   },
   "report": {
    "R1": {
     "role": "http://cgen.com/role/cgen-daei1",
     "longName": "0001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2330082.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2330082.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://cgen.com/role/cgen-cbs",
     "longName": "0002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_20230630",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230630",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://cgen.com/role/cgen-cbsp",
     "longName": "0003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_20230630",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "ILSPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230630",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://cgen.com/role/cgen-csocl",
     "longName": "0004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://cgen.com/role/cgen-socise1",
     "longName": "0005 - Statement - CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "shortName": "CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
     "longName": "0006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://cgen.com/role/cgen-g",
     "longName": "0007 - Disclosure - GENERAL",
     "shortName": "GENERAL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://cgen.com/role/cgen-sap1",
     "longName": "0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://cgen.com/role/UnauditedInterimConsolidatedFinancialStatements",
     "longName": "0009 - Disclosure - UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS",
     "shortName": "UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "cgen:UnauditedInterimConsolidatedFinancialStatementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "cgen:UnauditedInterimConsolidatedFinancialStatementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://cgen.com/role/MARKETABLESECURITIES",
     "longName": "0010 - Disclosure - MARKETABLE SECURITIES",
     "shortName": "MARKETABLE SECURITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://cgen.com/role/cgen-cac",
     "longName": "0011 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://cgen.com/role/cgen-se1",
     "longName": "0012 - Disclosure - SHAREHOLDERS' EQUITY",
     "shortName": "SHAREHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://cgen.com/role/cgen-fin",
     "longName": "0013 - Disclosure - FINANCIAL AND OTHER INCOME, NET",
     "shortName": "FINANCIAL AND OTHER INCOME, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://cgen.com/role/cgen-rpbat",
     "longName": "0014 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://cgen.com/role/SUBSEQUENTEVENTS",
     "longName": "0015 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "0016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:MarketableSecuritiesPolicy",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:MarketableSecuritiesPolicy",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://cgen.com/role/MARKETABLESECURITIESTables",
     "longName": "0017 - Disclosure - MARKETABLE SECURITIES (Tables)",
     "shortName": "MARKETABLE SECURITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://cgen.com/role/cgen-set",
     "longName": "0018 - Disclosure - SHAREHOLDERS' EQUITY (Tables)",
     "shortName": "SHAREHOLDERS' EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://cgen.com/role/cgen-fint",
     "longName": "0019 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Tables)",
     "shortName": "FINANCIAL AND OTHER INCOME, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables",
     "longName": "0020 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://cgen.com/role/cgen-gd1",
     "longName": "0021 - Disclosure - GENERAL (Details)",
     "shortName": "GENERAL (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_20130801to20130805",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20130801to20130805",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://cgen.com/role/MARKETABLESECURITIESDetails",
     "longName": "0022 - Disclosure - MARKETABLE SECURITIES (Details)",
     "shortName": "MARKETABLE SECURITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_20230630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230630_usgaapFinancialInstrumentAxis_usgaapCorporateDebtSecuritiesMember",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://cgen.com/role/CommitmentsAndContingenciesDetails",
     "longName": "0023 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_20230630",
      "name": "us-gaap:GuaranteeObligationsMaximumExposure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230630",
      "name": "us-gaap:GuaranteeObligationsMaximumExposure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
     "longName": "0024 - Disclosure - SHAREHOLDERS' EQUITY (Detail Textuals)",
     "shortName": "SHAREHOLDERS' EQUITY (Detail Textuals)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_20230630",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "ILSPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "unique": true
     }
    },
    "R25": {
     "role": "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails",
     "longName": "0025 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of fair value assumptions) (Details)",
     "shortName": "SHAREHOLDERS' EQUITY (Schedule of fair value assumptions) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://cgen.com/role/cgen-find",
     "longName": "0026 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Details)",
     "shortName": "FINANCIAL AND OTHER INCOME, NET (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20230630",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://cgen.com/role/cgen-rpbatd",
     "longName": "0027 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Details)",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_20230630",
      "name": "cgen:TradeAndOtherPayablesRelatedParties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230630",
      "name": "cgen:TradeAndOtherPayablesRelatedParties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails",
     "longName": "0028 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)",
     "shortName": "SUBSEQUENT EVENTS (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_20230803_usgaapPlanNameAxis_cgenPlan2010Member_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230803_usgaapPlanNameAxis_cgenPlan2010Member_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES [Abstract]",
        "verboseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r456"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade receivables",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141"
     ]
    },
    "cgen_AccretionOfDiscountOnMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "AccretionOfDiscountOnMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the amount of Accretion of discount on marketable securities",
        "negatedLabel": "Accretion of discount on marketable securities",
        "label": "Accretion Of Discount On Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AccruedMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "AccruedMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of accrued milestone payment.",
        "label": "Accrued Milestone Payment",
        "terseLabel": "Accrued milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r360",
      "r483",
      "r484",
      "r485",
      "r541",
      "r555"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "AgreementMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement [Member]",
        "label": "Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AgreementStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "AgreementStartDate",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of the agreement, in CCYY-MM-DD format.",
        "label": "Agreement, start date"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AgreementTerminationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "AgreementTerminationDescription",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement termination description.",
        "label": "Agreement termination description",
        "terseLabel": "Agreement termination description"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AmountIncurredMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "AmountIncurredMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount incurred milestone payments.",
        "label": "Amount incurred milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total weighted average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r87",
      "r106",
      "r130",
      "r134",
      "r136",
      "r176",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r260",
      "r262",
      "r276",
      "r334",
      "r386",
      "r456",
      "r468",
      "r507",
      "r508",
      "r543"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r88",
      "r106",
      "r176",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r260",
      "r262",
      "r276",
      "r456",
      "r507",
      "r508",
      "r543"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r176",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r260",
      "r262",
      "r276",
      "r507",
      "r508",
      "r543"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON-CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AtMarketOfferingProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "AtMarketOfferingProgramMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering Program [Member]",
        "label": "At Market Offering Program [Member]",
        "terseLabel": "At The Market Offering Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Gross unrealized losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Amortized cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r184",
      "r333"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r184",
      "r327",
      "r486"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ]
    },
    "us-gaap_BusinessDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Marketing and business development expenses",
        "label": "Marketing and business development expenses",
        "documentation": "Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r86",
      "r444"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the period",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r57",
      "r104"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r57"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration period of warrants.",
        "label": "Class Of Warrant Or Righst Period From Which Warrants Or Rights Exercisable",
        "terseLabel": "Expiration period of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price of warrants",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants purchase to ordinary shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants purchase to ordinary shares remain outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_CollaborationAgreementWithUSAntibodyCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "CollaborationAgreementWithUSAntibodyCompanyMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement With U.S. Antibody Company [Member]",
        "label": "Collaboration Agreement With U.S. Antibody Company [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_CollaborativeArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "CollaborativeArrangementsMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements [Member]",
        "label": "Collaborative Arrangements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_CollaborativeArrangementsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "CollaborativeArrangementsTwoMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements Two Member.",
        "label": "Collaborative Arrangements Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_CommercialLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "CommercialLicenseAgreementMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial License Agreement [Member]",
        "label": "Commercial License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENT LIABILITIES (NOTE 4)",
        "verboseLabel": "COMMITMENTS AND CONTINGENT LIABILITIES (NOTE 5)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r29",
      "r335",
      "r373"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-cac"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r188",
      "r189",
      "r430",
      "r505"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r462",
      "r463",
      "r464",
      "r465",
      "r483",
      "r484",
      "r541",
      "r554",
      "r555"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/cgen-cbsp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, par value per share",
        "verboseLabel": "Ordinary shares, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/cgen-cbsp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r374"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://cgen.com/role/cgen-cbsp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://cgen.com/role/cgen-cbsp",
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "label": "Ordinary shares, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r41",
      "r374",
      "r392",
      "r555",
      "r556"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares of NIS 0.01 par value per share: 200,000,000 shares authorized on June 30, 2021 and December 31, 2020; 83,917,929 and 83,675,856 shares issued and outstanding on June 30, 2021 and December 31, 2020, respectively",
        "terseLabel": "Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized on June 30, 2023, and December 31, 2022; 88,233,766 and 86,624,643 shares issued and outstanding on June 30, 2023, and December 31, 2022, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r336",
      "r456"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r93",
      "r95",
      "r99",
      "r328",
      "r343"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of credit risks",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r79"
     ]
    },
    "cgen_ContingentFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "ContingentFees",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent fees.",
        "label": "Contingent fees",
        "terseLabel": "Contingent fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Governmental bonds [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r453",
      "r553"
     ]
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-rpbatd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related parties' expenses amounts charged to research and development expenses",
        "terseLabel": "Research and development expenses",
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of available-for-sale marketable securities",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499"
     ]
    },
    "cgen_DeferredParticipationOfBmsInRdExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "DeferredParticipationOfBmsInRdExpenses",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred participation of BMS in R&amp;amp;D expenses.",
        "label": "Deferred Participation Of Bms In Rd Expenses",
        "terseLabel": "Deferred participation of BMS in R&amp;D expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r23"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted net loss per share",
        "terseLabel": "Basic net loss per share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r120",
      "r122",
      "r124",
      "r125",
      "r126",
      "r128",
      "r272",
      "r273",
      "r329",
      "r344",
      "r446"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r122",
      "r124",
      "r125",
      "r126",
      "r128",
      "r272",
      "r273",
      "r329",
      "r344",
      "r446"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted loss per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period over which compensation expense will be recognized",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "verboseLabel": "Unrecognized estimated compensation cost",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "cgen_EmployeeSharePurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "EmployeeSharePurchasePlanMember",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the Employee Share Purchase Plan member.",
        "label": "Employee Share Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails",
      "http://cgen.com/role/cgen-set"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation ESPP",
        "documentation": "The amount of plan compensation cost recognized during the period."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r82",
      "r96",
      "r97",
      "r98",
      "r107",
      "r108",
      "r109",
      "r111",
      "r117",
      "r119",
      "r129",
      "r177",
      "r178",
      "r210",
      "r246",
      "r247",
      "r248",
      "r256",
      "r257",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r286",
      "r347",
      "r348",
      "r349",
      "r360",
      "r414"
     ]
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentAggregateCost",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity investment",
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "cgen_FinancialIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "FinancialIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 10.0
      },
      "http://cgen.com/role/cgen-find": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl",
      "http://cgen.com/role/cgen-find"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate of financial and other income net of expense.",
        "negatedLabel": "Financial and other income, net",
        "label": "Financial Income Expense Net",
        "totalLabel": "Financial and other income, net",
        "verboseLabel": "Financial and other income, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r185",
      "r186",
      "r187",
      "r207",
      "r208",
      "r270",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r342",
      "r449",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r499",
      "r500",
      "r501",
      "r502"
     ]
    },
    "us-gaap_GainContingenciesByNatureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainContingenciesByNatureAxis",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain Contingencies, Nature [Axis]",
        "documentation": "Information by nature of gain contingency."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_GainContingencyNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainContingencyNatureDomain",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "General and administrative expenses",
        "label": "General and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r396"
     ]
    },
    "cgen_GovernmentAndOtherGrantsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "GovernmentAndOtherGrantsAxis",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government and Other Grants [Axis]",
        "label": "Government and Other Grants [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_GovernmentAndOtherGrantsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "GovernmentAndOtherGrantsDomain",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government And Other Grants [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_GovernmentAndOtherGrantsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "GovernmentAndOtherGrantsLineItems",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government And Other Grants [Line Items]",
        "label": "Government and Other Grants [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_GovernmentAndOtherGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "GovernmentAndOtherGrantsMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government and Other Grants [Member]",
        "label": "Government and Other Grants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_GovernmentAndOtherGrantsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "GovernmentAndOtherGrantsTable",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government And Other Grants [Table]",
        "label": "Government and Other Grants [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GuaranteeObligationsByNatureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsByNatureAxis",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guarantor Obligations, Nature [Axis]",
        "documentation": "Information by nature of guarantee."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r197"
     ]
    },
    "us-gaap_GuaranteeObligationsMaximumExposure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsMaximumExposure",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security",
        "terseLabel": "Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security",
        "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "us-gaap_GuaranteeObligationsNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsNatureDomain",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r197"
     ]
    },
    "country_IL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "IL",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israel [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Loss before taxes on income",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before taxes on income",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r48",
      "r74",
      "r130",
      "r133",
      "r135",
      "r137",
      "r330",
      "r340",
      "r447"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax benefit",
        "negativeTerseLabel": "Tax benefit",
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Tax benefit",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r80",
      "r118",
      "r119",
      "r132",
      "r255",
      "r258",
      "r345"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 140.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease (increase) in other accounts receivable and prepaid expenses",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 90.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in other accounts payable and accrued expenses",
        "verboseLabel": "Increase (decrease) in other accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 130.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in trade payables",
        "terseLabel": "Decrease in trade payables",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 70.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in other accounts receivable and prepaid expenses",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Increase in interest receivables from short-term bank deposits",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 100.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in deferred participation in R&amp;amp;D expenses.",
        "label": "Increase Decrease In Deferred Participation In Research And Development Expenses",
        "terseLabel": "Decrease in deferred participation in R&amp;D expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 120.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in operating lease right of use asset.",
        "negatedLabel": "Decrease in operating lease right of use asset",
        "label": "Increase Decrease In Operating Lease Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 110.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in operating lease liability",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 80.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease (increase) in long-term prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-find": {
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-find"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "totalLabel": "Interest Income, Deposits with Financial Institutions, Total",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r131"
     ]
    },
    "us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentOwnedUnderlyingFaceAmountAtMarketValue",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of investment in Compugen",
        "documentation": "Nominal or face amount on the investment owned."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "MARKETABLE SECURITIES",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r76",
      "r77",
      "r81",
      "r142",
      "r144",
      "r274",
      "r275"
     ]
    },
    "cgen_IssuanceExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "IssuanceExpenses",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the amount of Issuance expenses",
        "label": "Issuance Expenses",
        "verboseLabel": "Issuance expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r73",
      "r338",
      "r456",
      "r482",
      "r503",
      "r542"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r85",
      "r106",
      "r176",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r261",
      "r262",
      "r263",
      "r276",
      "r456",
      "r507",
      "r543",
      "r544"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r35",
      "r36",
      "r37",
      "r38",
      "r106",
      "r176",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r261",
      "r262",
      "r263",
      "r276",
      "r507",
      "r543",
      "r544"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON- CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "LongTermDeferredParticipationinResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term deferred participation in R&amp;amp;D expenses.",
        "label": "Long Term Deferred Participationin Research And Development Expenses",
        "verboseLabel": "Long-term deferred participation in R&amp;D expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Current",
        "verboseLabel": "Investment in marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Investments in marketable securities:",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Realized gain on sale of marketable securities, net",
        "label": "Marketable Securities, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI)."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_MasterClinicalAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "MasterClinicalAgreementMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master Clinical Agreement [Member]",
        "label": "Master Clinical Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "MaximumAuthorizedProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum authorized proceeds from issuance of common stock.",
        "label": "Maximum Authorized Proceeds From Issuance Of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r212",
      "r325",
      "r346",
      "r365",
      "r366",
      "r419",
      "r421",
      "r423",
      "r424",
      "r426",
      "r440",
      "r441",
      "r448",
      "r450",
      "r454",
      "r457",
      "r509",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550"
     ]
    },
    "cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "MaximumRoyaltyRepaidAsPercentageOfGrantReceived",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Royalty Repaid As Percentage Of Grant Received",
        "label": "Maximum royalty repaid as percentage of grant received",
        "terseLabel": "Maximum royalty repaid as percentage of grant received"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_May2012AgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "May2012AgreementMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the May 2012 Agreement.",
        "label": "May 2012 Agreement [Member]",
        "terseLabel": "May 2012 Agreement With Advisor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r212",
      "r325",
      "r346",
      "r365",
      "r366",
      "r419",
      "r421",
      "r423",
      "r424",
      "r426",
      "r440",
      "r441",
      "r448",
      "r450",
      "r454",
      "r457",
      "r509",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r59"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/cgen-csocl",
      "http://cgen.com/role/cgen-gd1",
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss",
        "negatedTotalLabel": "Net loss",
        "label": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r59",
      "r75",
      "r83",
      "r92",
      "r94",
      "r98",
      "r106",
      "r110",
      "r112",
      "r113",
      "r114",
      "r115",
      "r118",
      "r119",
      "r123",
      "r130",
      "r133",
      "r135",
      "r137",
      "r176",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r273",
      "r276",
      "r341",
      "r394",
      "r412",
      "r413",
      "r447",
      "r466",
      "r507"
     ]
    },
    "cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements not yet adopted, that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Not Yet Adopted Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting pronouncements, not yet adopted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently adopted accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_NumberOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "NumberOfWarrantsExercised",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised.",
        "label": "Number Of Warrants Exercised",
        "verboseLabel": "Warrants exercised, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Total operating expenses",
        "negatedTotalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current maturity of operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long term operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right to use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "GENERAL [Abstract]",
        "verboseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-g"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GENERAL",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r69",
      "r352",
      "r353"
     ]
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accounts payable and accrued expenses",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "verboseLabel": "Other comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "terseLabel": "Other comprehensive income (loss) from marketable securities, net",
        "verboseLabel": "Change in unrealized gains (losses) on marketable securities: Unrealized gains (losses) arising during the period, net",
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r47",
      "r91",
      "r175"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Other comprehensive income (loss) from marketable securities, net",
        "verboseLabel": "Change in unrealized gains (losses) on marketable securities: Unrealized gains (losses) arising during the period, net",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r175"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncomeAndExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "FINANCIAL AND OTHER INCOME, NET [Abstract]",
        "verboseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-fin"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "FINANCIAL AND OTHER INCOME, NET",
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r68"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-find": {
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-find"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Exchange rate differences and other",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_OtherShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term bank deposits",
        "documentation": "Amount of short-term investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r332",
      "r479"
     ]
    },
    "cgen_ParticipationRights": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "ParticipationRights",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to advisor.",
        "label": "Participation Rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance expenses",
        "verboseLabel": "Issuance expenses",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment in marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment in short-term bank deposits",
        "label": "Payments to Acquire Short-term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "cgen_PercentageOfClosingPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "PercentageOfClosingPrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of closing price.",
        "label": "Percentage of closing price"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_PercentageOfRoyaltiesOnNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "PercentageOfRoyaltiesOnNetSales",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalties on net sales.",
        "label": "Percentage of royalties on net sales"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_Plan2010Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "Plan2010Member",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the plan 2010 member.",
        "label": "Plan 2010 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538"
     ]
    },
    "us-gaap_PostemploymentBenefitsLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PostemploymentBenefitsLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued severance pay",
        "documentation": "For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r512"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accounts receivable and prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term prepaid expenses",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from ordinary shares in offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of ordinary shares, net",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from maturity of short-term bank deposits",
        "totalLabel": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r487"
     ]
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Equity Method Investments",
        "verboseLabel": "Proceeds from equity investments",
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfHeldToMaturitySecurities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Held-to-Maturity Securities",
        "totalLabel": "Proceeds from Sale and Maturity of Held-to-Maturity Securities, Total",
        "verboseLabel": "Proceeds from maturity of marketable securities",
        "documentation": "The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r143"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of warrants",
        "verboseLabel": "Proceeds from warrant exercised",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_PropertyLeaseGuaranteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyLeaseGuaranteeMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office leases [Member]",
        "documentation": "A guarantee of performance by a third party lessee under terms of a lease agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r331",
      "r339",
      "r456"
     ]
    },
    "cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "PurchaseOfPropertyAndEquipmentAsNonCashTransaction",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchase property and equipment as non cash transaction.",
        "negatedLabel": "Purchase of property and equipment",
        "label": "Purchase Of Property And Equipment As Non Cash Transaction",
        "terseLabel": "Purchase of property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "verboseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r211",
      "r212",
      "r241",
      "r242",
      "r243",
      "r301",
      "r325",
      "r346",
      "r365",
      "r366",
      "r419",
      "r421",
      "r423",
      "r424",
      "r426",
      "r440",
      "r441",
      "r448",
      "r450",
      "r454",
      "r457",
      "r460",
      "r504",
      "r509",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r211",
      "r212",
      "r241",
      "r242",
      "r243",
      "r301",
      "r325",
      "r346",
      "r365",
      "r366",
      "r419",
      "r421",
      "r423",
      "r424",
      "r426",
      "r440",
      "r441",
      "r448",
      "r450",
      "r454",
      "r457",
      "r460",
      "r504",
      "r509",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550"
     ]
    },
    "cgen_RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "RegisteredDirectOfferingMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registered direct offering [Member]",
        "label": "Registered direct offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_RelatedPartyBalancesAndTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "RelatedPartyBalancesAndTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Balances And Transactions Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY BALANCES AND TRANSACTIONS [Abstract]",
        "verboseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-rpbat"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY BALANCES AND TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r357",
      "r358",
      "r359",
      "r397",
      "r398",
      "r399",
      "r417",
      "r418"
     ]
    },
    "cgen_RelativeFairValueOfDeferredParticipation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "RelativeFairValueOfDeferredParticipation",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Relative fair value of deferred participation.",
        "label": "Relative Fair Value Of Deferred Participation",
        "verboseLabel": "Relative fair value of deferred participation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront payment received",
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "cgen_ResearchAndDevelopmentArrangementPaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "ResearchAndDevelopmentArrangementPaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.",
        "label": "Research And Development Arrangement Payments Receivable",
        "terseLabel": "Potential milestone compensation"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone compensation company is now eligible for.",
        "label": "Research And Development Arrangement Payments Receivable On Remaining Program",
        "verboseLabel": "Potential milestone compensation company is now eligible for"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone revenue for preclinical stages of research from arrangements for research and development, including collaboration and licenses agreements.",
        "label": "Research And Development Arrangement Preclinical Payments Receivable",
        "terseLabel": "Preclinical milestone compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development expenses, net",
        "label": "Research and development expenses, net",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r253",
      "r551"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r86",
      "r104"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of workforce reduction from restructuring activities",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs",
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated deficit",
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r64",
      "r337",
      "r350",
      "r351",
      "r356",
      "r375",
      "r456"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r107",
      "r108",
      "r109",
      "r111",
      "r117",
      "r119",
      "r177",
      "r178",
      "r246",
      "r247",
      "r248",
      "r256",
      "r257",
      "r264",
      "r266",
      "r267",
      "r269",
      "r271",
      "r347",
      "r349",
      "r360",
      "r555"
     ]
    },
    "cgen_RetainerFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "RetainerFee",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retainer fee per month.",
        "label": "Retainer Fee",
        "terseLabel": "Retainer fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r442",
      "r445"
     ]
    },
    "cgen_RoyaltyContingentObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "RoyaltyContingentObligations",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued.",
        "label": "Royalty Contingent Obligations",
        "terseLabel": "Contingent royalty obligations"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_RoyaltyPercentageBasedOnFutureRevenues": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "RoyaltyPercentageBasedOnFutureRevenues",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Percentage Based On Future Revenues",
        "label": "Royalty percentage based on future revenues",
        "terseLabel": "Royalty percentage based on future revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails",
      "http://cgen.com/role/cgen-set"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_SalesAgreementWithLeerinkPartnerLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "SalesAgreementWithLeerinkPartnerLlcMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the Sales Agreement with Leerink Partner LLC member.",
        "label": "Sales Agreement With Leerink Partner Llc [Member]",
        "terseLabel": "Sales Agreement With Leerink Partner LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156"
     ]
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-fint"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of financial and other income, net",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of related party balances and transactions",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-set"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted-average Assumptions Used to Estimate Fair Value of Options Granted",
        "terseLabel": "Schedule of weighted-average assumptions used to estimate fair value of options granted",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "auth_ref": [
      "r138",
      "r139",
      "r362",
      "r363",
      "r364",
      "r420",
      "r422",
      "r425",
      "r427",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r443",
      "r451",
      "r460",
      "r510",
      "r552"
     ]
    },
    "cgen_SeverancePayFundNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "SeverancePayFundNonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly deposits in externally managed funds which primarily cover Israeli law severance pay liability of one month's salary for each year of employment upon the retirement or death of an employee or termination of employment without a valid legal reason.",
        "label": "Severance Pay Fund Non Current",
        "terseLabel": "Severance pay fund"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_SeverancePayNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "SeverancePayNet",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Severance pay, net.",
        "label": "Severance Pay Net",
        "terseLabel": "Increase (decrease) in severance pay, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Expected risk free interest rates range",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected risk free interest rate range, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected risk free interest rates range, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares available for issuance | shares",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value of options granted during period",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award",
        "verboseLabel": "Number of shares purchased for ESPP",
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options granted, exercise price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r219",
      "r238",
      "r239",
      "r240",
      "r241",
      "r244",
      "r249",
      "r250",
      "r251",
      "r252"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options granted, exercise price, minimum",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options granted, exercise price, maximum",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life",
        "terseLabel": "Expected life (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-se1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r66"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "ShortTermDeferredParticipationInResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term deferred participation in R&amp;amp;D expenses.",
        "label": "Short Term Deferred Participation In Research And Development Expenses",
        "verboseLabel": "Short-term deferred participation in R&amp;D expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sap1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r105"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r15",
      "r82",
      "r96",
      "r97",
      "r98",
      "r107",
      "r108",
      "r109",
      "r111",
      "r117",
      "r119",
      "r129",
      "r177",
      "r178",
      "r210",
      "r246",
      "r247",
      "r248",
      "r256",
      "r257",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r286",
      "r347",
      "r348",
      "r349",
      "r360",
      "r414"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "verboseLabel": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r362",
      "r363",
      "r364",
      "r420",
      "r422",
      "r425",
      "r427",
      "r429",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r443",
      "r451",
      "r460",
      "r510",
      "r552"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/cgen-set",
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r129",
      "r326",
      "r354",
      "r361",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r395",
      "r396",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r414",
      "r461"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/cgen-set",
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r129",
      "r326",
      "r354",
      "r361",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r395",
      "r396",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r414",
      "r461"
     ]
    },
    "cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation relating to options issued to employees and directors.",
        "label": "Stock Based Compensation Relating To Options Issued To Employees And Directors Value",
        "terseLabel": "Stock-based compensation issued to employees, directors and non-employees",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of ordinary shares pursuant to the ESPP, shares",
        "terseLabel": "Issuance of ESPP shares, (in shares)",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r40",
      "r41",
      "r64"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of shares, net, (in shares)",
        "verboseLabel": "Ordinary shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r40",
      "r41",
      "r64",
      "r355",
      "r414",
      "r428"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercised, shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r40",
      "r41",
      "r64",
      "r225"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of ordinary shares pursuant to the ESPP",
        "terseLabel": "Issuance of ESPP shares",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r40",
      "r41",
      "r64"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of shares, net",
        "verboseLabel": "Value of shares issued",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r40",
      "r41",
      "r64",
      "r360",
      "r414",
      "r428",
      "r467"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r15",
      "r64"
     ]
    },
    "cgen_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period Value Warrants Exercised",
        "verboseLabel": "Warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionPlanExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionPlanExpense",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation stock options",
        "documentation": "Amount of noncash expense for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs",
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r44",
      "r45",
      "r61",
      "r376",
      "r392",
      "r415",
      "r416",
      "r456",
      "r468",
      "r482",
      "r503",
      "r542",
      "r555"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r293"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r293"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r293"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r293"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r293"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r294"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails",
      "http://cgen.com/role/cgen-set"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "SupplementalRightOfUseAssetAndOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the Right-of-use asset obtained in exchange for operating lease liability",
        "label": "Supplemental Right Of Use Asset And Operating Lease Liability",
        "verboseLabel": "Right-of-use asset obtained in exchange for operating lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplyCommitmentArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplyCommitmentArrangementMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r72"
     ]
    },
    "us-gaap_SupplyCommitmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplyCommitmentAxis",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supply Commitment [Axis]",
        "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r72"
     ]
    },
    "cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "SvbLeerinkLlcAndStifelNicolausAndCompanyMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]",
        "label": "Svb Leerink Llc And Stifel Nicolaus And Company [Member]",
        "terseLabel": "SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_TradeAndOtherPayablesRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "TradeAndOtherPayablesRelatedParties",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-rpbatd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade and other payables related parties.",
        "label": "Trade And Other Payables Related Parties",
        "terseLabel": "Trade and other payables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://cgen.com/role/MARKETABLESECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r207",
      "r208",
      "r270",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r342",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r499",
      "r500",
      "r501",
      "r502"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "UnauditedInterimConsolidatedFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unaudited Interim Consolidated Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "UnauditedInterimConsolidatedFinancialStatementsTextBlock",
     "presentation": [
      "http://cgen.com/role/UnauditedInterimConsolidatedFinancialStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of unaudited interim consolidated financial statements.",
        "label": "Unaudited Interim Consolidated Financial Statements [Text Block]",
        "verboseLabel": "UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_UnderwritersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20230630",
     "localname": "UnderwritersMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriters [Member]",
        "label": "Underwriters [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r462",
      "r463",
      "r464",
      "r465"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of ordinary shares used in computing diluted net loss per share",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r126"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares used in computing basic and diluted net loss per share",
        "terseLabel": "Weighted average number of ordinary shares used in computing basic net loss per share",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r126"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.12)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480489/718-40-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "10",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480679/815-10-10-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "20",
   "Section": "10",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480769/815-20-10-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "610",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//610/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "720",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//720/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483049/450-30-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "712",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481179/712-10-25-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "712",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481179/712-10-25-5"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>47
<FILENAME>0001178913-23-002711-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-23-002711-xbrl.zip
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M<%(3VJ=&+'B<:A-!^V734([.RL=(=CG/R/J0LD:_"LCE- I6@M0\XHLFDG3
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M'N3MY;C,H+R]');IROL8D-@'WUY'UF;;V?NN>;Z./B)KE$G'*NB4J$Y*VHD
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M][%>_33$&!/)^;BP'<AI_#D9CYS?B9<?Y9>P/=W 'KSM"$F+'G"9]KN.>B[
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M 2%AAF=>Y6HRQH1N?G2_?HIH,)G/2:HN!:/-8_;!>$9ED6R3>2-]>$=<6[2
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M!N0W[A?31<S2U8)5JPM^X#I&B=X8:3$ 9,9]V#)?/-<<G%M)S$)<U8F%E'2
MP[AW6<JC==ZRUQ@D-N[9E4),YAA=?!,EKSHQ^"HR0&'<=ZK%J6H0E*'!W=!(
MR6<?C-<$J<1J#7W::@B2&O=I#JEPK:AI_<%X/8U]8>Z27*<6@)H0D!BWZ65B
M.!(V,ZUR0W;-$H,1PAJ5^W'FGK1![,X1L!NW\ YA-^X=J"2](Z_L3P=#K1@
M,O/>@2EDYOT%4\C,^Q4*P;H^4^[.#!";]T&$0K)#=.E"T1VTFM_L@_$J"Z[@
MMN+S2.0\8NINTP,N*YZ0 5R.^$6]XW+$YV%R];30RGD!7BM^3GVNUIZ!6TP
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M"PF5REPP\3@7\"^]F@^.*N/DE:QL*;(V5)46IP74E$/U,PPV+J'"V"X8U'1
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M2[QQEOHDHE[DOWI9^77T'V!K[C_1"-,:@A/ -C'XM7_.,*;*3S?,SR ^L-R
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M?W9_UR"P.W&2Y3*)V7M?7@QHLLZS'"2&,1/.BPL_PK0P0Q87[:+C*O%%*FQ
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M/"!5:$[#76E&Y@VXRFB>=JF B/='35_;F=@Z$0P>Q]-E.#B%][?B_UWP#A7
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M%<[THS*?5[T0 FRQ1W(<5WOZ?%Q?B!V5([FZVA?"'I#Y,MUY.:L#0MPRU^<
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MV=I5=Z$\Y_< 7W-P/A_5=W(GOO^O.3B#C^H[N7O?_]><GK-_3B*,[JM!-4(
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MK1'UNXJP5F@&7O O-1 ][*_?C81)_P9X50:0=AQAW787<!>X2)X"08S?K7?
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M9O^C@8XDE .=ZAX&]*Z##QX("@=JT0&T!T;BU/KH/N=<^0?M%$6JR7!28DG
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M1,J+'3^,X983T3NW-67W:FNI=>;Z1RBGSH N <P]-&O AWX5('A*8)12Y:$
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MMY;<@J0^_>44@8NBY__Z_U!+ P04    "  2. =7)>H#_[8F  #U_0$ $
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MU9V>WG<E&#<(QC2F88)R. I!JG)HHF@NQ*SMPRK'WP&2%6H+L?V@E%ZD1P@
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M#A5R.6H?M^$?Y-$N+(O"%_%HY#./#'A[_BVK]O3"\WS$ HRC %2;Y*.]S,5
MW0F2$%HZ1WPQK$>](MR_@7=EH?]GQ@K7R#WHV0 3!!:A$VB+.J,9C:IT7-"8
MS3@O%IB<;?*ONET: FLH&0#G$75(UXP):":"K[%?\[>DY/#ZZ (GRG&9C*([
MG+B;Q5QH0">3*$R0:0/T@LS-5X56$I3Z ;\X,]^[D0\3A+6$U4))BG?RA>+C
MN^/#O_6C+ FFM9G@<F,+ )R8PR/%L U)LW$4)VUR _-/HQ2893K%]<!%Y^W!
MG4@L(%BRX9 E:37[= 3/XWVYF+8I!HIJNY% 7[>"I"81#A,7!]J+/ ^71XR
M R.:\-WCLP V3&\CL40)]5B*LXAX( EI'X??2J.6&'[A"0.<HA,L$?2+.QR#
MI@'SN#QNG6JXZ; 0"?81 +D'\TM>.=1&$4<)5S#@60UVR8NIDT; HJJI3R(_
M%+ZZ"+>KG%R^$F/F^CPD-F;.B(9^PH<"K<  VCD%-H"M' /::]0/M F,4BGH
M]R+C/%Y,!9;>R1($'2PAK";E%%6A)'=O(J$Y8N^59RA\T$J-F)[GQE00_T')
MZO)-\,-;P"8.HV8^5;*E)!E_C.YZ' HR2.1>N.] * D36'81'M&$HQ)0,4+,
MW0'D.%^P6> SCFBDG!&'-I DRY #5"A ;BB P)GGQ5E?U0E-H#TA5O!)X=&M
M9L]=NV,Z1;?8.(/!VA@(92CK*&?["9M?X08C"?DX4%<-3;GLRJ7VO/!"KH5D
MQ]V#^9;FK(NS8%S'RIP0?*X0#?E2U_E.M:PS5%Z@#UN;=?[ YMP![O!?U-KK
MIGDN/9_2"MODL'PPF"K%A%Q #"R4$,@)$\RPDM)"&K(R0C!B,P"$%8K]X)8-
MHR2-QCZ(#E#N;U$MRA55!!;(,1P@@BMD<37UPR2-Z;]9R!RZ(:0X ?IPB0UR
MIPPT\RBWL$CR*V5<'"^6-M#7J\MOEZ!M?H5]^GX(?ST4)IW 32W<S>\MZJ48
M=:?!'9TF#S0U:P)@"#^,DA%0VN>]_,-<%+^56Q4B_GY_1B)FSW^=,;&*U=+K
M<?O<NEH4MR\-K^>&;I\9I3TJM=X_N-:[_^H69\+F+S>'#=WI.X9F:)ZG&<RR
MK;[NF;1G==TNZQC][JZ8PQL+PSR9_W!&8Q T:.3LYYD/Y!NW+0K]TXT2H3DN
ME,WW8XCW8X[<I7,P9P, 2P76Y'Q'GHA68<"@S5HLL?VF)O82D/2\/F#19%1E
M\$]?MZFEJBY5S3XS^TZ72DBN&I)')V<WY S4H#HJA5/@4N@#PLX#R5A(Y_LB
M&;8(M#DAL=& %=H\.3EM:=;72_X-4\D4$*<)C%@(9U"L,K#_"VU>/,.MH])0
M*QP*A7,BB* WV$!76%&"2EAXZ\,M NMHMX$^%[F9\/??)QF ?1;"%)(1*BF@
MOX!Q&(BA<H/A%NVQ7#40O?!!%+HF:*ZHX@(5<:T)E0O0K0(6@JG&;0X7?D ;
M,<;?*7&F:?0=V'Q=<]T8N6E>1S5U#\2 V3$L5^TSIENVW>M[7=WNL9T)F3:7
MW+A? DDMI[3]AP3 P[;< BE08_UM,JA8?^Y*0!&0@"I?&#=(:8X_08-9(2.X
M#C-$_7G&VKKC?D?X/P61!38 FJ%5R]P8X'Z&/+^ DT[)*FHZ?0+R*]D8XCNF
M:3F.ZM >=8V^H]&>ZO5['5OUJ.EXNQ,"V +$ERK/O]#E)LSY019'$P8PNZ1<
M!@CW)ODPN+SX6#@1XBQ@[GW0 [:SR0CZX T="6\X][Z;!XDPYLGE_[LZ^0UI
M2T3'A!^[Y@3S"M*)F1> &E6P=##D@*&CN5NY6<NF\^;0V$O9D,N*$$3"?0^[
M\/'!5' *W"(&,LSL_T!'W(TU@9D'&Z,,H "CT^]W#,_VC(YCV'K/<#6KUV7,
M,!Q=4L;**8/[JN^3QT*UB_L?%CGC%]D$E7?^0YY3(Q2Z1Z*Z'Q\T.A8YVD7<
M>-Z]C@Z1/' DW.SW'+WH7F>XL*!2H5.<$V#,ZK[A"1L#[8*2QX>)JA?H5BA8
M0M_>&*WTNI;F]%35=JAJ]'H]ZO6IRS17I7;'LTQIIC2%5F8C1Z#JWW/2%7]J
MSCI4;6:\?F#"8!A#^Y63!K%]C&_X()D6N0,5PCBA^,*@\#&P*8(HW&X8T7A,
M'6X"<)]U'EC!WPKZJ1D^=0/$&3'G.X][P#=>H $W8# M!H)":^C\^NCT:);
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MY,&FPBW5U&<K)[CC49PBF],Q*$!WZ6BVDF*^7J--[K$XM-IRR2D2X4^2F+)
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MLOSE*;/MDQT_]G/5;'U-GVJT&M:G44SR-798")18KJD US[F+["%4!.FK1W
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MM2;LC%JK/IL1JFHKR*5JP>T(8"%5M//?)M15")Y;I?_U]!^_GUQ8)DRY6WV
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MJ:K>Q ,HH-H7&V9Z#K"(K)\I6*ETU1S.9^Y:-\&@UQ6C#Z:][>$<+O"U/;7
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M01RYK5W&*>-B$$?.-_PD^^[+(;L=W%;W7ESBJ/(9LY81D7=Z^//$A='&>T[
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M2C19' SAB/DEQS7X1HG7X)?Z,'LF)77PN='G)!\\4_$T(+BVMZA((FGSC(K
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M]Q<2Y(\6F<F^%,O^2A<#S%#B2YJF(01>"'P9!7['O*PM!;Z(7(IZ19:$QA<
M<!0 L#ZS82L$V#&;:DL$*"3AH=FLM-N<8\"^.:>P[ :!3T>,3]G!TX[Y6 A/
MF1@6[7:EU2FE8R%2$ YG"$<<PB_?9'$P!,$O)9HL#H8@^*5$D\7!$ 2_E&BR
M.!C"$?.+2$$X.<>^)BP'P1H1ARWI5HA)W8,-18CD@R1W7^[*W7;,W6_6&O5Z
MPW?WNZV4_:C]O  8#3N45*VS/JO66=]S10JITJIU*Y+,>6"R#"(A)"X+B6M+
MM9:4O-MG1>?WX@5M]X#='O=3"S$38K9"L<7*V1<O;ODOPDL5J5G*4#E?\B'$
M+T/Q6^H*T^@T);F;G.96J#0>7!=6(7U"^E8HOUA&>4;BEIG2*J7-N/?UW9($
MGQBS59^P^2[,S[S[+M$9 Q+7(C3LMULA6MANERBF1H EJK.#/+6_Y2 F6HY0
M\;Y!M+@^J6+9@[LA'!@OIS,(ZMU:78X9!$%W]%B3QF:G(;<*ZY6^YV 5)Z:Z
M0 KNAB"08ADI@C9M9<"&(B)K[8XL (,7:>5@" (P-IH6M5:KU2D!?!Q<*%#
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M1H*_+P9?[QZ_7-V2FX?+4]*[O23]AR$9/GX>]B_[O?M_K^#I)-6\_'5;O90
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MO)B$H4A_J$ZE)<4[R!'-LYEQ!V_IZ*]@K)GNV,'ZR4"$?Z Y5P=6QR%5&(&
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MM&CB&%"!HA/M&KXN5_U&>1& 9<:6:GF&QOHG&_I$-YG%YDV!C &X(R:'EUH
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M--T_+Y\< \*,P@98UQ,@CNEYJ7+-7(Z:#8?R@#ZD=R.KJB;3_:)%[MQ0UVZ
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MS8I?'$6E\MK%?'Z+F8+F^A"+N=U=JE7(-!^V54BLD+%P7ZU6EJ^5]5'!^FR
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MF4-B/QT%X,88O!2E1^2B@?_$H6<?47?, TZ<CGP[5#15DX=]"OEVMW"-_^[
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M,G_OMRXG4TQ>=)U\JG?.M]1+[-OH_U!+ 0(4 Q0    ( !(X!U=R$+'$2@T
M '!W   1              "  0    !C9V5N+3(P,C,P-C,P+GAS9%!+ 0(4
M Q0    ( !(X!U<:LPB&>PD  &UZ   5              "  7D-  !C9V5N
M+3(P,C,P-C,P7V-A;"YX;6Q02P$"% ,4    "  2. =7(JPF(L,3   @)@$
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M=%\Y.2TQ+FAT;5!+ 0(4 Q0    ( !(X!U>O.^*85HL  #C:"  0
M      "  ?SA  !E>&AI8FET7SDY+3(N:'1M4$L! A0#%     @ $C@'5Z=)
MO]P&"   :2   !               ( !@&T! &5X:&EB:71?.3DM,RYH=&U0
M2P$"% ,4    "  2. =7S>^)U$D-  !+9   #0              @ &T=0$
C>FLR,S,P,#@R+FAT;5!+!08     "0 ) $ "   H@P$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
